var title_f33_9_33936="McRoberts maneuver and suprapubic pressure";
var content_f33_9_33936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    McRoberts maneuver and suprapubic pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An assistant applies pressure suprapubically with the palm or fist, directing the pressure on the anterior shoulder both downward (to below the pubic bone) and laterally (toward the baby's face or sternum), and in conjunction with the McRoberts maneuver. Suprapubic pressure is supposed to adduct the shoulders or bring them into an oblique plane, since the oblique diameter is the widest diameter of the maternal pelvis. It is most useful in mild cases and those caused by an impacted anterior shoulder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33936=[""].join("\n");
var outline_f33_9_33936=null;
var title_f33_9_33937="Electromagnetic spectrum and medical laser wavelengths";
var content_f33_9_33937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Electromagnetic spectrum and medical laser wavelengths",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33937=[""].join("\n");
var outline_f33_9_33937=null;
var title_f33_9_33938="Patient information: Migraine headaches in children (The Basics)";
var content_f33_9_33938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83061\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/43/25264\">",
"         Wong-Baker FACES pain rating scale",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/31/3570\">",
"         Patient information: Headache (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/29/27090\">",
"         Patient information: Headaches in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/15/36086\">",
"         Patient information: Headache in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/57/35731\">",
"         Patient information: Migraine headaches in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Migraine headaches in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/migraine-headaches-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9361708\">",
"      <span class=\"h1\">",
"       What are migraine headaches?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Migraine headaches or &ldquo;migraines&rdquo; are a kind of headache that can happen in adults and children. Migraines often start off mild and then get worse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361725\">",
"      <span class=\"h1\">",
"       What are the symptoms of migraines in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of migraines are different based on the child&rsquo;s age:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        In toddlers, symptoms include suddenly getting very pale, being less active than normal, and vomiting.",
"       </li>",
"       <li>",
"        In young children, migraines can cause nausea, vomiting, and belly pain, and make children sensitive to light and noise. The headache can affect the whole head or just parts of the head. For example, it might affect just the forehead or just the sides of the head.",
"       </li>",
"       <li>",
"        In teens, the symptoms tend to be more like the symptoms adults get. The headache usually starts off slowly and affects only 1 side of the head. But in about one-third of teens, both sides of the head are affected.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      No matter what age, most children feel better if they lie down in a quiet, dark room while they are having a migraine.",
"     </p>",
"     <p>",
"      Some children have something called an &ldquo;aura&rdquo; before a migraine starts. An aura is a weird symptom or feeling that warns the child that a migraine is coming. Each child&rsquo;s aura is different, but in most cases auras affect a child&rsquo;s vision. As part of an aura a child might see flashing lights, bright spots, zig-zag lines, or lose part of his or her vision. Another child might have numbness and tingling of the lips, lower face, and fingers of one hand. The aura usually lasts a few minutes and goes away when the headache starts.",
"     </p>",
"     <p>",
"      Some teenage girls get migraines every month, around the time their menstrual periods begin. These are called &ldquo;menstrual migraines.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361742\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Take your child to the doctor right away (without giving any medicine) if he or she has a headache that:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Starts after a head injury",
"       </li>",
"       <li>",
"        Wakes him or her up from sleeping",
"       </li>",
"       <li>",
"        Is sudden and severe and happens with other symptoms, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Neck pain or stiffness",
"       </li>",
"       <li>",
"        Double vision or changes in vision",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Loss of balance",
"       </li>",
"       <li>",
"        Fever of 100.4&deg;F (38&deg;C) or higher",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also take your child to see a doctor or nurse if he or she has a headache and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Gets headaches more than once a month",
"       </li>",
"       <li>",
"        Is younger than 3 years old",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361759\">",
"      <span class=\"h1\">",
"       Are there tests my child should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your child&rsquo;s doctor or nurse will probably be able to tell what is causing your child&rsquo;s headaches by doing an exam and by learning about his or her symptoms. But if your child&rsquo;s doctor or nurse thinks your child has a serious problem, he or she might order an imaging test such as an MRI or a CT scan. Imaging tests create pictures of the inside of the body. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361776\">",
"      <span class=\"h1\">",
"       What can I do to help when my child has a migraine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When your child&rsquo;s migraine starts:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have your child rest in a quiet dark room with a cool cloth on his or her forehead.",
"       </li>",
"       <li>",
"        Encourage him or her to sleep.",
"       </li>",
"       <li>",
"        Give your child only the medicine or medicines that you have talked to your doctor about.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361793\">",
"      <span class=\"h1\">",
"       How are migraines treated in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are lots of prescription and non-prescription medicines that can ease the pain of migraines. There are also prescription medicines that can help prevent migraines from happening in the first place. The right medicine for your child will depend on how often he or she gets migraines and how severe they are. If your child gets migraines often, work with his or her doctor to find a treatment that helps.",
"     </p>",
"     <p>",
"      If your child has headaches often, do not try to manage them on your own with non-prescription pain medicines. Giving non-prescription pain medicines too often can cause more headaches later.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361808\">",
"      <span class=\"h1\">",
"       Is there anything I can do to keep my child from getting a migraine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. In some cases, migraines can be &ldquo;triggered&rdquo; or set off by certain foods or things that children do. Some possible headache triggers are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Skipping meals",
"       </li>",
"       <li>",
"        Not drinking enough fluids",
"       </li>",
"       <li>",
"        Having too little or too much caffeine",
"       </li>",
"       <li>",
"        Sleeping too much or too little",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"       <li>",
"        Certain foods containing nitrates, such as bologna or hot dogs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you can figure out what is triggering your child&rsquo;s headaches, you might be able to help your child avoid those triggers. To find possible triggers, keep a headache diary for your child. In the diary, write down every time your child has a headache along with the following information:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The times it started and ended",
"       </li>",
"       <li>",
"        Where in the head the headache was, for example left side, right side, both sides or behind the eyes",
"       </li>",
"       <li>",
"        How the headache felt, for example, &ldquo;pounding&rdquo; or &ldquo;sharp&rdquo;",
"       </li>",
"       <li>",
"        What your child ate and did before the headache started",
"       </li>",
"       <li>",
"        How bad the headache was &ndash; Using the FACES pain scale can help (",
"        <a class=\"graphic graphic_figure graphicRef51303 \" href=\"mobipreview.htm?24/43/25264\">",
"         figure 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        What you did to try to help, for example having your child rest in a dark room",
"       </li>",
"       <li>",
"        What, if any, medicine you gave, including the name of the medicine and how much you gave",
"       </li>",
"       <li>",
"        Any other symptoms your child had with the headache, for example numbness in his or her lips",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After you have been keeping a diary for a while, check to see if there are any foods or events that seem to bring on a headache. Then, try avoiding those triggers to see if headaches happen less. Share the diary with your child&rsquo;s doctor or nurse. It can help him or her understand your child&rsquo;s headaches and choose the best treatment for your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9361825\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/29/27090?source=see_link\">",
"       Patient information: Headaches in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       Patient information: Headache (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36086?source=see_link\">",
"       Patient information: Headache in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/57/35731?source=see_link\">",
"       Patient information: Migraine headaches in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/9/33938?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83061 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-B40BC8A1ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33938=[""].join("\n");
var outline_f33_9_33938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361708\">",
"      What are migraine headaches?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361725\">",
"      What are the symptoms of migraines in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361742\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361759\">",
"      Are there tests my child should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361776\">",
"      What can I do to help when my child has a migraine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361793\">",
"      How are migraines treated in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361808\">",
"      Is there anything I can do to keep my child from getting a migraine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9361825\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83061\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/43/25264\">",
"      Wong-Baker FACES pain rating scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/15/36086?source=related_link\">",
"      Patient information: Headache in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/29/27090?source=related_link\">",
"      Patient information: Headaches in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/57/35731?source=related_link\">",
"      Patient information: Migraine headaches in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_9_33939="Coloplasty neorectal reservoir";
var content_f33_9_33939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Coloplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 619px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJrAfEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6popvmJ5vl718zG7bnnHrinUAFRyypF984qSuT8cXU1mbd4zhHBH4j/8AXUzlyq5vh6Pt6iprqdCb6PnaQcVn3mtCB1XjnP6VyeiXsk9xh2Jz/wDq/rVjVI5JYEkiBZl+YgdenP8Aj+dYe1bV0elHAQhU5Zm5/bme9KdaHrXGLdKxwm4nuADxUm+YjIB/Go9qzq/s+mdW2s/7VS2OqmWVlLZwM1xUk0sfMiMR6qM1raQjpH5rcGQggZ7f5NONRtk1cFThC51P9qqkgU9xmp11WDIDMBXJamJAkc0eTsXJA7j/AOtXPXWoyGQbWJB6U3WcTKnl0aquj1yN1kQMhyD3p1Zfhou2jW7yfeYE/rWpXTF3VzxqkOSbj2CiiimQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfPcFr4qT4lW/jxvD+oi2uNTezdAGMosCBEm6DbuXaUMme+4dua+hKKKACub8ewJJoZkb70TggdznjA/z2rpK4Tx9eGS8itFPyxjJ+p/+tisqzSgzty6Ep4iPL01Mbw1HKJmlcAKq8DOTmrt9K8j/AGdWKoPvYPX2q3psXkWcfHbJ9+/9BWfHl55GPOWxXNaySPd5ueo5diWGDgBRgVObY4qxbINoNXFTK5qlExnWaZhyR7eDT9Ik2Sy256D94vtyMird2grPtwV1GIj+JWX9DU7M1vzwZrSv5KEvyqjOPpx/SuWuLbN2JFVFQnPlg9PpXSX53W7H3P8AMH+tc5qLFTkdRSqMeEXU9S0vyhp1sIDmMRjafXirVc74JuvP0toz1jbP4H/6+a6Ku2DvFM+bxFN06sovuFFFFUYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5f4km87xBcHsHK/lx/SvUK8h1N86zMT/z0b+dc+IeiPZyaN5yfkdagxanHYEfoBWDanj3rfjYfZT6H+tc5AdszoeoJFZT6Hdh9VI2raQbashwB1rIRytPM/IBPJ6ChSJlSuyxdSA9KpQc6jb/71KzE9aZaNnUYsdsn9KTd2axjyxfoX7s/6H7lh/IVzurHFbmoybIox6nNcrrVxlsKamozTCx6nZ/D6bE8keeGj4/A/wD167mvPfh8jG7iPojE16FXVQ+A8LNUliHYKKKK2POCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAryLxDEbbXrlD08wkfQnNeu15z8RLQxanHcgfLKvX3HH+Fc+IV43PXyeoo1nB9UW9PmEtggPdcflWLqQMGpFuzgN+Pf9at6BKxtnzyqMCP61a1WxjuIH3OIzGSQ/pj+hrF+9E9KLVKq09mUElDKDWZcXuPE9lbDp9nkZvqSMf+g1PZQTEZkYbc8ADrXPeb/xcCQMflRUi/NR/U1KOpRTb9Dq5JgAeaXSvnvnc9FQ5/Hj+tRXForcglT6itLSViFk4jTa4JD5OSWxwfpTirsyqSUYaFTxDKI5l54A4/l/SuOlZri6wOea6rxPayzXIeMrt29Cfc1X8JaDJqF9ggqqcufQVMouUrF0qkaVHnb2Oz8CWRhtXnYYBAjX+Zrqqjt4Ut4EiiXaiDAFSV3wjyxsfK4mt7ao59woooqjAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuW+IKxtpkIbiTf8v0xz/SuprgvHd0ZdRS3B+WJQPxPP8AhWVZ2gzvy2DliItdNShopKWzxD/V4JGeoNXNYJMZUHhn5/P/AOtUGkx5jYe3+NT6wMBB/tD+tcy+E9mVvbEVrAXXivPnz/wmOqTDpFcAZ+jAf0r0/Th8leUafN52s6pnrKZJfykA/wDZqdtDehJuUv63PS7mHaT6VHpPF68Z6OufyP8Ahmrr4ks4ZB/Ein9KoWh26nER7/ypNWZhF80GmT6nFvhD9wdv6Z/xrK0q+l0/UFkiOCD36H2NdDqS/wChvjsQf1I/rXIXvyS596U9HdGmGtUg4y2PXrG6jvLWOeI/K46eh9KnrkPA16W327N8rLvUe46/59q6+uyEuaNz5vFUfYVXAKKKKs5wooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8r8ST+brc7Z4MhA/Dj+leqV5J4hjMWqzK3USN/OufEbI9nJknUl6G5ogDQt9D/ACpdc4Cn0YfyNQ+HJMhl/wA+lTa7lrQuOwVv8f51l9g7WrYgdZybYj9K8c0ebb4itIz1ms7hvqQ6H+hr1a3mxCSP7p/lXjtm5HjbQEH8VlMPz3H+lC1N4rkUvVHtNjLv0Ozbv5QH5cf0qvbnOoQ/U/yqDSZd2kQJ/d3D/wAeNWLHnUk9gT+lJu7RCjyqXzNTUD/orD1B/wDQq5DVjhq6y/b/AEYZ9P5muR1hsP8ASpqlYJG34NmK3tqQf49v58V6XXlfg/m8tsf89V/nXqldGGfunk5wrVl6BRRRXQeSFFFFABRRRQAUUUUAFFFFABRR0qrPfwwnBYE0m7FRi5aJFqisptWTcAMYzikl1EheDycj8aXOjT6vPsa1Fc1FrwfktVhdZQ9TS9pE0eDqrobtFYbawgHDVC2u7edwo9pESwlV9DoqKz01AYBOOf8ACnR6lCxAJwafMjN0Z9i9RTI5EkGUINPqjJqwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQaKKACvN/H9sYdTMoHyygMP5H+VekVzfjuy+06R5y/egOfwPB/pWVaPNA78treyxCvs9DjfD8+24VB1b5a37xfOtZV67lIH4jP9RXMeH1DalGSyqqHdljjcewFdZjjAPGF/nj/Cuanse1i7KpdHM2k3+jyAnkIx/Q15LasB8Q/Da9vsxX8xJXrF7CsU98YGOxUfII43YOce1eO+Zs+IPhpvRYx+bsP60RNqrThzLq0ex6M3/EuX2Zh+tXNLbOpOfSM/zA/rVLR0zaSjsJCP0FXdHj8nUJFkJbevyE9sHkf59KS3FUa5ZF/UG2xEE/xAfz/wAK43VpN8zAV1evHbYlhzIHG1e54Of51ycULXV0E2tknpjmpq66F4OyjzHU+BbZpLu3wOFPmE+w/wDr16RWN4Z0r+zbIGQYncDd/sjsK2a7KMOWNmfOZhXVes3HZBRRRWpwhRRRQAUUUUAFeF/GjxT4n0rxxc2egajc21ta+H/7TMcTQKodZ2VnbzVO8bRjYpBJxjvn3SsnVfDWhavdx3eraLpl9dRqESa5tY5XVQSQAzAkDJJx7mgCfw/fLqehabfxuZEuraOdXKbCwZQ2dvbr07VfpFUKoVQAAMADtS0AB5GK88164lt7mSPkFGI/wr0OuY8Y6WZ4vtcS5KjEgHp2NZVk3G6PQy6pGFW09mctDePKpye1a9vK89sHzh/lb8c4P6iuXgDiQhOB6mul00bbBN3Hyrn/AL6J/lXLB3PbxMFFJoyLsNZ3L5DeSxyrent+FOS6yOGzU+oZkuNjHKoOn+0eT/hUYjOOKT30NItOK5hj3RA5OBVSeYvwrZz6VdZOxGaiiiihuElMeVU5K9vrS1LTitUjfaRlTAPT/DH9K5641GWJhg9hW/kbcHkYPPr0P+NclqqeVcsmQQDxirm2jDCQjJtNHaeDtSa7ufLY/wAJNdhXEfD6ycNJdNwigqPcn/P6129dNG/LqeHmSgq7UAooorU4AooooAKKKKACiiigAooooAKKKKACiikLAdSKAFophlQdWFHnJ/eouOzH0UzzU/vCl8xP7woCzHUUgIPQ0tAgooooAKKKKACiiigAooooAKKKKACuf8Z3ot9M8ngmY4P0H+RXQV5742uTLqbpn5YwEH8z/Osq0uWJ3ZdS9rXV+mpj27eYCrDg10dsT5KFjyQCT+R/pXOWvC10rptg+XoIz+imuame5iuiMWGHzdNvZW5JjkYn8Ca8L1U+V4w8OyD+7Cf/ACKa+grFB/Y9wPWFx/46a+efEZ26z4fk9I1/SU00rJBKV4z8mv1PevDcQlt71e6Tf0/+tUkq+VcRvnG1uvt3pvhM4n1Jf9tT/wChVPqg5bFD2uK79q4v+tCbVIw8LZHzIdw+nf8AQisKzuXstRjlTG9GyuRmunQCa1jY9WjXP4giuMvyUnU981NTTUvC+8nBnsVpOtzbRTJ911DCpaw/Bs3m6MozyjEf1/rW5XbF3SZ8xXp+zqSh2YUUUVRkFFFFABRRRQAUUUUAFFFFABWB4u1E2dkIYjiSbIPsvf8AOt+uA8czbtU8v+6qj+v9ayrS5Yndl1JVa6T6amPCNzY9eK6MIAoUcL/+ofyzWFp6gzxA/wB4VuzMfKBHdCf0auaGx7eKfvJGRH+8kZz1Yk/nV+KDcOlUbXqK2YSAgxTiia8nHYo3FvgdKz5Fxmt24wUrGuQMmlJDoTb3LdmDJZpzk42/kcfyIrHvo9jHcM87vz5rX0o/uAP+mh/9lqlrCjd+H9aUvhNKTtVaOv8ABdys2kCIAAwtjj0PI/rW/XBeALgrfPETw6kfiOf8a72uqjK8EeDmNL2eIku+oUUUVqcIUUUUAFFFFABRRRQB4z8QrzT1+J32fx3f39j4aGnK+n+TPNDDJcbjvLNEQTIB0BPTtzz61oxibR7E20k8sBgjMck5JkddowWzzuI655zVyigAqhqWoJZkKxGSM1frjfHyyI1vMmdpUqT7g5/rUVJOMbo6cHSjWqqEupbuNfBB2kVF/axkBCnquR+Wa4mOZieTWpp0u5Fc9U4P4Ef0NcqqtnuTwEKa0RevtYkWaMqxw6Bv6UR6zL3as/UIGkiKx/6yJiU9x3FZsUzNwUYEdalzaZvTw9OUdjpm1qTHBqBtdlTkmsVmbHAzVcmSaQRquGY4GeBSdRlRwlPqjuLDWiYImc/eBb9cCtaPVkxyw9Oa4+CMbY0B+UFUHuADVO+u2W4ABIwC35mtVVcUcMsDCrKyPSre8imIAYZNWa8qsdXmSccnrXqaEsik8EgE1tTqc55uNwbwzXmOooorU4QooooAKKKKACiiigAryrX5TLqM7H+KRj+teq15LrgMV84YdHYH8658Rsj2cmSc5Ba8riurhxJap/tKR+a//XrlLM8Cui02TNpj+6wH5H/A1jTPRxa0TK+nH/iXTIf+ebD9DXzz4qXFzobekbfo+a9/tX2faI/dl/nXgXi3lNGcdhMPyINO+g3H3JvzR7n4XkAvr8eoU/qf8auag2S1Y3hubF3cMe8YP61fu3LnaOrHA+tJvSw3D95zehsWjhbOPPaJa4vVz++yPXNdbdOIbNgPZR+A/wD1Vx2qMGnOOlTVelisGvecj0P4euWsZwegKn+ddZXKfDxCumzse7Afp/8AXrq666PwI+dzD/eJ2/rQKKKK1OMKKKKACiiigAooooAKKKKACvNfGrEa5KT6gf8Ajor0qvPfHsO3Umf+8qt/T+lYYj4T1MoaVfXsZtlIFliftuFdAw3LED7ofyI/rXJW8uIyp/Cuisrj7RbIwPzd/Yj/ACPzrng+h7GKg9JFCJtpq/FcYGDWbORFdSp/CGyPoeaUSj1oTsVKHOrmlLcZWs+Zs5NIZQR1qCeUBTSbuFOnymrpBH2ZSe7k/wAqo6u4LY9FFXbRTDZIGO0hec9if/1/pWJfTh9zZ+8ePp2pydo2FRjzVHI0PBzFNXt8d3x+YNem15n4KiMmrQezFvyBr0yujD/CeRnFvbL0CiiitzyQooooAKKKKACiiigAooooAKqarYx6jYyW0vAYfK3909jVuqWs3o07TZ7nqyjCj1Y8ClK1tTSlzc65N76Hk9zbTW15LA42PG21s/0rQ0qMp5gLZ3ED+VVAzTTs8hLMx3Enua07ZdtqH7/M39BXnxWp9fVk+Sz3Ib+U7Qi5DSkuT6LnAqGOLjgU+4+a8K9kAT8hVyCEsKdrsjmUIopNGRUE8YZT6juK2HtxiqM0eKTQ4VLlmwnLxQM33twDfUHB/mDWXrBBlHlhvNQYYY4xVzT/APVOPR8/p/8AWqHUl/0qRh/Fz+tN6xFTSjVZL4P083+rxblPlxne+fQdvxNeqVw3w9uo1nubZgBI4DKe5x2/Wu5rpw6SjdHh5vUlKvyvZbBRRRW55YUUUUAFFFFABRRRQAV5v48tTBqLSAYWT5x/X9a9IrlfH6Qy2ESFwLkNlB7d81lWjeB6GWVHDELz0OIsZMrW9pLk27+jS4H5CuetbRwyfvMqWCkKME5PY10d8Vt4I4IBgldqgdh3NckNNT3sTZtRXUzrdzLNM6fdMjYPrzXiPihf9H03PaScfote/wBjaAooAwBxXgvi5CEslHUXEy/oP8KpLQfMpQkl5Hq2gg+bIV726H+VaenxPPqBE5VfKG9QOdx6A/hVDwYPPRD13WUTfolbMQ8rUYjj72UP4j/ECi2pMp6NLt+hLr3yWLOo4U5/DcK46QGScd8mu01p2Maxq2EdirEenPH8qwNJsIX1aCOSTbEXAbPOBUVFd2Kws+Sm2z0fwnam10SEMMM/zn8en6VsUigKoVRgAYApa9CK5VY+Uq1HUm5vqFFFFMzCiiigAooooAKKKKACiiigArm/G1j59gtwq5aPhv8AdP8A9f8AnXSVl+I79LHTZC6h2kBRVPQ5FRUScXc6MJKUa0XDe55Xyr7QCT7V0Okw+VaIxOS53n2H+RWfaw5PoXOK3LthbQBY8BgAq+x/+tzXFBdT6fE1L2gjJ1eLfcgwN+8ChXHaqYsZW6ufoK0YwAea0bfywOgo5bsXtXSikjnvsEo53mnwRBLhDdEmMHJx/WuidUI4ArNuo1yfSm4WCNdz0YurSFbSTZ3ABP481zkjFyAPpXQ2/wC+t5YGPzKvHuv/ANaqEMdvaXyNdws0YPzIDjNTLUui1BNdUdV4F04xo924wMbE9/U/0rr6rafNb3FnE9mV8jGFA7e1Wa7oRUY2R8tiq0q1VykrBRRRVnOFFFFABRRRQAUUUUAFFFFABXHfEG6IS2tlPBzIw/Qf1rsa4Dx9n+0xnp5S4/M1jXdoHoZZFSxCv0OctutbEHNpH9CP/Hqx7c/NWrbP/oyr6Mw/rXJE+irornnUJ/8AfP8AOtq3QeUMVhOdt9P7sT+daVvc7Vxmqi9TGtFtKxemUCOsq4xzVqW5DL1qhcSDnFOTJoxa3F0wZeUf7Q/kaivh85z7/wBKsaN/qpnP97+Q/wDr1DqRAlI+v+f0qfsmqf71kGhXJs9Zgl7K4z9Oh/SvW68WjOLkYr2S0ffawv8A3kB/StsM90ebnUNYTJaKKK6jwgooooAKKKKACiiigBk0iwxPI5wqAsfwrzDV7yS+vXlkPLHp6DsK7zxRIY9Glwcbiq/rXmqN5k+a5cRLVI93KKS5ZVOuxsabbKzqxHyx/N+P+c0ty/m6hJ/sYQfh1/XNaOkRhrYk9yQaxy3/ABMLj/fP86zeiR2RfPUl5G5ZDEea+ffGqlZSvQxX8i/mG/wr6AsnHlkV4V8TU8ifWGx/q79ZB9G3f/FVT2FR2qJ+X5no3w4bdDa56nT4/wCSV0Fx8l7E3pIp/WuZ+HDYisT/AHtOQ/otdJdMDdIPVwP1pdB29/5ItatEGt9w7H+WP8K5V5DFqAIOOa63UWzZZ9Sf51xeoNi747Goq7muCV4tM9k0+YXFjBMP40BP171YrI8KuX0ODPbI/Wteu6Lukz5atDkqSiujYUUUVRkFFFFABRRRQAUUUUAFFFFABXC+O7jOowwZztjB2j3J/wDrV1Wt6ium2ZlI3SNwgPr7+1edSXDXV3Jc3DbpGPU1z15q3KevlWHk5e2eyLWnRtIDJ0I+UKevrk/hS6tI5uQkeDtG459T/n9asWMZjgLHhjlmJ4AqhPMrXDsgZwQOQPQYrB6I9WPvVG+xGq3B7j8qsKJlHWmRykH7pH1q4LqNVG/Aycc+tJIucn2KxmmHUVXe6OTvVvritTz4iOQKqzGNicAYpteYoSV9Yla0uB9vgaM87gCPUHg1Y1mNdqMT6r/h/WqzRLuDRna46EcEVahX7fE0U+DIvOR/OktrDnZSU1si34F1EwXzWcjfupeFz2bt/hXoFeQ7W06/jfJG1gc/jXrFpcRXduk9u4eNxkEV0YeWnKzx83opTVWOzJqKKK6DyAooooAKKKKACiiigAooooAK5Dx/alooLgDjmNj+o/rXX1Q1uyN/pk1uuN5GUz6jkVFSPNFo6cHV9jWjN7Hk8LY+orS0+QHzA3QEN+HSsyZGiuGTadwOCPQ1f06F1zI/8fygCuCO59bWs43G6j+7vEP99B+Y4P8AKkWbjrRdkXTbOsatkHuTQlpkcCjroSrKK5hxn461BLLkVM1kccg1Wktip6sQOqk9aHcqPL0NTTCY7RSf4sv/AIfyNULuTdcSZPI4q9bzrLF8nygHBX0wOB+WaxZi/mOxVsEnmnJ6IilG822OtwZLtVUZY8AV7Lbp5VvHH/dUL+QrzTwPY/a9aSQjKQ/vD+HT9a9Prow0dGzx86qp1I010Ciiiuk8QKKKKACiiigAooooAxPGIP8AYrY/vj+tea2Z/enPrXqXiWEzaNcADlQG/I15UhMdwR71x4j4kfSZQ70GvM7HSZMWxHuf5VhX7eTqsw6BjuFX9Im3eYvoAw+vIo1fT2u0SW3wJV45PDDripesdDWDVOs+bqLZXA45ryT4uqC2v4HVIZR+aV6JamcStGyEFTgnPA/GuA+LMZI1Id5LAN/3yf8A7GiLubezS5rdUzq/h83l2Vkx/h06L9VSuh8zfexY5+bNc54QQiyhQHBFjCB/3yldNpMIMsjyOPOXgIP50t3YTtGPN5L8i3qj7LUAnpgD8q42dt9znrk10mvs5t0kUExjO4+npWb4a0l9W1VI8ERKd0jDsv8AnipneUrIvDSjSpOpJ6I9M8MwmHRLUMMFl3fmc1qUiKFUKowoGAKWvQirKx8jUnzzc+4UUUUyAooooAKKKKACiiigAooqjrV01npk80Zw4GF9iTik3ZXKhFzkorqcr47u/Pu4LSFwSgO/HYntVHR9PiCedIN2Dhc9zWfbq9zO23JYnluuK1Li4EEexDll+6g6jjjNcV+ZuTPp/ZujTjQgyO+m8+Uxg/uUOMDox9aWIRqvQZrMjFztAwowKlVHAzI/Sp5jX2aStcuzbMZGK888aa0z6hb2VpJhbeQO7r3kHQfh/P6Vsa3r6ojW2lsJbhuDKvKx/T1NeVeJdYg0S8WDAuLoMDKm7lB3yf7x9Pzp77GsFGkueoz2nRtQTU7BJlwJB8si/wB1v8D1q/8AZhIOCQa830PUvIhg1TS5FuLOYBXAPGe6N/dYf54rvNK1e3v0zbSYkA+aJuGX8KVu4Ti0uaD0LElnKn3XNS6ZILeV/OOHYYDdhz3pzXEhXBGaru6n7wNGid0Z+9NcsifW4y4DFDjBBx27g1r/AA6nc/a7cklFw4Hoen+fpWdpVyGLW78qBlCe3tUEsk2k6h59hJtzzgdCPQiqi+VqZhVpurTlh3v0PTaKzdC1NNVshKoCyDh1HY1pV2ppq6PmpwlTk4y3QUUUUyAooooAKKKKACiiigArnfFeuPpqrDbbfPcZLHnYO3HrUfiXxL/Z8jW1moe4H3mPIT2x3Nce63OqXLTXL7nblmPQVz1av2Y7nr4HANtVay938yuzvczl5XLzStySeSfWtC9ljt7IiPrjYD6Z4/xpssEFmobALngccmqwRpnDSH6DsK5tj2tJ2fREUMsYAAOKvQTqpBOKUWasOCKT7FzgU0mglKEiy1zGRVKdgx4p5sn7Go3spQDhjQ7smKhF6Mr25EN8mfuSHY349D+Bqa+tTHhv4WODjsary28iMGZs4IPNXWnN1byjGCTkj+6f8ikuzNJOzUkO8Oau+kXjfIGikwJFxyQPQ16ZBMlxCksTBo3GQR3FePzhlcbwAR1xXofgeUyaOwPKrKQp/AH+tbYebvynl5th4uKrrfqdDRRRXWeAFFFFABRRRQAUUUUANkQSRsjDKsCCPavI9Xs5LPU5oCpLq2OP5169XmfiC7W71aeQYxuwD7DgfyrnxCVkezk8pKcktrEmgbEjYOD5/wB5vQj2q5qUjQ2LhTgttUH0zkVU0tMzDHeNqta5j+z2Po6/zasl8J2zV6yv1KdnEuxVUcVwnxXtf3kfH+ts54//AB0/416BppBRa5H4qp+40+Uj5Q7ofxA/wpLY6Kbbq8ve/wCRZ8Fx73I7LaRD9BW+3+j3KS44Bw3071k+BI/3l2eqrHHGD+Brb1BRzR0uKT/ecj7L8izcwCe3dSfbI/MH+R/CsWK4uNJu/MgYowPOO/19a3NKkMtoM/wgqffH/wBY1Q1q3GM9xwT646fpRJacyMqTtJ0pbHbaDq0eq2gcYWVfvqP5j2rTryjwzqT6dqaHJ8snDD1HevVlYMoZTlSMg+tdNGpzrXc8bMML9Xqe7s9haKKK1OAKKKKACiq9+t28GLCWCKbI+aaIyLjvwGXn8ax7jS9enbjxEtuv/TvYID/4+WoA6CiubbwxcTEG78S69L6hJY4R/wCQ41P61YHhjTzF5c8mo3A7+dqE75/8fxQBsXE0dvC8s7rHGoyWY4Ari9W8T6Xft9kbUbJUZvlhWdGlkI7BQc1Lrfg7w5bWJkGi2LuZFBeaISnr6tmuE8XW0Frq8FvFBDaWTRgqIIlQNz83QDOPSsasraHqZdh/aSUv60N+71e2jUxrcQW8Y/hDjd+NZx1vTYufNeQ/7CE/rXCanceIbOab+yPC9ld2qsdkyzGZ2XsSqkYPtiuS1Txd4riYq9nDpp6fJYYI/Fwaw5Wz1va04aWZ7JLrzyxt/Z1hK4HWSThV+uP8RXH+IfFFjF/yF9XjfP8Ay6WX71vxCnH/AH01eVX2p6rrIC6nql1dKOiSSnaP+A9P0qOCxVccCiyJVeX2Fb8ToNX8ZX12rwaFbjTbZuPNJ3TsP97ov/AefeuSGnsSS5LMTkk8kn1rorSzzjitFbJQOVFLnsL2MqjvJ3Oc0a9v9DuTLp8hUN/rInG6OQejL3+vUV3uj+JNIv2iE8raXe/9NSfLz/syDkf8C/OsKbT1YZC1m3Gm5zxS5k9y4qpR+E9q0/Ur+OEOpjv4B/y0Rwx/76XIrVh16zcATxSxHvuTIH4ivnaGG5sZvMsp5reQfxQuUP6VrW3i7xJanm/+1D+7dRLIPzIz+tPQHVv8UfuPeftllMcw3MP/AH3g/kasxzK67ZlWaP1Bya8QT4hXmALzQ9PkPdoneMn8MkVctfiBpW7/AEnTL62b1hlV8fgQtHL2K9rBqzue6aJdQ6XeeZBMGjkG1omYBvqM9xXb2lzFdwiWBtyH8wfQ1852OpaV4kz9mD3bW6mTy7+0BCjIBwTkdx0Oa7Xw7o3h+aGK7bR7SPkLKIlMf4jbj0Na058ujODG4T2y9pB3PXaKxIvDGmRLiBbyEf8ATO9nX+T1Xk8KIX3Qa1r1uf8AZv2cfk+6uk8I6OiucOhaxER9l8VagVH8NzbW8gP4hFP61s6dFdw2+2/uY7mXP+sSLy+Ppk80AWqKKKACsjWtetdLOx90s5GRGn9T2qzquow6dbNJKw8zB2J3Y+mK84dJ553uLplUu24sx5rGrU5dFuelgcGqz56nwr8SRoW1G7mupvl8xy21T69qV5o7bKx/M3oOn40T3gW3MdtycYz0xWcshT70Z/CuRux78YOW+3RDp/PmkDs2CBgAUsZnXqM1KkyNjnH1qyjoQKVi3LlVrEcc8q4+U1Otw2MdKmjWIjk08xxkcEVaTOdyi+hWa8Ze2ahe/kxwhrQ8mEr2zUbxQqO2aLMIyh2MuS6L/eQ0/SpFN1Lu4UqOD65qSYJnjFVZRGevBHpU7M3spRsWdSSPcGU/LjBPoR0/Sn+HtauNKuNqN5lux+aMnj6j0NR2EiTZjnbkDhvUf41HfWiod0Z6dfandp8yJ5YyXsaiueqWdxHd20c8BzG4yKmrgPB+vx2e60vCREzZV/7p9/au+UhgCDkHoRXbTmpq58xi8NLDVHF7dBaKKKs5QooooAKKKKAIrt/LtZnHVUY/kK8hlkP2jmvXryMy2k8Y6ujL+Yrxy8BSbNcuJ6HvZKk1P5HQabII54T2Pyn8RV/WkLWFwAM/LvH4EH/GueglLW5IOCBwa6OOTz4Iy4zuUZHrkdP1rOLurHVXi4TUzF0u4AAyazPiXEJ/DDSLyYpkb8Dlf6ipbiF9OujGc+UxyjHuP8ai8Qubvw1fxL8x8vcP+AkN/SpTtozp5PfjUjsWvAXy6NLOessuB9FUD/GtG9kyTWZ4ZBg8PWKHOWQyf99En+WKfc3AD7Tu3dhjrTbsrE8nNUlI2dCbELj1lP8A6DT9SAa1R/7wUn68iodHhkht1aUFSz7iD1GSAKmvzmwcDqgJ/I//AK6r7Jyyt7a67nISN5d4COzV67oMhl0e0c9dgH5cf0rx+5bdcjHrXsGgxmLRrND18sH8+f608N8TIzm3sod7l+iiiuw+dCiiigCC+tUvLZ4JHmjVsZaGVo2GDnhlIIrMHh2ADC32rD/t/lP82raooAxP+EeQdNT1cf8Ab45pToGemrasPpc//WraooA5y88Lm5tpIW1rWMMMczr17fw+tcTd+HxcsbTU9Q1GSaFs7JZFZSR3+7/WvWaxPEmjjUYfNg+W7j+6RxuHpWVSLaujuwVeNOXLPRd+zPNbnQLWJ8fvYfR43yD+eaYunahCD9k1NmHZXyP5H+lb0NzktbXyYbO3kd6r3tq8I8yAlkHbuP8A61cnmj6JTbfLL/gHK6lo895/yENJsrzH8YjQt+Yw1c7eeHtDJ2SWVzYS+sUzD/x1816FFdno1TmWKZdsiq6+jAEUKRbprrE8qfwwY4t2napFMR0iuY/KY/RgSv54rInnltbg295E0M46q3f3B7j3FetXeg2NwrG3BtpT0MZ+XPuvT8sVwPinTZYSLXUo9y9Y5EPB91Pb6UNJhGF9IPXzMZr+NEy5AFXrPRNQ1FEnEKW1s4ysty2wMPULyx/AU7w7pMFo0Mqk3t8xyjOmVj9Aq929z+FegWmjsQZdTndpW5KhufxNLlSDlnb3tDjP+ETs1I+1anI47iCEJn8WP9K0rXwto+39xpFzdH+/PK5/ltFdhELaAYgijT328/nTnuM9STT5kL2SfQ5qLw1boR5Whaeh9ZEVv5k1p2+nzQAeXFp0B/6ZwqP5LWpbxy3HKcJ3ZuBV6KK2t13SsHb1bp+AoTbFJQjpbU5+60/VrhAYGS4OfuvIYlA9c4P8q2dGstauDHY2trpkMaYaQmeSTA9/kXrW/o1jJq2SC0NqpwzgfM3sPSuusrSCygEVsgRB+ZPqT3renC+rPLxuM5PcW/bsYjWviqXI/tTR7cf7FhJIR+JlA/SmpomuOf8ASvFd2Ae1rZwR/wDoSua6Siuk8Iwo/Dpxi41nWbj13XIj/wDRarWpp1jFp9t5MDTsu4sTPO8zEn/ack/rVmigArM13VU0yAbQHuJOI0/qfatOuD1h2uNfut5zsIVQewGKzqS5VodmCoRrVPe2Wpn3t2wmZ5n827flnbovsBVEFpXLO24/WnxmBWf7TPFHIWJPmMATz71z/i3V7XTJrC2jlK3d9PHBbyKMpuZsDJ6HvwORx61x2cj6RShSWuh0KoAalWNGPNMXT2VeGc+5NZmo3UlhNEisJGkkWPZn5lLZwT7cH8jS2KunszZ+zKehBpv2cDoarRm66sV/Co7m7ltonlkQtGgLMV7AdTRdByy7mgkTDvTwGHesyyvnvII54FPkyKHRjxuBGQRUzTzKM7N3sDTuiXBstuGIwOtQm2djyT+dUrfU/tDyJEjlo22uMfdOAcH3wR+dWzcSgZ259qLoOWS2HfYie5/OozZhc5UfU81Amrq901su77Qqh2jxyFJwD9ODU7TSsPu/hmloUufqRtCOhApFLxEYJIz0NVn1ELfRWjxMs8qs6BiMMFxnB9sj86tlZGHG0UivJg9sJwXgI3dSprW0HxDcaYVtrtS9uOAD1Uex/pXOXt19gj864BRAQPMB4BJwPpkkCtFZzIm29iOP74HI+tVGTTujOrSjUjyTV1+J6jbzR3EKSwuHjcZBHepK4vwpdvZ3QtXffbTH5DnhW7H8a7Su2EuZXPl8TQ9hPl3XQKKKKs5wooooAK8r8WWf2TV5owMITvX6HmvVK4Xx9Lby3lvGozNECHPbnkD/AD61hiFeNz1MpqSjXstmjlrGMyHYxKRH7zkdBXW7FVFVOgU4+ny4rBtVyvyjk8Ctt/3NvI/aNcD8Of6CsIaI9fFPmkjO1WY3cz2yKvlKfmbGST7elEFknkmMINhBUjHUHrUVguQCep61t26DAoS5ncVSXso8qM9LMQwpHGuERQqj0AGBVeaHPUc10DICtZ93GBzTlEzp1m2V9NuXdJbaUlnUeZGx6kA5INWr2QQRTvsD7QflPQ/5BrLVvJvIZB/C3P06H9K2pIcrsbkEBT78EURd0KqlGV+jOQSxH22Lc6hC4z7DNewRBREgjxsAG3HTFeQ326KRR/dr0HwXfG70vy3Yl4Tjn+6en9arDtKTRnm9OU6cal9F+p0FFFFdZ88FFFFABRRRQAUUUUAFFFFAGLr2hQ6mpkTEdyBw3Zvr/jXGzrdaXP5F+rKuflc9Pzr0yuB8XX322+8hTmGHKgerdz/SuetFL3up7GW1qk37J6x/Ixb2yd38y3Q7j1UDr9KoRpKzkBCCDg54rq7FS1rDnqAlY0AzI+eu45/OueUep7NKs3dPoRRW8vVmwfalv9Lg1G0e2u13I3Rh1U+o960Y13GrsNupHNNRInWscf4Y8Otpe97grJMCURh02+vsTW68IP3hW4LZahmgAzVchl9Z5pXZz8tlG2SNwPsaSysUeVwzMwQAjP8An2rQmTaaXTky1x+A/Q1CWpu6r5G7lC7mkjZYYyMnjgZx7VsaN4Wubt1mvi0UXXDfeP4dqyL1SkjsOCGzXf8AhfUDqGlIzsWlT5XJ6n0NXSipStI5cbWqUKKlS67s07eCO2hSKFAkajAAqSiiu0+abbd2FFFFAgooooAK4jxbE1lq63ar+7lXJ/Dg/wBK7eqeqWEWo2phm47qwHKn1qKkeZWR1YOuqFTmls9GecXh8pvPRRJDJywxkfWub12GwvNR0RPssQRb3zpCibdu2KTaSR0+Yrz611l3Z3ejzNHPEWgJ/wCAn3BqjNaQ3CloCpH90/54rid0z6WPJKO+ndEkMAj5gvryMf3WcSL/AOPAn9a4/wAQaTJ/wnGg6hHdu0zyyh0LssbqsTdVJIGDg8Y5roGSSFthLxn0NV5LHz7mG4Zy00JJjYn7uRg4+opKVi5UFLW5tKdSx8lvYyD0+0FT+q1ynxMi1OfwrfNas9jNFCzfu2WRXOMckEH1Hcc9OmN9TdDpg1V1azuNS0+ezlbZFMpRivXHtTUrEyo8ya0/EuaZJJDZQRtpt0SiKhEYXAwMcZbpUs1ywGf7Nv1+qL/8VVaK4uowFkXLeo6VI1zcuPlQ/jSuX7NpnL+HJ9ZXxFq808KNprXbKtvDCzSH5EAYsSADgDjnv9a6/wC1sy/8grUB/wBs1/8AiqztPhurN7liquJ5TMQDyCQBj9Ku/a7gjAjI+pp8xCpNf8Ocb4nn1mPxZpkmj2oiM9tNBIJ0Ic4KuNuNy54OMg9TXaw3RMa502/JwM/ux1/Osq5trm41SzvmZR9mEgWP+9vABJPtj9a0FuZhwYyD7GjmBUndvuc748a+NrYz6TbPDfW93GUkuYztAfMbD5c5zv6V0OjTaiunRJeWXmXQGHcOqBvfk5+vA+gqnqSXN9GkeAiLKkhzznawYD8xVhZrkcFR+dHMP2OtyDxTDqV9ol/bQWtpDLLA6o7z79rYOCVC84OO9VPBSaivh2znvdTS6+0QpNmWPcV3LuOOR1JJ5z6DAAFX5kuJkKtIEBGOKXT9PSxsoLfzW+zwIsaIeu0DAFHN0E6STTbNjTiyx2oB+cygrgY6sMV6XXD+FLF7y+W6kGIIDlfdu3+P5V3FdVBaXPCzSadRRW6/UKKKK2PMCiiigAJwCfSvJNRna51CR3OWZiT+NetMMqR6ivHr8GO9YHqDXNieh7eTJNz76Gtpw/fRD/a/lzV/WAY9Mmx124/lWbpzhbi3/wBpsfmK2NRXzrGUAclcD8RkfqKyj8LO2tpVi2Y1i42A5rYtpxjBrlbS5EY5OBWjFcs2Nqtg98VMZWN61HmZ0LTKF61QuZN1Zd1etB95SfXFJFerPGHQnbnHI71pJu2pyUVBytF3Y+5PBrpWGUU+w/xrlXbfn1NdVIdoI7bsfl/+qlT6lYpW5UcVrJxM+P7xFdL8OJCbidexT+RH+Ncpqsm+Rj6nNdN8NATd3B7CM/zFRTf7xHRjY/7JK56DRRRXoHyIUUUUAFFFFABRRRQAUUUUAR3D+XBI46qpP6V5ZI5a4JJyepr1WVPMidD/ABAivJbvdDeMrcEHB/CubEdD28ns+dddDo9NIa1THXGPxBrIuAIdSnQdC24fQ81Z0m4G5os8n51/r/SoddiIdLmNTwNrfTt/hWT1id9NctVp9SWN8GrsE6gcmsGK63YABLe1WVLkZJxSUi50b7m4bhfWoZJ896xbiR4h8rAtTLa7aZWKggqcMDVu6V2c0FTlLli9S/O2STT9G+f7S3YED9DWe1yrK2D0rR0UFNPZzxvJb8+B/I1EdWdFWPLTaKOp4Vpfr/Stv4eTESzxdimfyP8A9eue1OUM0mDnLGuh+HcJ8y4lPQKB+Z/+tTp/xERjElhJXO3oooruPlgooooAKKKKACiiigCC/gFzZTwkZ3oV5+leQyxyQzkK5VgePavZa4PxdorQTNcwrmFzuz/dY9QfaufEQuro9jKMQoSdOXUw7efzsQXqLk/dcdD/AIGor+2NmqyRvujZtoU9Qf60kZ3oUPDjp7GtSaD7dYAR4D8Mv1Hb+YrmSuj2pS9nJPoYsdy3TBqwkrnqpFNtACcMPmHHPatCKEMetJJlzlGJXDe1OyKuNAF96hkCKp5G70q1Fs55V4xXMyGmNIF60kUz+esciZVjjcOMVdMCtxQ4tBTrwqK6M83C54o87PSrMtkh5wKpyWoU/KzD6VDudEXFi76E3SPtjG4+1VnjbdtV3YnjA71qAm0s083G8DHHc+n/ANehajm+XbcgnZbSHe3zNnA+vt/jW7oXhu4vdtxqGYYjghP4mH9K5/R7d9R1eJSC29xn6d/wxXrgGBgdK2owU9WeXmOKlh0oQ3fUitoIraFYoECRqMACpaKK7D55tt3YUUUUCCiiigArzHxtYta6rI6rhHO9T9f/AK+a9OrJ8SaYmpae4OBLGCyMenuDWVaHPE7svxP1esm9noee6MGnuYAuT5Z3t7AV0wztK+yj8Qa5WzRYpNoPzeo4NdHA5ktY3J+Yjk+44/pXNT2PcxavJPoYlwtqbqW4ESqm4hQP4vfFRNNJJ935F9utQrlmG7ovAFXIkBrWEEtWediMVKT5YvRFcoSSW5+tORAiFVVdp5K471aaLAqA8cVbVzmhNxd0NsVD38KFsLuBIbrxziugvJClrI5PKxlvxIP+Nc2y/vUYcEMCDW+1wslvKXUMQNjIehzxWTiorQ7415VmufdHHXzZfA9K7z4bWxWyuLgj7zBAfpyf5iuKurVftG1W5J4Br1fQLWKz0e1ihIK7Axb1J5JqaEbzudGbVlHDqC6mhRRRXafMBRRRQAUUUUAFFFFABRRRQAV5z42sfsuqeag/dyjePr3/AM+9ejVz/jWFJdKRnHKyDB/A5rKtHmid+W1nSrrs9DhtG5vY2ZtqgEAnuSOldK4Vi24ArkE59xz/ACrm0AYEDjHSugt38+2LHqwGfyP+Nc0Ox7eKWqkYMRRVaTaFLnOFH6UMzv3wPQVCh3MB2HAq5EoNawhZXZ5+JxLnJqL0K2z2pOV5U4NX2iG3NVJBg1ZyJtO6ICscs8fm5UFgGK9xW9cfuLZlQfLGpOPYcD+VYJG51HuK1J5m8kxk4YnH1WspRUdUehRryqtQn0OeeUvgZya9K8FWht9IEjDDSnP4Dgf1rz8QxC6AK4Ge1es2DQtZQm24hKDYPalh4+82aZxVapRgtmT0UUV2HzgUUUUAFFFFABRRRQAU2REljZJFDIwwQRkGnUUBscbrnhUgtPphJI5MR6/ge9c/Z3htpik4KDODn+E16lXlHiNP+J7e4JUmVun1rkrQUPeifQZbiJYhOlV1t1LGqQhZPtcPH/PRf61HFcqBuJ7Zp+lM3kPFId+zoT6Ht/T8ao3MSwzvEgO0HI57dhURXM9Dqq1FSg1LW2xYe7kmOAdqe3U0qLxUMI5q9GgK10JJbHiSqSk7yICvFIszxHg7l9DTpmANV2bNDRUKjTvEufaQ6ZFVzumlCIMsegqoW2v1IB64q9bgW1nJMSWdsnJ9B2rnnGzPZw9ZThdbkhEGnR75Dumbpjr+Hp9azJ5ZLuYDrngAdB9KpzNPLOZJSGY+/T2r0DwRpEAtEv5QHnJIVT0TB6/WpinUfKjWvUjhKftZ6st+EdE/s+H7RcLidxhV/uj3966Siiu6MVFWR8rWrSrTc57hRRRVGQUUUUAFFFFABVDXnMej3bL12EfnxV+oL6AXNpNAf40K0paouk1Gab2ueSxvtuT9a3Y5dmmsvcvtH481gXsZhuCDwQcGr8Eu+BF9Pm/LiuGn8R9XjFelzIhmAS4cds5qaGQCob/5ZFPqMVXEmO9dSPn5aM1HmBXrVKV6hM3HWoJJc0EXLMcgMi/UVoTyCOUHOFYgH86w4nJmT6iruqS/6KxzzxUyVzopT5fe7FW/Yi8z716f4SlMuix7v4GKj6df615Zd5e69ya9Q8HKV0YZ7ucfkKxw/wAbPSzdL6vH1Nyiiiu0+aCiiigAooooAKKKKACiiigArI8VR79HkP8AdZW/XH9a16rajB9psJ4RyXQgfXtUyV00a0J8lSMuzPL0O2U/Wta2l8uxcjsdv61k3QMUvzAjnn2NW7aTdAyZ/iB/T/61cUNz6jEq9O5UnXybmRewPFSxSgU3Uwd8cnZlx+IqkJcGulHgy0ZrNNx1qnNIM1B53HWoZHJpk3LVswa7hH+2Kdq1x5ckDA9Dk/SoNMy14D2UFv0qprUuZ2XsoxSauaRk4q6Lkrf6QuOlej+EpC+jqGOdjso+nX+teYQEs0QP3sDNeneEkK6QCf4nYj+X9KxofGz0s11w8W/I2qKKK7D5wKKKKACiiigAooooAKKKKACvLvFieXrlyfVyf6/1r1GuD8fWRS7S4UfLIvP1HH8sVhiFeJ6mUTUa9n1RlaQwMrD1X+tVtSP+kb/7y/y4qLTptky8+oqxqC5hRh2P6GsqLO7MYtMqxy4NWRP8tZpyDThIa6Dx2WZZCxpgaoPMzTg1DHFCyHg1oyLt0wKeyKPzOazY182VEHc4rUvWzBx0LcfQD/8AVWNTY9DBX9qjHY/vBXpngkn+xee0h/kK80Vd8yj3r1PwrCYdFh3cFyX/AAPSow/xHXnDSopeZr0UUV2nzIUUUUAFFFFABRRRQAUUUUAef+N9MaC7+0xr+6mOeOzd/wDGudsZcSbHOM9K9bvLWK8t3hnXcjfp7ivPdf8ADF3Zs01shnhHO5ByPqK5KtNxfNE+hwOMp1afsKr1/MzdUjkjjG9TxyGHIP41nB8itOy1FvLaGVhgDGD6VEGtmfbLEm4HBI70KshVMvnd2Znu9RFzmtPUbaGPOxcfjVLT/JKy+dGHIbAJ7VrKXKrs4KVF1Z8kRtsczoPert1E2EeddsedwB6tj+lTWUkaTZijRCoPIHrWd4h1e2tke41C6it7ZCFaWVwqgk4HPuTisZVbrQ9OhgOSX7x6ImsIpL3UF2qSS3AHc169p1sLSyhgH8C4P17/AK1xPguTRLe6gV9U0+bUZziK3jnR3HGc4BPb8q7+taFNxV2cGaYuNaahDZBRRRW55QUUUUAFFFFABRRRQAUUUUAFFFFAHG+MNIwzXUK/u3Pz/wCy3r9DXJ20/kTBZQdvQj2r1x0WRGR1DKwwQehFcT4j8LON09iC6ddg6r/iK5atJp80T3cBjoSj7GsZF9AXtnKEOAd6kf4VhlvXj61agmlgPlPkY6e1SGfDFXwy9sipVa25vUy7mfuso76QtWjfpEqgqiDIzwMVQsJE8ybeFOMYyM+tbOVlc82lSdSapos6e21ZXAJPA4qhJbu8xknG1Sc7T1NbRu1itdikZPXFZ8Mct5chEUs7dFHJP4VhKq3oj1aGAiveqPRE2mQtNcDaCWJwB6k16xp9uLSyhgH8CgH696xPC+hpYqJrjabkfwA58v6+9dHW1Gnyq7PMzPFqvPkhsgooorc8sKKKKACiiigAooooAKKKKACqWrWCajZPA/BPKtjoau0UmrqzKjJwkpR3R4/qNlNp928cqlWU81bRlurUqCA5GOfWvRNZ0i21WHbMNsg+7IByP8a891fSbjRrsL5kcityNrc49x2rjlB0ndbH0dHE08dBQnpIy3jcDlT+HNQMCOoP5VceWRWLBSB3q5bTebaOT2b+lVCrzOxjicCqUOdMxA1PUsxwqsT7Cm3D7byIj++K0VuCxw7YHeqnU5THC4T2ybvaw/TbSUkzSDYMbVz1zSahOCdqH5FG0H1p93fxxwYBAwOSTgKKpQILmSPa6FXIC/MOc9MVjObloeph8PGj7zLeiWT3d3FGvWRtufT1NetRIscaRoMKoCgewrD8NaJ/Z6CacD7QwwB/cH+Nb1dNGHKtTxMyxSr1LR2QUUUVseaFFFFABRRRQAUUUUAFFFFABRRRQB554gni1LV5VaKIJCSoIUZPuTWFdWECTxqmQWPY11mu+Grw30t1pxVhIdxQnBBrAutI1WIiea1lOzrgZx+VcE4yu7o+rwtelyRUJq1trkz6aZ0zJIDntWRNp6QzeWjMpY84NXF1F1XDKwI9aqTTs8yyYPBpSldWNqNHkley+4JbBLdlMoJVurEmm6hp1mYAk8FvdQNgmKaJXQ49QRg1YmnkvFESIWY9ABk1rad4W1C7KC4XyIf4i/X8BSjFt+6iqlWMI3rSt+p0Hg3R4tPtYJ9OnmisZIzmych0RuOUY/Oo4Py5I54Arp6itYEtreOGIYSNQoqWvQW2p8dNpybjsFFFFMkKKKKACiiigAooooAKKKKACiiigApsjBEZj0UZNOoPPB6UAeYXtwNT1CaaZUQ5xgDHFUniSS58uPBA6k12eq+EYbmUy2cphY8lT0rn7zw/qOmyllj89D3jya4Z05LdH1WHxdCaShK3kN+xKy/O5P4Vm3drHFMoAUbjgkDGasfa3BZSh3KcEdwfei3sLzVZiLeIsV5+n1qXrojWCUPfk0kRywCLYGOVJwfao9O8C6J4g1me8uYSmqxQCOK6U71CZPytG2UIyc9M+9asXhrVrhwkkaxr3Z26V2Ph/RY9Jjc7zJPJ95u2PQVrShLmvY4swxFF0XDmu/IPC+kjR9MW2a206GXcd5sYPJST0YrzgkYyMn61r0UV1nzoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5hcTmTVLprk5k8xgd31r0+ud1vwvBqMzTwyGGZuTxkE1jWg5JWPRy7EU6Mmqml+pxGoSoSvlAAnjNWrSKMgeZV+fwZfqu6KeGQjouSD/Ksa8W70yVYb6LynYZXcw+Ye3rXLyyTu0e9GtRqx5ac0XLy2g2/u+v51nW8CSM6ttUr6CmDURJPHboUM8h2ogYFmPoB3rch8LaoYRMFRXb/lmWw2KOVyeiK9rClG05pfM569s7S9sZ7W/t47iCQGOWJxw6nqOMGuu8N+BdP0S4sZ9EgsorDblra4tVkkjBGV8ubhxg44Ytx0xRpXhCc3Ky6iyLGDkopyW9q7cAAYHAFdFCEo3ueLmtelVcVTd2uotFFFdB5AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeA6hpmoppWoXtvfzoIyzcSH1NdL8AN2qeEr2bVGN5MLxlDz/OQNq8ZPaoJ+fB+rg9dp/masfs38eDb8el8//oK0bmjqz2uepQWlvAcwQRRn1VAKmoootYhtvVhRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDxXXNDkub7XbpJAMTSv/48ad+ziGx4kLsWPnRrz7b637k/ufEIx/HL/wChmsH9nPOfE2e1wn/s9O7G23oez0UUUhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFecfE7TzqGt6UivtIifr7stej1xPjbP/CQaYe3lN/6EtF7DWh5Hbae2n/GDQISwO25HSvpKvANRU/8AC6tBIHH2gH+Ve/0XuDdwooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBw9x4df8Ase+tQOZQcfnS/CXw/N4d0G7tp1IaS6aUZ9CB/hXb4FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzFxovF+AP9fvP5kn+tZvwx8Mv4d/tYyKQLmUOPwz/jXc0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYuvaSb+6t5h1iUj8yD/StqigDgpPB0knjCw1bA2277yTXe0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXi3gj4i+JLrTfBura4dNubDxHdyWXk29u0UttIruqsGLsHU7MngYz+YB7TRRRQAUhIHUiqer3JtbMyA4OQK5E68zuQWJ5rOVRR0Z10MJOuuaOx3Hmp/eFBlQDk1yNpqbPIVz1FPv7+RbWRlPTY358fzpe1Vrmn1GSlys6sSoehpd6+tcTBqsgIJNXo9WPc0KqmOeXzidVketFc6usKByalXWF/vYqvaIxeEqLobtFUbK+W4UkYxnFXFdSOtUnc55QlF2Y6iiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn4c+Hfhfw5dW1xpOmGOW2DLbmW5lmEAb73liRmCE5OSMZzXWUUAFFFFAFDXLc3OlzxqMsBuH1HNeXSfubg+h5r1y5mjt4HlmYKiDJNeX3whuL6WRUIRmJVCeFHpXLiFsz3cnm+WUWtBbG7X7XCqkEsduK3ZUE0bp2kVl/AkkH8Dg1l6XZxtP52xRs+VMD+L1/AVcvpCkIEbFWl4U9wg7/U1nHRanXWtKolExvNeCRopVPmKcHbyKlW4b+635VMkQUYA4p2zHapszoco9irJebBkqQKhilmvZhFbnJPU9lHqautGCCMU7RxsuriJQAjoDj3yB/Wi13YHJRi2lqbdkxtoUjU8KvX29fqTUlzrQtysZPztyRn7o7VAzhVdyQBktknoBwKxNAsJta1A7ywQHdK3p/ntWrk1ZI8+NGElKpU2R6BpEz3FsJW+6envV6mxIsUapGoVVGAB2p1dSVkeDOSlJtbBRRRTJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDk/Gl8Q0dorfKBvf69q5eJerGp9en8/VJ2zkGQ4+g4FLZx73jU9Cwrhm+aR9Vh6aoUUjTtYikCxAfM3y/ieT+lU7qXzrtyPur8i/QVpu21DIONkbP+JrDt+gJ605aaEUfebky9FHkVKYRiiAjAqclQuc00iJSdzNmTa1Racf8AiZ49Y2/x/pU9w2TUGmfNqLY7RtUdTf8A5du/Yta1kWe0dPMwfzNXPh/MftF1F2KhvyP/ANequuHFpJ/vf1NHw9JbUpj2CH+Yq4u1RGFVc2Dnc7+iiiuw+bCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoPSiigDyO+fF0c9QTV/TXBnh/wB6s/WB5eozr/ddh+tO0qY/bLdeo3V5ydpH2co81O67HSX7Ysbkr0EGP1xWPA2UrVux5tk6IOZInAHvgH/GuWgvNgAOc1c3ZnPhoXi7G6km2nmbIrIGoLjvn6U4ahGfr71PMaOi+xcmkwpJpPD5L307fwhAPzYVnXF0rKcMK1NBXybRpSPnlbcPp0H6k/lRF3kFWPLSfmN8R3G2MRjq7bvwFaXw4hbzLib+ELt/En/61cvrU/2i8YKchPkFei+DbL7HosbEYeb5z9O3+ferpLmqXOXHNUcJy9WbtFFFdp80FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAjEBck4oUhhkEEeoqO6/1D/SvKta8TX/hrUmZGM9qxzsPBH07H6H86mUlHc3o0JVrqG561RXMeFvGema/EPKmRJxjcjcEfgeldPTTvqjKUXB8slZhRRRTJCiiigAooooAKgvLqGzgMtzIEQdz3+lR6nfR6fatNJyeirn7x9K881K+uNRuS8z59B2A9BWVSooadTuweCeIfM9IlbUQl7qdzOu7y5JCyj0BNX9O0yOIiUriQfdGenvTLGNc5HQcA+/c/59amv7gl2to+AuPMI7n0/CuVJbs9+cpO1OGwXd1vBitzxjBfpkeg9BVeKzBHK5p0ahauxSoMZp77kt+zVolYWQ/uCopbJe6CtTzo8dagmnXbgUNIiNSdzCudPTqoAIrWsZHvrR1jISdBtI9DggEe1V5Zo1zvYD2qHSrlYtUXBKpKChJGOe361Ksmbz5pwv1RS0y3iXU4k1B/LiDfvDjOK9dt3ikhRoGVoiPlKnjFeba9ErILgjDA4fA/z3/nSeHdafTrlRvJhb7yE9f/AK9XTmqbszkxuHljIKpF6roenUUyGVJokkiYMjDII7in12nzbVtGFFFFABRRRQAUUUUAFFFV729t7KIyXMiooGcHqaALFBIHUgfWvJPFfxat7eRrfRlE8gOC4PyD6t/QfnVTw34j1bU5Va7uCC5yEjXB/M81m6kb2OyOBrOPO1ZeZ7MCCMiiqelsTaJuOT65zVytDkas7BRRRQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGTDMTfSvGPiNb7i4U4BJ617UwyCK8p+I9qdrvGVyCcqTwf8ACsqux6GXStUPFUuZ7O6VleS3nQ5SRDg/UHofcV698PficZHi07X2VZTxHMOFk+hPQ/7P5elePXcg82SNhjB5RhVTO3Kkboyfut/jXLCo4PQ+gxGEhiY2lv3PsuCaOeMSQuHQ9CKfXzj4A+IN5oMyQX0klzp54yxy8f19R79RX0FpWo22qWaXNnKskbDOVOa7ITU1dHzGJws8NK0tu5coooqzmCq19ewWMBluH2jsO5+lSXM6W0DzSnCIMmvONa1GXULou7bV6KueFHpWVSpyLzO3BYR4mWuyH6/qsmq3eVLJCgwqDt6kn1qlDpszkMztGnfcef8AP1q3bxxWsXmyjp0B65/xoaV7gZcbU7IP6+tcr1d2fQQ9yKhTVkh6zJCgjhXzNvQ9vz71UaCR5XkaRgzkscccmrIAFTxKDRa4X5NUUlgcHmRjUqxuO5NX1RfSn7V6Yp8pm6xQ2MaaYN3UE1pEL6U7A9Binyk+1aMn7MOu39KY8CMpBArVfGOgqlMRnipasaQqNkdvdeURDefPEeA55x9fUUzUNIAXfbZx129fypk+GGO1SaLe7Jms5DviYEpk/dI5IH+eoo0ejLalH34fNFjw54hm0wLbTr5ltnp3X6V6Ba3Ed1Ak0DBo2GQa8v1q3aKXzEXcjnnb0B9foa3/AALqYRpLSdgqt8y7jxn0/wA+laUqjT5WcGPwkKlP29Na9TtqKKK6zwAooooAKKCQASTgCvMPiP8AEmDRw9hpZE98Rzg8L7kjoP1Pt1pOSirs0pUp1ZckFdnQ+N/G+n+GLNmkcSXB4SNeST6Ad/5Cvn7xR4v1XxJI7XMpitsk+WjHbj/aP8X06e1YupX1xqN61xfyvc3LdM9APQDoBUexnKq7DPZR91R6muOpVctFsfS4TLoYdc0tZfl6BbDy2WR/mb+EV6f4JyAu9jvY/Oe/0rzS3/1ok6gH5Ae59a9H8GEYXJxzUQ3OjFfAe6aOQbNMdMVeqlpC4sojgjirtd62PkJ/EwooopkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV558SbKX7JNIsbSREEkqMla9DrPvFDFg3I9KwxE+SNzfD1HTnzI+RL1mFwVkHmR5ODnkUwcDKHeh9eo/wAa9q8f+AYNSEl7o6pFqC/M0fRZfY+/v+deLXELxTSRyI8U0bbXQ8MD6GuKM4zV4n1eGxEa8dN+wAd4zg/3T/Q11ngXxtd+GL9VYu1mx/eRHtnuo/mO/wBa5FdzDKsrnup+U0rOPuOpxnlWGCpq4ycXdGlWlCtFwmro+s7DxPpd5Bp0qXKhb9vLhOCVZ9u7bu6AkA4zjOD34rRg1C1nF0YZ0cWshimIPCOACQfwYV8l2fiTWdG0a+sdIEMwucGPz5Cq28gYMJBjuCM/UD3z7PoV7fJ4f06x1I2YvLgPe3D2s29biWRi7sBgEAMxwOeNvJ4rrVVOPMfNVMvnCuqXR9Tpdd1F9WP2a2DLbq2S3d8f0rCItLRv3aiaf+8TwPxp95KfMWzjJRQMyEdSfT6U147eJMT4iU8K78Kf+Bdj9a55Nydz2aVONKCitF/W5DMrXRBnbIHRRwBSLb7PuOw/Gsm11qzutRjt9LmF8rhyzQkERhTjLH0J6evbitxSyjLKRU27m6kmvdeg1TIp+bkVKshp0bow61MqIfSnYzlLuhFlIqVJM03y17YpwjxTMm0P3U15SOlKqZp/kjuaepN0im8jGoHDt0wK0TEBSGJRyTSsWqiWxmG2L/6xifaj7LEBgKBWg2wDtULsKVkaKo2NhnlhG1j5kfoeopRa2tz/AMe58uQ/w9D+X+FQvKqjnJ+gzVCK/iurmWCLCyRuI2EnyncRuAAPJyOePQ+lFx8vVOx0WnapeaTKEnJltgcMvoPUeldxDKk8SSwsHjcZVh0Irz2J7iOMCcCWMdAeo+hq5p19JYEy2RLwZ/eQt2/wPuK1p1OXRnm4vCKr70dJfg/+CdzQSACScAV5h44+Imj+EtQtNYuLx/Jniazmtm3geZtaSIg42A5DKTno4J4Ws/x743uNA0C30qK7W71iWPdPPkFVLcsRx90EkKO4A9Dnocklc8inQnUqezitSx8VPiALCJ9M0d1e8cYZuoQf3j/Qd/p18KkxI7vKzzTOdzOzHLE96HaSaZmkZmllJd5H6n1Y0jc8J8qjpn/PWuKpUc2fVYTCQw0bLV9WMXy4z2A6mkIcszn5EIwF7kU5pEhHGAf1rsfBXgi716SO61FXt9P6heQ8o/oP1/nWbaiuZ7G9WrGkuaTMTw9ot9rd2IdPiLhWAkmP3I/x7/QV7z4M8J2mkQI0mbi4673HA+gq1Yafbabax21nCkUSYAVewrctCQo4rkjjOafLDbv/AFseHi8TOqrbLsa8X3BT6ZD9wU+vch8KPGe4UUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz77OTitCqV4QrHNcuMV6ZpT3OflLCTvnPWuP8feDotcga8sUWDVEXhgPllA/hb/HtXaTnMwPbNLI6gCvmqNV0ZuUX/wT0ozlFqUdz5auIZEmeGeIRTo21lOVZSOxow/l4uVV0H8SnO3/AA/lXsfxP8ILqMB1TTog17Ev72Mceao/qO1eNiQp82SU7MR+hFe1CcZx5onuYeuq8b9epWmtt0wcTywtjaJEIww/2gQRn3rtvh1qEFjfC1vmLXEmFt7qY7mX/plnoqnJIAwMmuQ3ruwpG1unOfwpWDLGOyk4Hpn+laKVi6lJTXmfRJRLwB1/d3CcHPf61TvNSj06zuG1EBYY0Z5FdchgBk49a4XwX4waa3+x6kZTfQqfKkXlpVHUe7Adu/1rvrbULe9tk87ZJDIoZJF+6wPf2q33OVJ6xktv608jnfCOgtpdpPd2sdtHfajL9ru4sYTceiKeoCjA5z3PeuhbU7eNHW/jeylUZ/ej5T/usOD/AD9qJbOW1G+1fdF2B7VXub/92Uu4/kxzkbhSb7lRpppKO34mDp2sR+INaK6JMPs1rvW7kGD8+SEQDpk4LZ9Nvrx03lzpgltw+mK5zwbp0CWD39rJJaXOoStdTYUc5PyBlI/hXaPwrpjLqceOLO6T8Ym/qKGkJSlZX/r+vUie8FuMznYn989B+NWIr6NwCjqwPQg5zXC+OrvVZL7TLGOAR6bqEhtbqPq4Qgs7qVznCqRjj7x68Y7CwNhJGqW0tsNowEUgEfh2o1D3Xe62Lwu1HcfnQ16ucZGfrVPUY4ILWaadUMcaF2b2Aya5b4X6tb6v4btpNsyFY1LT3ClRKSMkgt15yPoB609SX7NNLudhJfogJd1UD1qGC/ju41ktm82Nujr90/Q0lxf6bBw1/b7v7qtuP5CuM8I32qxa1qNmbVTo1vcSmBIgWcpId6HkDHJYYyMDjnrS+Y9Fa0Xqds/nEfuyo+vNc/qGuxaTqq2+tSxxRzBTbMGwJDuw+c4xtyCeeh/Ct8z6lMMQWdvaxn+O4k3N/wB8r/jXM+MtHV7aLVJ3+232mOLiAeWqcZHmKuOcsuR164oSV9RuUrO2/wB50v26xQKsbSXMzAERW6F259ey/iRXG+MNJnl8R6Nq8ryWFvFMtvN5EoLsHyEZ+MDDNt4J4kbtkV1lvfwR24SyUCI8gIuAao6hG1+hjuQGiJBKHocHIz+NLmsV7Fy0f4mgJYLaMhWkllPWSWQux/Pp+FTadIZbtD/CQQw9sVStNPd8EDCf3mpmr6xBo0yWkCF5mjM00zfcgiBxuf3J4VRyT9DTjdsKrhCLSM3xN4hPh3w9e2es6bFrNpPOWtNypKQcfdeNuhBz84zx1wa8jFxPeN9pnRkkboJMfIBwAOTgAdB2rT8R6tLrWotcyApCPlgiJztX1+p6msxiq8uST6Cic7+6gw2GVNuo95DQrAsS6knr1pHKqPmbaP1oKKSWcFR/dDfzNdj8OPCY16/F5dw/8S2E8AjIlb+oH6n8azbS1b0OirVVKDlIvfDrwZ/aMkWpapDssl+aKFhzIf7zA9vQV7EirCqBE2qvGKS3VIwqooCjgAVYlZSleLiMQ6+qdktjw6tWVSd5f8MNbbtG3qetXbbO0A9qzl7Vp2JG3nrRhfemc9TRGtB/qxUlRwfdqSvqqfwo86W4UUUVYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKpXy7j+FXapXuRnA7VzYv+GzSn8RhTowc7evvSLCxGSalZgM+tRLKcc18rJQvqeim7aCLkArjNeTfFLwebNpNb01cQMc3Majpn+LH869X3fPUkyRSoY3AdHGGU8gitsLX9k/I0hUlSmpxPlwiEn540PuPlNBQgHYS6nqp+9j+tdZ8RvC//COaik1nj+zbgnZu/wCWbf3c+npXIq6n+NFP14Ne0ndXWqPepVI1YqcRIj82QxBGCGHB46H8K9A8OeIrg28bSeXIkTgXsbcEKxwLhMehIDr/AMC45rz/AJ3blGD19R/k1c069ewvYbq2A3L0V+Qw6Mh9iODVxfRkVqbkrx3X9WPbbe7a3fETcd42P8qvbIryLfENjjqp9a5/SpoL7S4XgcyKFBRm+8U7A+4wVPuK19FjBkkUMRuXoTRqnysxbjKHtI6Mge1UMduUbPOKP9JT7pDD61LqcU0N2ehVxuH9RVbzXXqrfzpPQ2i+ZJ7lOaOd9YtLyeMFLaORV553OVyfyXH41rfbYJF2zxxuPSRA386ricngg/lUoCv/AAg/hRdicI9UZ+tRafPp90sVrAsjROF2JjkqcdKi8MrZ2+j2CvZQpOlvGrq8YyGCgEHI9a1DGuf9WKUIP7mKLhZEpv40UhEjjHoqgfyrFhN0mv3d5EgME8EUZBPO5C/OPQhgPwrTZgB0FMMgz8oZj7LRdgoR7Enn3DjBAWkjs3uHy26T27VPptvJczEum2NBk56k9hV3VJmskWGELv7k9Pc/0ppXV2ZyqWlyQ3IU08Kv711jHp3pvmWkLfugZSPQVkzXU7nLspz6ihpWhtzLMWck7Y4lODIx6KPr/wDXoT6Ip02lzTloO1bX1huY7MFWvpkLx2itztHV3P8ACg7k/QZPFeZeJtWF1JJbwP5ke8PPNjb9okAwDjsoHCr2HuTSa1cx6d9tiglEt9eSeZf3a8+Y3aND2jXoB3xmueTnBckD0pydtCKNPnfO1p0X6jsAnLMT9OKZkK3yD5jT8joMAU6G3luJ44LcBp5WCIo6kms1qdjdldmt4R8PyeItYS2yfs8ZDzsOij+79TX0Hp9rFYWyQWkSpFGu1QBgYrD8FeHYvDuixw4BuZMPM/dmx/KujWTC4FeVjMQpS9mnovzPCxFZ1pXW3Qi7ntSt7ndTyo2ZPX0qMY3CvNtYzuPTJ44FaNqMAVVTbt6c1btD0+td2GjaSMKjujXg+5UlMh4QU+vqafwo857hRRRViCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqpdnAPFW6rXg+TPesMSvcZcNzDkjyxY1X2BjwOKnnJBZc8Go0dQpyOa+UmouVj0VdIQxfLwTikVtvbPqad5pwRimD7wHrWbsvhKV3uZ/iDS4db0u6sZR8sykA4ztPY18839rPpt7PZ3MUYkhco3yAg+/4jmvppV4LDjFeR/GbR1iurTVYtyiU+TLgd+SD/MflXp4Gro6cvVfqdeCq8lTk6P8AM84IQnOwI3qnH6U3BBAIAD9COmaAv92Xn/aH+FB3+U6soII6qc89jXoI9lnYeAtZMErWcpOxsyIuM8/xr+OMj3HvXfwzm3uEljIZThgR0INeLwtJFNHNExVwd6spwQfb9D+Nej+HdXjuRb2txlTdKzwE9N68ug/AhwPQsP4at6o5dITs9pfn/wAE9EYRahajng8gjqD/AJ6isiaF7V9soBB6MOhqHTbuS3l2qNyZwwPSujeJLhTFINySHafrjIP1qvj9TF3w7t0MFWTvgVMjIRwRTYrSNeCg3Dg1dgtFxwAKlJms5xRVIFMbaK1PsnFRSWuByKfKzNVYszd8Y7qKfFiV9seGb2NSPbpnBQH8K07a0it4coq7icE46n/PH50KLY6lWMUELR2kGAc4+Zj6tXPancNNMSM+lWNYZZHIPKrwP8axY8GYLkgE+tKcuhrh6KXvvcnKxwxSXN5KkNvENzySMFVR6kmuW8Va8Y0VIt0c0qfIvQxRMOPo79/Rfcmua8QwXmofF+S31KeafQNKt49Q+yucxZ2gKCOhzIR+tZ+q3b3N1NcTNmSZzkk9zyT+WBTS5VczcnXnyvZFRz5r5blR0APBoIQnAjXPstClT0bA9uadgdnB/wCA/wD16zudtkhhQD7yKPXBFep/Cfwv5UQ1u9T55ARbow+6p7/U/wAvrXGeB9DbX9figkAe0ixJOOxHZfxP6Cvf1iWCGOKNQqKAAAMYFcuLrulC0d3+B52Nra+yXz/yJkQNyx/GmSIFzg0A8cGh920k9K8Z2cdjzVe4x88DNKYjjIzTGPzK3tU6SArURSbdypNpaDYQzcVqWcZCjIrPQjdkcVo2jk4Ga7sGkpamFVto1ovuCnU2P7op1fUx2POe4UUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKr3XIFWKguvuisq/wMqG5jXKKAexqiv3jzgVbuVLSHFVJEZPqa+Tr/FdI9Knta48YPCg49aV0CruB5qONj2FKysR/jWSd1sU1qP3EDFc38RtOW+8G3ysAWjXzl+q8/0xXRx/Nkfxe9R6lAJbGeBjlZIyDn6V0YWXLUjJi5uV3XTU+YVMbKC0MeP93H60vAIKZA9M5pG/cSPCzbXjYoQfUcUhSNjkSOrf7IGPyr2z6X0LNoQ7bCuCPmGP8/Wr8lvPLY2awOVlttSt542zg/f2nH/AZD+VZdu7288cm4NhuuMce4roreVVlhYgBI5Mt7YNaROWuj0vASUoowA3Aro7Rj5CP6bD+XFc9Ou27PoTmrUmtR28AhhTzZwp3ZOEQdcsaIOzJrxc0rF+5TZeSLj+LI/Gnfbba3H7+eKM+jMM/lXlfiH4iW/nvHBJJqMw4/cHy4B/wLq34fnXMP4y1mXIgS0tgT1SEMw/Fs0+ZJmap8ySZ71/ben9rqMj2BP9KY+sae44vIvxBH9K+fX1jXZzl9Vu/wDgMhUfkKli1TXouU1a8z15kJ/nS9oNYby/r7j3m3vbWS5Qpcwtg5++OvatW9cRxIB/DHnPuf8A9dfP0PiTXF/1721yP+msC5/MAGun0XxWpCxzCayc8EqTJEfqDyP1oU0OWGcmn2Ow1B+DWfa8zinTXXmRI8mwo/3Zozujb8e1TafFmYE8Cs2tTsi0oHHeKgi69q0o4e4+zWjN/sohkb/0MflXGTHM5I4wMcdieT/OugvJ21Ga4uckrcXEkyj0U4Rf/HQK5niR3cITuYnIbHetJbHPh1ZtiSEB9rgOexAzmgyKoOVYY/2TQhcZLRPn1ApylptseGG9ggz7nFQdVz234U6KdM8PLdTLi6vD5rDuFx8o/LH5mu2di5HFQWEa29lHEo+6gAqaHLPwcV4WIqe0qv8ArY+clJzbm9xjqy89KacsOSasXHTBOaihAyM1zSj71hqXu3GN0HGAKVI8jOeKdLgudvTFRYPTNQ9GNaouIo29au2XUe9Z0THGDWjZnoRXoYVpzRhUWhsp0FLSL0FLX1S2PNYUUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqG5+6KmqG5+6KzrfAyo7mPcEK5qlNJuOegFW7yJskg1njqcrk18piZSUuVno0krXHxnoTUskmEx2qABgcYHNP2Pjv+VYRk0rItpXux0a78YOG7E08QO5w4471CGKkA1IWfG4saqDj1E0zxHx34Q1qy127mtNPnu7GaQyxvCu8rnkgjqOc1x89peW5/f2F1Ef8AbiK/0rvfi7rt3Lrq6bFPJHbQRKZEQ43scnn2AxxXCw6hdQ8Q3MyD0WQj+tfQxacU3ue1hXVdJOVikWJDZKqMdO9dFbYNp844KeYc9/l5/pVFNVlMyPdxQ3gH8MyAk/jjNbV/JDdW0lxbDakkLMAOwAHFaQt0HXbbSaOr0bWF1Lw1bzJJm9hVYJgeofGN30PUGsL4h2erN4fgg0i2nltZmY3bQjc5AxtBA529T+Fc74XGdXVVkdRsdiVOCcdj+Neo2LauYIjHbmWEnAkKYwM9SR298UlqFaSiuVs8MsbNk2rJC6c4+ZSOa3LXTw5xiku9bk1TWru+ni8iK4k3BIxvUYAGc4zk4zmulsJNNnjVpdSVGxj51ww/GspWNqKlZXRSt9FDKO1WhoijvWkTpSjnWIwMYyBz/n8KYJ9GHXUZpTjH7tWyfxFRbzOpSVvh/r+v+GKv9lQAHeVGOvNKulwl1WMguxwqjqT7VeSSxddtpp17dnOR5ikD82qW3W8+1QmSGHTYfMUsy/O4GfyH60tB3k1tb8TT0TRb2yldbjyls3B82MyBjnHBAH8VZ3iLUzo+g6hHE4FxJiC355BYckf7oyfyrWv4tXhg+0PeeZbE48yFo2Xn1wvH415j4llkl1mbzZnkER2qWxxkAn9f5V0JKK0OGNT2rZfiQLpgMYOVhGP++Cf6VzcY/dqNwHA7ZrrdLUrbWRkUY4Vge42dP1rK1G10uyuXiiN1OUOGQuERD/d3YJOKqSurkUpqMnEymVNuPNYH1CjFaHhSyl1HxDp9tGvmN5yyPgdFU5JP5UfbLNMGPTbPcP76NJ+rN/Sup8AeK57bW4LI2mnxxXbbC8NuI2BwSOR1FKKjdajrzqKlJxj07ntr246gke1VcMrcdanM8rZYkYz0xSI26TJr5yfLJ3joeHFyitSIq5601CV6/WrYZd3bFQzEEnFRKCWqY1K+lgVkOSRzUIPz+2aDjOD6UqjPAFZt82hSVifK7eOtX7PtWekZXk1o2YORnvXfhb86ujGpbl0NhPuilpF6UtfVR2PNCiiimAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFRXH3alqK4+5WdX4GVHcxL1juIqgjhTV6/b5sdqoqRk5Ga+SxLftNz0qa90f5hc7iMDtUnmgLgVHGm80NEQ2OKzTna6G1G9hpOT+NP+bbjPFM5V/mp207d/SpRTPDfi4oh8YzOQSJIkI9O4/pXIoMjLLCB/tcn9K674n3MjeMb4AnCBFwPTbnp+Nce0kbfeWPP+7g19HF+6vQ9zCp+xjfsPOOgCf8BXFben3LWukCWNFZkjbhhkHLY5FYBkRVO0Zxz8ozXRCQWWgR5jDLKqxOD6HJbHoeOtaQ6sK6vyrzF8NwIdWE9so8gxNuGeYye3uPQ1tfEfUryODw3ZxXEqWU1lI0sSuQsh8zHIHXgCuZ0mKW31O2kgLS25cLvUdAeMMOx9vyrpfiLGG0vwrORx/pMOf+BKQP50XsY1Yp1YX1/wCGZz2lNHHNiBCq54VhkKPTua6tNSjSICWzUkdwBg/jXK6U6q+O4NdbEQ2lb9wzgsB3rnlLyPTpUrLRh/aduBhbIbuvMf8AWpV1mQDEFsq+5jwKjsJBPdxjgfJmmytt89G4KtwfY1N/I0dPWzY99S1GY7QPLPoMDioEhnmmKzzknGTgkH6VNqTCCOKVWBZSNw9qitLhDfPvbC7M/rS5mUqUba6/15G7phEfg+8xwJbmOP8AIZNeYXqEXtxdXybd0rFYW4Z+eM+i9Pr2r0XUTJa+E4lh5knlnnQd+BtX9c15n5Ai+a9cZ/55hsu59/QfrXRDSJ5ujqzku/8AwP0OmsXln0u2kmJaRm3AkYyuSB/KuSuWBvLoFskTPn/vo112lzPLp9nJL1IkUcY4BOMe3NcjcYF9dowBYTPkEdfmNaS+EiirVGNAQ/eLj3Uir/h9jD4i0pgyun2lPmHBGTjBFU0YD7sduP8AeWrGjyGTX9ODLhjdRA4GB94enFTHdG1XWEvRn0rGAy8tjgGmLkZxTsZQEDjApFQ43c181Ja6Hz621GruJ5/KpNoAySM1GCd23jNT/Z/lyTk0oJy2CTtuQNjacjipYm2tmoXBJA6j0pUJPH61KlaQ2rotmXcMcVeshkrisuNCCOOK1rInKivRwknKacjnqK0dDVHSigUV9OjzwooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUVwMoalqOf8A1ZqKnwscdzGuiok+aqM2wnIFXr2PecVQkTbwTXymKvzPTQ9GnYbE+w8duKcJCZQT0pkIBHPFK+AcKcn3rlTaVzVpXFuGDPkcUKxYBc8UjJgAsQSe1OD7toA5od3K7DpoeM/GKx+zeK45o2Gbm3WRgeOQSvH4YrhxJIp5P54Ne2/Fjwrd6zp1ne6fEJLy0BUpkDehxxk9wa8afTL2OQpcRLbYOGaVwNv4Dk/gK+jpJygmj1cFXg6Si3qgsLebU7+G0jyQ7DfjgAZrofE0qQWi2rIvlSOMMOq7R1H/AH10q/4PttPjiuVsZHmuo1+aRk25LZGfoBnAqn41hBW2gHEymR1HTcN2CoPrwDXTy8sCPbe1rqNrJf1c5mBp7KaOSN3XkYdDww+v9DXe+O8HwTozn70eoOgPsUJrz63nkif927K44ODg59xXeeOsr4P0WJur6hI/1xHj+tZG9de/D1OLUtHcbwDtcdvWuysom/shY2UeYyE5I5BPSsjSkIcY6V0URAI5rmkz1YO0TL8P7nvF8wEqEOQf8+tTaoGS+ZVU4kA2gVsWyRozFEVS3UgdakcjGaZLk+YzdQi82zaHjcVwGPr61k6TFOty0k8bJtXA3evtW7NyKrgZOKkuOxY+IYI0LToI3VWFtGWLNgYLbjXmxRUOZGVyOir0/E/4V6N8WI8SJEhVdnlKATjICdvzrzgAI2XIfuVGSPxNdC0SPLw7vC/c6iwE5sdOD5MknmYB9DgqPyArI1yJo9Yfy1jeO4RZwHx1IwevuDXRaXbTGzt9xIlj53Hsxy388D8Kj8V2cN+EWyZPtqr58cP8RVvvRj3yCQK35bxOZVlGsjknilXOYGX6DNTaC4OuadkFSLqPgjB+8KpoQwzkD2PWtnwbaNf+L9Itk5JuFdiOyryT+lYx3R3VXanJvsz6G/5Yjn8Kl84eVtxzTHBI4HTrTdyYORzXzTk09D5+10Nyd2an8xyMCmKhaMtjp0pYunUUQuvmErMTY2MkYFIDg5olcjIzxQq7oycik97RDpqWY3U4q9bY3jHSseL7/wBD61sW45X0Nd2Em5Mxqxsay0tIn3RS19THY85hRRRTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmTfcNPpk33DUz+FjW5j3qsORWc4Zj8xAz3NaN2wBztzWduCuTjn0r5TFW5z0ad7C+Wn8MgHtSIF3c7iPYU2R9xPGKcGkRQccH2rmvG+iNNbDz5G3dl29ulGdrD7qZ9OtQHk5bgVJGFJPG73JoUrvRA0JPEs6tC2XVwVbnsa8F1rwdqWk6jNFcbU05CSL48ps7cdS3QY7mvf1aPBHCj+dY3iLRYde0iewuHaON8FHX7ysDkEV2YbEexlZ6p/ga0K0qT0PD9Nv2iv4ILEywWcbebKA3zMqjLFyOvA6dBnHvWyFHinRSbi5gt9SS5Zbfd8ofcAfL/wDr+3vU2r+C9Q8O6LdNDnULm5kWFjbxH93D1PHXJIUH0Fc6+l6gugxy/ZLnm7cbfKbcMIvOMZx15r2o1FJaO6O793N88HZ3tf8AruXtN0HVkv4lvLNURHG55lVgAPQ9fpW18SwYbfw3ZOcSKk1w656biAP5H8q6nwHFfXujwtrKmNoWOWk4bywOC2eh6/hXnHifWF17xPeaimTbZEVvu/55rwD+JyfxoqWjsKhUlXra2tHtsWtJYdst9BWzGTnkY+prn7W7EcfFWI7uaU/uY3kPooJrkZ7Smkjoo3Cj7woklB7isqO01mVcxaXfMPaB/wDCnnTNfAydIv8A/vw3+FVZ9jF1oX3LUjccEH8ajVyOSrfXrVG5S/tl/wBJsrqL/fiZf5iorbUNrAOCKlo3hUTO38faQutx2zKxUOiyq6ruKnHcdxXBpo+kabdRLeXkl5cPIqKkSAKpJ/i5Of8APWvRFt4fFfg5bZZWSeEeWWQ8jHKn3GMcexrgX8F6zYWN5dyRefNEu23W3O/IJwz+xAzgdfyrrjKNk2eBGbpuVGUrW6frcfHqbyzawtpIEtoIMxkKM5LBd2fcZNY13JJe6PFqIbM0En2e4x6nlGP1yfxq34c0q/l0/Wx9lmjkkgVYhIhXewJbAz14FafgTw7qr3d4t7pdymnXduY5PNTaGOQVx3z157Vo3spaXG5UqXNKLV42+atr+vzOc03+z9W1OGDVY51muHWNbm2ba248DeCMN9ev1r2jwZ4V0/w1E8trG/2uQDfNK29wPQHt+FUvBngWx0O8N6xa6vBnyjNgiIewH8XvXXyLu3FcK2eV7fhXk4vFtx5ab9fM58RWVSVoN8vb/gD2uJcYY7vdqQOmR5kS/UcVHLKWUKRgimu2UCjk15bqO+ruYKPkWjMudqjj2NRkxZyyMPoaiify2+YdqSaQSOCOlDq3V2ChZ2RYVYSCcH8TUDKM/K/B9eKHbc3y9x2o3krt280pST0sNJ7kkUDBgcg+wNaturblyDWVAw80KT8orXt2O8AdK78Eo30MKzfU01+6KWgdKK+nWx54UUUUwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApk/8AqzT6bICUIHWpkrpoa3MW/IC8dazwyrnI5PrWhe294eY7fd9GFUWtb4cmzlLeu5a+ZxGHrObai/uPSp25d196GMV+UMfqRT1AYfKzlR7YqJor3obKYD/ZUUCO7HAs7nHptrnVCqnrFmvLpuvvQoID/OCaa7fMSvApxgvHORYz7vfAp4tL9sZs3I9C6il9VrPRRf3Bot2vvREQVUMeh7U8uvlgL971qVdP1Bj/AMeqL/vyjj8qmXSL9x8z20WfQFjWsMBXeyJc4dZL7/8AIqEsFL7hn+dKd4O5hzjqe1aEegnIM10x9kQD/GrqaTZiMpJCJlP3hKdwP1HSuqjlVST/AHmhlLEU47O55D4v1PUNfkk0HwjbS3KyHbeXcK4U9igfpj1OfYd6seGfg85jSTX7zyv+mFtgn8WPH5CvYoo0hjWOJFSNRhVUYAHsKfXsU8LCKSYnmM4x5aS5fzOd0zwX4e05VEGl27Mv8cy+Yx/Fs1vQwRQLtgijjX0RQP5VJRXQoqOyOKdWc9ZtsKKKKogCARg9KytQ8PaPqAP2zTbWUn+IxgH8xzWrRSaT3KjOUHeLschb+BrTTb03Wi3E1qWGGgc742H48j65qS7hnsiwlj2qf41GVP8AhXV0da5K+Cp1lbY6VjKjd6mv5/ecbGYpUCqsZYdDkcVYYBVIcEED5TW5c6TZXBJeBQx7p8p/SqEnh4A/6Ndyxj0Ybv8ACvLnldSPw6/18vzNlXpS62/r+uhSZD5ImjJDEfMtQ5BUljk1dbR9TXHlXsTAdNwIqFtK1QHJFs/44/pXLUwFa+kTWMofzojhdmXG4ceozSKVZjkAfSnSafqxOTBEf91gKPsWqYCmyiIH+0P8aj6nX2cX9zK93pJfehIgHLD5cZ4yKcNrI67FDD070i2GpnraRD6OP8acNP1UZCwwr7lhTjgq3WP4P/IT5f5l96GRqqgkMQ1Kzs33gSB1xUo0fU35eS3T9f6VMuh3hHz34X2SOrjl9d6JaCc6a1cl+P8AkVUCtKNin8q2LRSGFQQ6Cqtulu53PtgVowWUMJBUMT6k5r0MJgJ03zSOatVg1aLuWR0ooAxRXsnEFHeiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coloplasty is created by initially making a longitudinal colotomy proximal to the distal end of the colon (A), which is then widened by applying tension laterally (B). The longitudinal opening is then closed in a transverse fashion (C) and then anastomosed to the anus (D) resulting in the formation of a neorectal reservoir.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33939=[""].join("\n");
var outline_f33_9_33939=null;
var title_f33_9_33940="Banana sign";
var content_f33_9_33940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The \"banana\" sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cerebellum as it herniates through the foramen magnum takes up the shape of a banana (arrows). When both the lemon and banana signs are seen together, an open spinal defect is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33940=[""].join("\n");
var outline_f33_9_33940=null;
var title_f33_9_33941="Complications of urinary bladder catheters and preventive strategies";
var content_f33_9_33941=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of urinary bladder catheters and preventive strategies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33941/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33941/contributors\">",
"     Anthony J Schaeffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33941/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33941/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33941/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33941/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/9/33941/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary bladder catheters are used for urinary drainage or as a means to collect urine for measurement. Many clinical situations are appropriate for the placement of indwelling urethral catheters (",
"    <a class=\"graphic graphic_table graphicRef76684 \" href=\"mobipreview.htm?4/10/4269\">",
"     table 1",
"    </a>",
"    ), but too frequently they are used without proper indication or continued longer than needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/1\">",
"     1",
"    </a>",
"    ]. Daily evaluation of the ongoing need for the indwelling catheters with removal when no longer indicated is essential to reduce complications.",
"   </p>",
"   <p>",
"    This topic will discuss the complications associated with urinary catheter use. The indications for placement, types, and the management of urinary catheters are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"     \"Placement and management of urinary bladder catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bacteriuria and urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of bacteria in the urine is almost universal in patients with catheters in place for over one week. Rates vary depending upon the type of catheter and duration of use. The evaluation of bacteriuria and diagnosis of catheter-associated urinary tract infection is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinary tract infection associated with urethral catheters\", section on 'Asymptomatic bacteriuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=see_link&amp;anchor=H7#H7\">",
"     \"Urinary tract infection associated with urethral catheters\", section on 'Urinary tract infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent urinary tract infections as a result of chronic catheter use can lead to acute or chronic pyelonephritis, or bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=see_link\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40409?source=see_link\">",
"     \"Nonurothelial bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Epididymitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral instrumentation of any type can cause epididymitis which may rarely disseminate to the testes as orchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=see_link\">",
"     \"Evaluation of the acute scrotum in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Retained balloon fragments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spontaneous rupture of the urinary catheter balloon can occur. If the catheter spontaneously falls out, the integrity of the balloon should be examined carefully for any missing material. If balloon fragments cannot be located, cystoscopy should be performed to identify fragments retained in the bladder as these have the potential to cause urethral obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Balloon rupture can occur spontaneously, but also from the attempt to bluntly rupture or overdistend a balloon that will not deflate; this practice is not advised. Sharp balloon puncture to manage a non-deflating balloon (ie, percutaneous spinal needle) was not found to be associated with retained balloon fragments in one experimental study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H30#H30\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Troubleshooting catheter removal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bladder fistula",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of air or feces in the urine of a patient with an indwelling catheter may indicate the formation of a fistula. Fistulas can occur between the bladder and small intestine, colon, rectum, or vagina (ie, enterovesical, colovesical, rectovesical, and vesicovaginal). They are an uncommon complication of indwelling bladder catheters and more likely to occur in the setting of prolonged catheterization with risk factors that include malignancy, inflammation, radiotherapy or trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bladder perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder perforation, both intraperitoneal and extraperitoneal, is rare but has been reported with long-term indwelling catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Hematuria and abdominal pain may indicate acute perforation; free air is seen only with intraperitoneal perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bladder stone formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stones can form in the bladder due to the presence of a foreign body. Bacteria that are urea-splitting (ie, Proteus mirabilis) are frequently associated with stone formation. The type of catheter may influence stone formation; however, there are no data to support the use of one catheter material (ie, latex, silicon) over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS SPECIFIC TO TYPE OF CATHETER",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Condom catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most complications related to condom catheter usage are due to improper or prolonged application, and inadequate monitoring of the device when in place. Most complications are minor and self limited; however, significant penile injury resulting in scarring and deformity can occur.",
"   </p>",
"   <p>",
"    Patients with penile skin sensory loss (ie, spinal injury patients) are at the highest risk for more severe complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/9\">",
"     9",
"    </a>",
"    ]. Instruction of the patient, relatives, and medical personnel on the proper application of the condom device is essential in preventing associated complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H17#H17\">",
"     \"Placement and management of urinary bladder catheters\", section on 'External catheter placement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pressure effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin depigmentation can occur but is more likely in patients with underlying dermatologic conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=see_link\">",
"     \"Vitiligo\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Constrictive effects of the condom catheter's adhesive band or roller ring can lead to superficial ulceration. Reapplication exacerbates the ulcer and can prevent healing. The condom catheter should be temporarily discontinued and a catheter (intermittent or indwelling) used until the site is healed.",
"   </p>",
"   <p>",
"    Prolonged continuous pressure of the penis from an improperly placed condom catheter can cause tissue ischemia which may lead to penile",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urethral necrosis. Treatment with surgical debridement is necessary to remove devitalized tissue, and reconstruction with skin grafts to the penis may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urethral catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical catheter problems such as leakage, blockage, and catheter rejection can frustrate and annoy both patient and clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/10\">",
"     10",
"    </a>",
"    ]. Knowledge of catheter technology and routine catheter care can help reduce mechanical problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H11#H11\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Catheter technology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H22#H22\">",
"     \"Placement and management of urinary bladder catheters\", section on 'Catheter care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Effects of urethral trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic urethral catheter placement can lead to urethral injury. The presence of pain and bleeding following attempted catheter insertion, and subsequent inability to pass the catheter into the bladder suggests that a false urethral passage may have been created. Such injuries usually require significant reconstructive surgery.",
"   </p>",
"   <p>",
"    Inflammation and infection of the periurethral soft tissues may create an abscess as a consequence of the creation of a false passage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/11\">",
"     11",
"    </a>",
"    ]. If the abscess is not visible on physical examination, diagnosis may be delayed and the infection can spread into surrounding tissues. Urethrocutaneous fistulae may result as the infection tracks to the skin. Fournier's gangrene has been reported as a consequence of urethral catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=see_link\">",
"     \"Evaluation of the acute scrotum in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stricture associated with urethral catheterization occurs almost exclusively in male patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/11\">",
"     11",
"    </a>",
"    ]. Repeated urethral trauma from intermittent catheterization can cause urethral stricture formation, which in turn increases the likelihood of traumatic catheterization. The incidence of urethral stricture increases with duration of chronic catheterization; most have developed following at least five years of intermittent catheterization (IC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review found urethral stricture in 3.7 percent of 230 men with a history of indwelling catheter usage; chronic changes of the urethra were documented in nearly one-third of the patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incontinence can occur due to catheterization and is also related to urethral sphincter dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=see_link\">",
"     \"Clinical presentation and diagnosis of urinary incontinence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Suprapubic catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;When performed properly, complications from suprapubic catheter placement are uncommon. Complications associated with initial placement include cutaneous or bladder bleeding and bowel injury, which is more common if suprapubic catheter placement is attempted when the bladder is not fully distended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term complications include skin erosion and problems with chronic leakage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PREVENTION OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate urinary catheter implementation and management can reduce the incidence of complications. The most effective strategies to reduce infectious complications of urinary catheters are avoidance of unnecessary catheterization, and catheter removal when the catheter is no longer indicated. Adherence to a protocol for indwelling catheter placement, care, and removal can reduce the incidence of urinary tract infection and other complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33941/abstract/1,17\">",
"     1,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measures which help prevent complications associated with urinary catheters include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of urinary catheters only for appropriate indications (",
"      <a class=\"graphic graphic_table graphicRef76684 \" href=\"mobipreview.htm?4/10/4269\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H2#H2\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Indications for catheterization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Considering alternatives to indwelling urethral catheters. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H5#H5\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Choice of catheter'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Provision of adequate training to medical staff, patients, and other caregivers on catheter placement and management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link\">",
"       \"Placement and management of urinary bladder catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Removal of catheters when no longer indicated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H22#H22\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Catheter care'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Not routinely replacing urethral catheters. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H22#H22\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Catheter care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific measures to prevent catheter-associated urinary tract infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using a continuously closed drainage system. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H11#H11\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Catheter technology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Not routinely irrigating catheters; catheters are irrigated only under select circumstances. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=see_link&amp;anchor=H22#H22\">",
"       \"Placement and management of urinary bladder catheters\", section on 'Catheter care'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most effective strategy to reduce complications of urinary bladder catheters is the avoidance of unnecessary catheterization. When urinary bladder catheters are required, adequate training of the patient, hospital personnel, and caregivers is essential to avoid complications related to placement, ensure proper care, and to promptly recognize and treat complications expeditiously when they do occur. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Prevention of complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common complication of urinary bladder catheters is catheter-associated urinary tract infection. In males, urinary infection can lead to epididymitis or orchitis. Other rare complications of indwelling catheters include urinary tract obstruction from retained balloon fragments, bladder fistula, bladder perforation, or bladder stone formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improper or prolonged application of condom catheters can cause pressure-related complications including skin depigmentation, ulceration, or penile necrosis. These complications are more frequent in patients with penile sensory loss and can be prevented with proper application of the device and frequent patient monitoring. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Condom catheters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The traumatic insertion of urethral catheters can create a false passage which may, if infected, lead to periurethral abscess. This complication is more frequent in patients with prior urethral stricture and can result in significant soft tissue infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Effects of urethral trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term complications associated with chronic urethral catheters (indwelling or intermittent) include urethral stricture and incontinence (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Urethral catheters'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      When properly placed, complications from the placement of suprapubic catheters are uncommon. Inadvertent bowel injury can occur during percutaneous suprapubic catheter placement if the bladder is not fully distended, or the needle is not visualized with cystoscopy when performing the procedure in patients with prior pelvic surgery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Suprapubic catheters'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/1\">",
"      Hooten, TM, Bradley, SF, Cardenas, DD, et al. Diagnosis, prevention and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society. Clinical Infectious Diseases 2010; 50:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/2\">",
"      Igawa Y, Wyndaele JJ, Nishizawa O. Catheterization: possible complications and their prevention and treatment. Int J Urol 2008; 15:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/3\">",
"      G&uuml;lmez I, Ekmekcioglu O, Karacagil M. A comparison of various methods to burst Foley catheter balloons and the risk of free-fragment formation. Br J Urol 1996; 77:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/4\">",
"      Daneshmand S, Youssefzadeh D, Skinner EC. Review of techniques to remove a Foley catheter when the balloon does not deflate. Urology 2002; 59:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/5\">",
"      Hawary, A, Clarke, L, Taylor, A, et al. Enterovesical fistula: a rare complication of urethral catheterization. Adv Urol 2009; 59:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/6\">",
"      Merguerian PA, Erturk E, Hulbert WC Jr, et al. Peritonitis and abdominal free air due to intraperitoneal bladder perforation associated with indwelling urethral catheter drainage. J Urol 1985; 134:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/7\">",
"      Farraye MJ, Seaberg D. Indwelling foley catheter causing extraperitoneal bladder perforation. Am J Emerg Med 2000; 18:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/8\">",
"      Spees EK, O'Mara C, Murphy JB, et al. Unsuspected intraperitoneal perforation of the urinary bladder as an iatrogenic disorder. Surgery 1981; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/9\">",
"      Jayachandran S, Mooppan UM, Kim H. Complications from external (condom) urinary drainage devices. Urology 1985; 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/10\">",
"      Belfield PW. Urinary catheters. Br Med J (Clin Res Ed) 1988; 296:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/11\">",
"      Pannek J, G&ouml;cking K, Bersch U. Perineal abscess formation as a complication of intermittent self-catheterization. Spinal Cord 2008; 46:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/12\">",
"      Conn IG, Lewi HJ. Fournier's gangrene of the scrotum following traumatic urethral catheterisation. J R Coll Surg Edinb 1987; 32:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/13\">",
"      Wyndaele JJ, Maes D. Clean intermittent self-catheterization: a 12-year followup. J Urol 1990; 143:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/14\">",
"      Perrouin-Verbe B, Labat JJ, Richard I, et al. Clean intermittent catheterisation from the acute period in spinal cord injury patients. Long term evaluation of urethral and genital tolerance. Paraplegia 1995; 33:619.",
"     </a>",
"    </li>",
"    <li>",
"     Gunther, M, Lochne, ED, Kramer, G, Stohrer, M. Intermittent catheterization in male neurogenics: No harm to the urethra. Abstract poster 93 presented during Annual Scientific Meeting of IMSOP, Sydney, Australia 2000. Abstract book p. 112.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/16\">",
"      Farina LA, Palou J. Re: Suprapubic catheterisation and bowel injury. Br J Urol 1993; 72:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33941/abstract/17\">",
"      St&eacute;phan F, Sax H, Wachsmuth M, et al. Reduction of urinary tract infection and antibiotic use after surgery: a controlled, prospective, before-after intervention study. Clin Infect Dis 2006; 42:1544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8095 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-1FFB8D27E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33941=[""].join("\n");
var outline_f33_9_33941=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bacteriuria and urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Epididymitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Retained balloon fragments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bladder fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bladder perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bladder stone formation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS SPECIFIC TO TYPE OF CATHETER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Condom catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pressure effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Effects of urethral trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Suprapubic catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PREVENTION OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/10/4269\" title=\"table 1\">",
"      Indications for urinary bladder catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/14/29929?source=related_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44360?source=related_link\">",
"      Evaluation of the acute scrotum in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40409?source=related_link\">",
"      Nonurothelial bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/24/44422?source=related_link\">",
"      Urinary tract infection associated with urethral catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21193?source=related_link\">",
"      Vitiligo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_9_33942="Stavudine: Pediatric drug information";
var content_f33_9_33942=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Stavudine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"    see \"Stavudine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/12/32965?source=see_link\">",
"    see \"Stavudine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zerit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zerit&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with other antiretroviral agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PNA 0-13 days: Oral: 0.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PNA &ge;14 days: Oral: 1 mg/kg/dose every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"      see \"Stavudine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with other antiretroviral agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &lt;30 kg: Oral: 1 mg/kg/dose every 12 hours; maximum dose: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;30 kg, Adolescents, and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     30-59 kg: 30 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;60 kg: 40 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The World Health Organization recommends 30 mg every 12 hours in all adult and adolescent patients regardless of body weight (DHHS, [adult], 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing  adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants, Children, and Adolescents: Insufficient data exists to recommend a specific dosage adjustment; however, a decrease in the dose should be considered in pediatric patients with renal impairment. The following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight &lt;30 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 0.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 0.25 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis or peritoneal dialysis: 0.25 mg/kg/dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Continuous renal replacement therapy (CRRT): 0.5 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight 30-59 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: 15 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 7.5 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis or peritoneal dialysis: 7.5 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Continuous renal replacement therapy (CRRT): 15 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight &lt;60 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     26-50 mL/minute: 15 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute: 15 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis: 15 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Weight &ge;60 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     26-50 mL/minute: 20 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute: 20 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Hemodialysis: 20 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 15 mg, 20 mg, 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zerit&reg;: 15 mg, 20 mg, 30 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral: 1 mg/mL (200 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zerit&reg;: 1 mg/mL (200 mL) [dye free; contains sucrose 50 mg/mL; fruit flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11370380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM238427.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM238427.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with or without food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Reconstitute with purified water to a final concentration of 1 mg/mL; shake well during reconstitution to ensure complete powder dissolution; shake well before using",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in a tightly closed container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Store intact bottle of powder at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from moisture. Dispense reconstituted solution in original container; store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); solution is stable for 30 days; discard any unused portion after that time.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in all ages).",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zerit&reg; may be confused with Zestril&reg;, Ziac&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F223067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported below represent experience with combination therapy with other nucleoside analogues and protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased, GGT increased, hyperbilirubinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Amylase increased, lipase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, allergic reaction, anemia, anorexia, chills, diabetes mellitus, fever, hepatic failure, hepatitis, hepatomegaly (with steatosis; some fatal), hyperglycemia, hyperlactatemia (symptomatic), hyperlipidemia, immune reconstitution syndrome, insomnia, insulin resistance, lactic acidosis (some fatal), leukopenia, macrocytosis, myalgia, neuromuscular weakness (severe-resembling Guillain-Barr&eacute;), neutropenia, pancreatitis (some fatal), redistribution/accumulation/atrophy of body fat, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to stavudine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with a history of peripheral neuropathy, or hepatic or renal impairment; dosage adjustment required in patients with impaired renal function. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave's disease, Guillain-Barr&eacute; syndrome, polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral solution contains sucrose (50 mg/mL); diabetic patients should be counseled.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The major clinical toxicity of stavudine is peripheral neuropathy which has occurred in 8% to 21% of patients in controlled trials; it can be dose-limiting and occurs more frequently in patients with a history of neuropathy, advanced HIV, and in patients receiving other drugs known to cause neuropathy (eg, didanosine). Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of NRTIs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; it may be more common with antiretroviral regimens containing stavudine. Risk may be increased in obesity, prolonged nucleoside exposure, prior liver disease, or in female patients. Increased risk of hepatotoxicity also occurs with combined use of stavudine with didanosine and hydroxyurea (avoid this combination). Fatal lactic acidosis has occurred in pregnant women who received stavudine plus didanosine with other antiretroviral agents; use stavudine plus didanosine with caution during pregnancy (and in other patients) and only if benefit clearly outweighs risks. Severe motor weakness (resembling Guillain-Barr&eacute; syndrome) has been reported, usually in association with lactic acidosis. Manufacturer recommends prompt suspension of all antiretroviral therapy in suspected cases of symptomatic hyperlactatemia, lactic acidosis (with or without neuromuscular weakness), or pronounced hepatotoxicity; signs and symptoms of symptomatic hyperlactemia or lactic acidosis syndrome may include generalized fatigue, GI symptoms (nausea, vomiting, abdominal pain, unexplained weight loss), respiratory symptoms (tachypnea, dyspnea), or neurologic symptoms (motor weakness, Guillain-Barr&eacute;-type syndrome).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal and nonfatal pancreatitis has occurred during combination antiretroviral therapy which included stavudine and didanosine",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid the use of stavudine with didanosine; discontinue these drugs (and any other drugs that are toxic to the pancreas) if pancreatitis is suspected; use extreme caution and closely monitor patient if stavudine is restarted in patients with confirmed pancreatitis; the new medication regimen should",
"     <b>",
"      not",
"     </b>",
"     contain didanosine.",
"     <b>",
"      Note:",
"     </b>",
"     The incidence of stavudine-associated toxicities may be increased when stavudine is used in combination with other medications that have similar toxicities. An increased risk of pancreatitis and hepatotoxicity (either of which may be fatal) and severe peripheral neuropathy may occur when patients are treated with stavudine in combination with didanosine (with or without hydroxyurea). The combined use of stavudine and hydroxyurea (with or without didanosine) should be avoided. According to AIDS",
"     <i>",
"      info",
"     </i>",
"     guidelines, the combined use of stavudine and didanosine is",
"     <b>",
"      not",
"     </b>",
"     recommended for use in adults and adolescents (DHHS [adult], 2013) and is not recommended as part of an initial antiretroviral regimen in pediatric patients; however, it may be considered for use in pediatric salvage regimens if the potential benefit clearly outweighs the risks (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Safety and efficacy have not been established in patients with significant liver disease; patients with liver impairment, including chronic active hepatitis, may be at increased risk for liver function abnormalities, including hepatic adverse events that may be severe and potentially fatal; monitor patients carefully; if liver function worsens, consider interruption or discontinuation of therapy. Concomitant use of combination antiretroviral therapy with interferon alfa (with or without ribavirin) has resulted in hepatic decompensation (with some fatalities) in patients coinfected with HIV and HCV; monitor patients closely, especially for hepatic decompensation, neutropenia, and anemia; consider discontinuation of stavudine if needed; consider dose reduction or discontinuation of interferon alfa, ribavirin, or both if clinical toxicities, including hepatic decompensation, worsen. Use of stavudine with zidovudine is",
"     <b>",
"      not",
"     </b>",
"     recommended due to antagonistic effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F222991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Stavudine may enhance the adverse/toxic effect of Didanosine. Lactic acidosis (possibly fatal) is of particular concern.  Management: Use extreme caution and monitor for lactic acidosis with concomitant stavudine and didanosine therapy. Avoid use of stavudine and didanosine (in combination or alone) with hydroxyurea due to increased risk of serious toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: May diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin (Liposomal): May diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydroxyurea: May enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: May diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F223007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Stavudine crosses the placenta. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Pharmacokinetics of stavudine are not significantly altered during pregnancy; dose adjustments are not needed. Cases of lactic acidosis/hepatic steatosis syndrome related to mitochondrial toxicity have been reported in pregnant women with prolonged use of nucleoside analogues. It is not known if pregnancy itself potentiates this known side effect; however, women may be at increased risk of lactic acidosis and liver damage. In addition, these adverse events are similar to other rare but life-threatening syndromes which occur during pregnancy (eg, HELLP syndrome). Combination treatment with didanosine may also contribute to the risk of lactic acidosis, and should be considered only if benefit outweighs risk. Hepatic enzymes and electrolytes should be monitored in women receiving nucleoside analogues and clinicians should watch for early signs of the syndrome. In addition, mitochondrial dysfunction may develop in infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure.  The DHHS Perinatal HIV Guidelines recommend stavudine to be used only in special circumstances during pregnancy; do not use with didanosine or zidovudine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Prior  to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections peripheral neuropathy, pancreatitis, hepatotoxicity, or lactic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antiviral activity is dependent on intracellular conversion of stavudine to the active metabolite d4-triphosphate; Inhibits replication of retroviruses by competing with thymidine triphosphate for viral RNA-directed DNA polymerase and incorporation into viral DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetrates into the CSF achieving 16% to 97% (mean: 59%) of concomitant plasma concentrations; distributes into extravascular spaces and equally between RBCs and plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.73 &plusmn; 0.32 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 46 &plusmn; 21 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Negligible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted intracellularly to active triphosphate form; metabolism of stavudine plays minimal role in its clearance; minor metabolites include oxidized stavudine and its glucuronide conjugate, glucuronide conjugate of stavudine, N-acetylcysteine conjugate of the ribose after glycosidic cleavage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Capsule and solution are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 77%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns (at birth): 5.3 &plusmn; 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates 14-28 days old: 1.6 &plusmn; 0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients 5 weeks to 15 years: 0.9 &plusmn; 0.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.6 &plusmn; 0.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Half-life is prolonged with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, intracellular: Adults: 3.5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine: 95% of dose (74% as unchanged drug); feces: 3% (62% as unchanged drug); undergoes glomerular filtration and active tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 31 &plusmn; 5% of the dose is removed by hemodialysis; hemodialysis clearance (n=12) (mean &plusmn; SD): 120 &plusmn; 18 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/12/32965?source=see_link\">",
"      see \"Stavudine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stavudine is not a cure for HIV. Take stavudine every day as prescribed; do not change dose or discontinue without physician's advice. If a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Avoid alcohol. Notify physician if tingling, burning, pain, numbness of hands or feet, unexplained weight loss, abdominal discomfort, nausea, vomiting, fatigue, dyspnea, or motor weakness occurs",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/9/33942/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kline MW, Dunkle LM, Church JA, et al, &ldquo;A Phase I/II Evaluation of Stavudine (d4T) in Children With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Pediatrics,",
"      </i>",
"      1995, 96(2 Pt 1):247-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/9/33942/abstract-text/7630678/pubmed\" id=\"7630678\" target=\"_blank\">",
"        7630678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13003 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-33503A3141-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33942=[""].join("\n");
var outline_f33_9_33942=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709417\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223021\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223022\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055485\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445114\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055478\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222997\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222982\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11370380\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055489\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055481\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055488\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223069\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223067\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055492\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055477\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055476\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300080\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222991\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222993\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223007\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055484\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055475\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055491\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055483\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13003|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=related_link\">",
"      Stavudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/12/32965?source=related_link\">",
"      Stavudine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_9_33943="Pathologic stage T3 and margin positive prostate cancer";
var content_f33_9_33943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathologic stage T3 and margin positive prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     John F Ward, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Brian Davis, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33943/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/9/33943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is increasingly diagnosed in younger men and at an earlier disease stage, when the tumor is confined to the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, some men with early stage disease (cT1 or cT2) who are managed with radical prostatectomy will have histopathologic extension beyond the prostate (pT3), positive margins upon examination of the surgical specimen, or microscopic lymph node involvement (",
"    <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"mobipreview.htm?38/23/39294\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The management of patients with pathologic T3 or margin positive prostate cancer following radical prostatectomy will be reviewed here. The management of patients with lymph node involvement is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link&amp;anchor=H32353885#H32353885\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'Clinical evidence of lymph node involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOLOGIC VERSUS CLINICAL STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AJCC",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    UICC system is used to stage newly diagnosed prostate cancer (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"mobipreview.htm?40/19/41277\">",
"     table 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"mobipreview.htm?10/43/10941\">",
"     table 1B",
"    </a>",
"    ). This system incorporates the anatomic extent of disease, including the primary tumor (T), regional lymph nodes (N), and distant metastases (M). In addition, the baseline serum prostate specific antigen (PSA) and the Gleason score are incorporated to divide patients into prognostic categories (",
"    <a class=\"graphic graphic_table graphicRef81673 \" href=\"mobipreview.htm?3/33/3612\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=see_link&amp;anchor=H686719716#H686719716\">",
"     \"Initial staging and evaluation of men with newly diagnosed prostate cancer\", section on 'Clinical versus pathologic staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pretreatment evaluation provides the information for the clinical (&ldquo;c&rdquo;) stage, which forms the basis for the initial treatment decisions, along with patient age, overall medical condition, and the presence or absence of symptoms. For patients whose initial treatment includes radical prostatectomy, additional information is obtained from the histopathologic examination of the prostatectomy specimen, and this forms the basis for the pathologic (&ldquo;p&rdquo;) stage.",
"   </p>",
"   <p>",
"    Clinical staging may underestimate or overestimate the anatomic extent of disease. Patients with cT1 or cT2 N0 disease may be reclassified as pT3, pT4, or N1 based upon these results. Conversely, patients thought to have more extensive cT3 disease may be reclassified pT2. If surgical margins are positive for tumor (residual microscopic disease), staging is modified by an &ldquo;R1&rdquo; descriptor.",
"   </p>",
"   <p>",
"    Pathologic T3 disease is defined by presence of extraprostatic extension. Pathologic stage T3 is subdivided into pT3a, which includes extraprostatic extension, sometimes also called \"extracapsular\" extension, or microscopic invasion of the bladder neck, and pT3b, which includes those cases with seminal vesicle invasion. Invasion into the rectum, levator muscles,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pelvic wall is defined as pT4 disease.",
"   </p>",
"   <p>",
"    In addition to better defining the anatomic extent of disease, examination of the more extensive surgical prostatectomy specimen may result in an increase in the Gleason grade compared with the original biopsy specimen. This may result in reclassification of a patient into a higher risk group compared with the original clinical evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contemporary series, between 50 and 75 percent of men with pT3 disease will ultimately have biochemical relapse following radical prostatectomy (defined as a detectable serum PSA [&gt;0.2",
"    <span class=\"nowrap\">",
"     ng/mL])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     T3a versus T3b disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of disease recurrence appears to differ for men with pT3a compared to those with pT3b disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/7\">",
"     7",
"    </a>",
"    ]. With extraprostatic extension (pT3a), local control tends to be more of a problem, particularly in the presence of positive margins. In contrast, men with seminal vesicle invasion (pT3b) are at higher risk for distant disease recurrence, regardless of the status of the surgical margins. The effectiveness of adjuvant radiation therapy (RT) may differ in patients with pT3a and pT3b disease. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Adjuvant RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Positive margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of men with positive resection margins after radical prostatectomy is variable. Even when multiple positive margins are present, not all men recur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The risk of recurrence is illustrated by a single institution series of 1268 patients, in which 21 percent of cases had positive surgical margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At a median follow-up of over six years, the risk of biochemical recurrence was increased in all risk groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk (PSA&lt;10",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      Gleason score &le;6, T1-T2a) &ndash; the risk of recurrence in those with positive and negative margins was 5.1 and 0.4 percent, respectively.",
"     </li>",
"     <li>",
"      Intermediate risk (PSA 10-20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or Gleason score 7 or",
"      <span class=\"nowrap\">",
"       T2b/T2c)",
"      </span>",
"      &ndash; the risk of recurrence was 17 and 6.5 percent, respectively.",
"     </li>",
"     <li>",
"      High risk (PSA &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or Gleason score &ge;8 or",
"      <span class=\"nowrap\">",
"       T3/4)",
"      </span>",
"      &ndash; the risk of recurrence was 43 and 21.5 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On multivariate analysis, these differences were significant for those with intermediate and high-risk disease.",
"   </p>",
"   <p>",
"    The frequency of recurrence is also affected by the number and location of positive margins. In another series of 1667 evaluable men who underwent radical prostatectomy, the three-year frequency of biochemical recurrence was 5.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/10\">",
"     10",
"    </a>",
"    ]. Among those with a solitary positive apical margin, a solitary positive non-apical margin, and multiple positive margins, the three-year rates of biochemical recurrence were 13.0, 18.6, and 27.0 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H255203697\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several approaches have been studied as ways to improve the prognosis for men with pathologic T3 or margin positive disease following radical prostatectomy. Adjuvant external beam radiation therapy (RT) has been shown to improve the prognosis. However, clinical trials have not established that immediate adjuvant RT is superior to close surveillance and salvage therapy; this issue is being further studied in a phase III trial (RTOG 0534, NCT00567580) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"     \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant RT decreases the risk of biochemical relapse, but it requires administering RT to some patients who would otherwise never require treatment. In contrast, postoperative surveillance without treatment followed by salvage RT at the first evidence of a rising serum PSA entails the risk that distant metastases might develop in some men who would have been rendered disease-free with immediate adjuvant RT.",
"   </p>",
"   <p>",
"    Extended follow-up from large clinical trials provides evidence that adjuvant RT is well tolerated and that it improves the biochemical and local control rates in men who are found to have pT3 disease or diffusely positive resection margins at RP. There is also increasing evidence that postoperative RT improves metastasis-free and overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative RT in men with pT3 or margin-positive disease has been compared with observation in several randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. The results of the two largest trials with extended follow-up illustrate the outcomes with this approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EORTC trial 22911 randomly assigned 1005 men with pT3 disease or positive margins following radical prostatectomy to postoperative external beam RT (60 Gy) to the surgical bed or to observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/15\">",
"       15",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      At a median follow-up of 10.6 years, 198 of 502 men (39.4 percent) who received adjuvant RT had biochemical or clinical progression, compared with 311 of 503 (61.8 percent) managed with a wait and see policy (HR 0.49, 95% CI 0.41-0.59). The 10-year incidence of locoregional failure was significantly decreased with adjuvant RT (7.0 versus 16.5 percent, HR 0.45, 95% CI 0.32-0.68).",
"     </li>",
"     <li>",
"      Postoperative RT significantly improved progression-free survival in those with positive surgical margins (HR 0.69, 95% CI 0.53-0.91), but not in those with negative surgical margins (HR 1.06, 95% CI 0.76-1.55).",
"     </li>",
"     <li>",
"      However, there was no significant difference in the 10-year overall survival (77 versus 81 percent for the RT and observation arms, HR 1.18, 95%CI 0.91-1.53) or in the incidence of prostate cancer mortality (3.9 versus 5.4 percent, HR 0.78, 95% CI 0.46-1.33).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Southwest Oncology Group (SWOG) trial 8794, 425 men with pT3 or margin-positive prostate cancer were randomly assigned to immediate RT (60 to 64 Gy) or observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12,16\">",
"       12,16",
"      </a>",
"      ]. At a longer median follow-up than the EORTC trial (12.6 years), adjuvant RT significantly improved both metastasis-free and overall survival compared to observation (median 14.7 versus 12.9 years, hazard ratio [HR] 0.71, 95% CI 0.54-0.94 and median 15.2 versus 13.3 years, HR 0.72, 95% CI 0.55-0.96) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Subset analyses found that the benefits in metastasis-free and overall survival were independent of the Gleason score and included men with either detectable or undetectable post-prostatectomy PSA levels and those with positive margins or seminal vesicle involvement. Adverse effects were more common in men receiving adjuvant RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12\">",
"       12",
"      </a>",
"      ]. These included rectal complications (3.3 versus 0 percent without adjuvant RT), urethral strictures (17.8 versus 9.5 percent) and total urinary incontinence (6.5 versus 2.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In this trial, only one-third of the patients originally assigned to observation received salvage RT at the time of a biochemical recurrence, and these results cannot be used to compare a strategy of adjuvant RT with observation followed by salvage RT at the first sign of PSA recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the EORTC 22911 and SWOG 8794 trials were initiated before the widespread use of sensitive assays to detect PSA recurrence, and patients in the observation group had no further treatment until clinical relapse. Current practice often involves salvage RT at the first sign of biochemical relapse (PSA &gt;0.10), and these trials thus did not adequately address the question of whether early salvage therapy is as effective as immediate adjuvant therapy.",
"   </p>",
"   <p>",
"    Several retrospective single-institution studies have analyzed the impact of salvage RT on survival in patients with a biochemical recurrence following radical prostatectomy. Although salvage RT decreases the incidence of local recurrence following biochemical relapse, the impact on survival remains uncertain. These studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link&amp;anchor=H6#H6\">",
"     \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\", section on 'Impact on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these results, our practice is to suggest adjuvant RT based upon risk factors. For patients choosing not to receive postoperative RT, we recommend careful monitoring for evidence of a biochemical recurrence, followed by salvage RT at the earliest evidence of relapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"     \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of radiation in the adjuvant setting has not been determined in randomized trials. In the EORTC 22911 and SWOG 8794 trials, the dose of radiation was 60 to 64 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12,17\">",
"     12,17",
"    </a>",
"    ]. At least one observational study, which included 334 men who received adjuvant RT following radical prostatectomy and a negative lymph node dissection, found improved biochemical relapse-free survival when doses greater than 70 Gy were used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/18\">",
"     18",
"    </a>",
"    ]. However, the applicability of this observation is limited by nonrandomized design of this study and the improvements in RT techniques during the study period.",
"   </p>",
"   <p>",
"    Our practice is to recommend a dose of 60 to 64 Gy in the adjuvant setting. This radiation dose is consistent with the results of both large adjuvant RT trials. Additional trials will be required before higher doses can be recommended. If higher doses are employed, radiation treatment planning should assure that dose to normal adjacent structures is well within tolerance doses. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Concurrent ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from randomized trials established the benefit of combining external beam RT and ADT for men undergoing RT as primary treatment for cT3 prostate cancer as well as for those with lower-stage but \"high-risk\" disease (ie, Gleason score 8 to 10, PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    In these settings, RT plus ADT therapy has become the standard of care. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=see_link&amp;anchor=H2956464#H2956464\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\", section on 'External beam RT plus ADT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of combining ADT with adjuvant RT is uncertain following radical prostatectomy that identifies pathologic T3 or margin positive disease. Two ongoing trials from the Radiation Therapy Oncology Group may provide additional information about the use of concurrent ADT in this situation and in men with a rising PSA following a prior radical prostatectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RTOG 9601 &ndash; In RTOG 9601, 771 men with an elevated serum PSA following radical prostatectomy were randomly assigned to RT alone or RT plus the antiandrogen",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"       bicalutamide",
"      </a>",
"      (150",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. All patients had pathologic T3N0 or pathologic T2N0R1 (margin positive) prostate cancer (",
"      <a class=\"graphic graphic_table graphicRef75565 graphicRef67222 \" href=\"mobipreview.htm?38/23/39294\">",
"       table 1A-B",
"      </a>",
"      ). Interim results were presented at the ASTRO meeting in 2010 and the ASCO Genitourinary Oncology symposium in 2011.",
"      <br/>",
"      <br/>",
"      At a median follow-up of seven years in surviving patients, there was a statistically significant improvement in freedom from PSA progression with adjuvant bicalutamide compared with RT alone (57 versus 40 percent; p&lt;0.0001) and a decrease in the incidence of metastatic disease (7 versus 13 percent; p&lt; 0.04). There was no statistically significant difference in the actuarial rates of overall survival at seven years (91 and 86 percent, respectively). All patients developed gynecomastia, which was symptomatic in most cases. Interpretation of the trial is difficult, since the patient population included both patients with a residual elevation of serum PSA following radical prostatectomy and those with a PSA that subsequently rose. Furthermore, there were too few deaths to permit a statistical comparison of overall survival; definitive conclusions about the impact on survival will require longer follow-up.",
"     </li>",
"     <li>",
"      RTOG 0534 &ndash; In RTOG 0534, men with a serum PSA &ge;0.2 and &lt;2.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at least six weeks after radical prostatectomy are being randomly assigned to RT to the prostate bed only, RT to the prostate bed with neoadjuvant and concurrent ADT, or RT to the prostate bed and pelvic lymph nodes with neoadjuvant and concurrent ADT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of data, we do not recommend using ADT in conjunction with adjuvant RT following prostatectomy except in the context of a clinical trial. For men with pT3 disease who refuse or are ineligible for a clinical trial, and who understand and accept the risks of long term ADT, this approach could be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ultrasensitive PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of PSA with an ultrasensitive PSA assay (&le;0.05",
"    <span class=\"nowrap\">",
"     ng/ml)",
"    </span>",
"    following radical prostatectomy appears to correlate with biochemical failure, but we do not recommend its use to determine who should undergo adjuvant RT. In a series of 525 men from a single institution, those with an undetectable ultrasensitive PSA immediately following radical prostatectomy were less likely to have biochemical failure at five years (14 versus 33 percent in those with a detectable PSA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adjuvant hormone therapy without RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data about the role of adjuvant hormone therapy without RT after radical prostatectomy for patients who are found to have pT3 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uncertain role of adjuvant hormone therapy without RT is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective, nonrandomized cohort of men who underwent radical prostatectomy for pathologic node negative prostate cancer at the Mayo Clinic between 1990 and 1999, 580 men received adjuvant ADT while 1160 were managed expectantly without adjuvant ADT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/22\">",
"       22",
"      </a>",
"      ]. Overall, approximately 55 percent of the men had a T3 or T4 primary tumor. Of those managed without adjuvant therapy, 343 (30 percent) subsequently received ADT for either a biochemical or systemic recurrence.",
"      <br/>",
"      <br/>",
"      Adjuvant ADT was associated with statistically significant improved rates of 10-year biochemical and systemic progression-free survival compared to delayed treatment (95 versus 90 and 98 versus 95 percent, respectively). However, there was no improvement in overall survival (84 versus 83 percent).",
"     </li>",
"     <li>",
"      The addition of high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"       bicalutamide",
"      </a>",
"      monotherapy (150 mg daily) to watchful waiting, radical prostatectomy, or RT was extensively evaluated in the Early Prostate Cancer program in 8113 men with localized (T1, T2) or locally advanced (T3, T4) nonmetastatic prostate cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/23\">",
"       23",
"      </a>",
"      ]. At a median follow-up of 10 years, treatment with bicalutamide was associated with a statistically significant improvement in progression-free survival in men with locally advanced (T3, T4) disease regardless of the initial management approach. However, there was no statistically significant difference in overall survival in these patients. The results in the 2734 men with locally advanced prostate cancer managed initially with radical prostatectomy also showed a statistically significant benefit in progression-free survival but not overall survival. The dose of bicalutamide used in these trials (150 mg daily) was three times the approved dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We reserve high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    (150 mg daily) as an alternative to adjuvant RT for a very select population of sexually active young men who have preserved erectile function after radical prostatectomy for high-risk completely resected disease (eg, Gleason score &ge;7, pT3b), who are aware of the risk of gynecomastia, and who wish to avoid RT. These men derive less benefit from adjuvant RT than those with extraprostatic extension (pT3a) because of their high rates of systemic relapse. Although no study has adequately examined the necessary length of adjuvant hormone therapy, the empiric recommendation is for a total of two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy does not have an established role in men with pathologic stage T3 or margin positive prostate cancer following radical prostatectomy. Before adjuvant chemotherapy can be recommended for patients with high-risk prostate cancer, an understanding of the effects of adjuvant chemotherapy on disease progression and overall survival is required, along with information about acute and late side effects.",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and other agents in men with systemic metastases has led to the evaluation of adjuvant chemotherapy in men with resected prostate cancer who are at high-risk for relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Multiple large randomized trials are in progress to determine whether this approach can improve long-term outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential importance of late toxicity was illustrated by a report from the Southwest Oncology Group (SWOG) trial 9921 in which patients with high-risk prostate cancer who had undergone radical prostatectomy were randomly assigned to two years of ADT with or without six cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/24\">",
"     24",
"    </a>",
"    ]. The trial was terminated after 983 of the planned 1360 patients were enrolled, when acute myeloid leukemia was observed in at least three patients who had received mitoxantrone. A subsequent update of this trial found that the five-year biochemical relapse-free survival rate was 93 percent for the two treatment arms, and there was no significant difference between those arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33943/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SWOG considered a follow-up trial in which patients would be randomly assigned to either one or two years of adjuvant hormone therapy. However, the trial would require nearly 20,000 patients and a follow-up of 23 years to detect a 10 percent difference in the two arms. Such a trial is not feasible, and two years of adjuvant hormone therapy after definitive surgery with or without adjuvant radiation therapy remains the de facto standard of care. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Adjuvant hormone therapy without RT'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Persistently elevated PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of early rather than deferred ADT in conjunction with RT for men who have a persistently detectable serum PSA level following radical prostatectomy for pT3 disease is unclear. Although most of these men have occult metastatic disease and are commonly started on continuous ADT, RT can cure a small but consistent fraction of these men. The role of salvage RT after radical prostatectomy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"     \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4111337\">",
"    <span class=\"h1\">",
"     SURVEILLANCE AFTER TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies after treatment for localized prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=see_link&amp;anchor=H7449313#H7449313\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Localized prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large randomized clinical trials in patients with pT3 and margin positive prostate cancer have demonstrated that adjuvant RT significantly improves biochemical relapse-free survival (RFS) and metastasis RFS. However, these trials have yielded conflicting results regarding the impact on overall survival. Whether these benefits apply to all patients with pT3 disease or only to those with positive surgical margins is uncertain. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These trials compared adjuvant RT to a treatment strategy of observation, in which salvage RT was not uniformly administered if a biochemical recurrence was observed. Whether or not adjuvant RT offers a benefit in terms of metastasis-free and overall survival compared to salvage RT given at the first evidence of a biochemical recurrence remains uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with positive surgical margins or pathologic stage T3 disease, we suggest adjuvant external beam RT following radical prostatectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients choosing not to receive postoperative RT, we recommend careful monitoring for evidence of a biochemical recurrence, followed by salvage RT at the earliest evidence of relapse (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Adjuvant RT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Patients with positive surgical margins or other evidence of extraprostatic extension should be informed about the metastasis-free and overall survival advantage observed with postoperative RT in the SWOG 8794 trial and the uncertainty of whether salvage RT can produce a comparable improvement in metastasis-free and overall survival.",
"     </li>",
"     <li>",
"      Whether there is benefit from adding ADT to adjuvant RT after surgery for pT3 prostate cancer is unknown, and ADT should be considered only in the context of a clinical trial. For men with pT3 disease who refuse or are ineligible for a clinical trial, and who understand and accept the risks, concurrent ADT could be considered. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Concurrent ADT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/1\">",
"      Roach M 3rd, Weinberg V, Sandler H, Thompson I. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer 2007; 109:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/2\">",
"      Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008; 101:1513.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on September 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/4\">",
"      Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/5\">",
"      Eggener SE, Roehl KA, Smith ND, et al. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy. J Urol 2005; 173:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/6\">",
"      Salomon L, Anastasiadis AG, Johnson CW, et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 2003; 62:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/7\">",
"      Kasibhatla M, Peterson B, Anscher MS. What is the best postoperative treatment for patients with pT3bN0M0 adenocarcinoma of the prostate? Prostate Cancer Prostatic Dis 2005; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/8\">",
"      Alkhateeb S, Alibhai S, Fleshner N, et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol 2010; 183:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/9\">",
"      Simon MA, Kim S, Soloway MS. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol 2006; 175:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/10\">",
"      Kordan Y, Salem S, Chang SS, et al. Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. J Urol 2009; 182:2695.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on July 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/12\">",
"      Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/13\">",
"      Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27:2924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/14\">",
"      Morgan SC, Waldron TS, Eapen L, et al. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/15\">",
"      Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380:2018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/16\">",
"      Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/17\">",
"      Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/18\">",
"      Cozzarini C, Montorsi F, Fiorino C, et al. Need for high radiation dose (&gt;or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 2009; 75:966.",
"     </a>",
"    </li>",
"    <li>",
"     Shipley WU, Hunt D, Lukka H, et al. Initial report of RTOG 9601: A phase III trial in prostate cancer: Anti-androgen therapy with bicalutamide during and after radiation therapy improves freedom from progression and reduces the incidence of metastatic disease in patients following radical prostatectomy with pT2-3, N0 disease, and elevated PSA levels (abstract). Int J Radiat Biol Phys 2010.",
"    </li>",
"    <li>",
"     Shipley WU, Hunt D, Lukka HR, et al. Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels (abstract #1). J Clin Oncol 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/21\">",
"      Eisenberg ML, Davies BJ, Cooperberg MR, et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010; 57:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/22\">",
"      Siddiqui SA, Boorjian SA, Inman B, et al. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 2008; 179:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/23\">",
"      Iversen P, McLeod DG, See WA, et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010; 105:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/24\">",
"      Flaig TW, Tangen CM, Hussain MH, et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008; 26:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/25\">",
"      Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007; 177:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Fizazi, K, Lesaunier, F, Delva, R, et al. A phase III trial of docetaxel-estramustine in high-risk localized prostate cancer (GETUG 12 trial): Design, tolerance, response, and quality of life (abstract #7). American Society of Clinical Oncology (ASCO) 2010 Genitourinary Cancers Sympsoium 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33943/abstract/27\">",
"      Dorff TB, Flaig TW, Tangen CM, et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011; 29:2040.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6934 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33943=[""].join("\n");
var outline_f33_9_33943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOLOGIC VERSUS CLINICAL STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      T3a versus T3b disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Positive margins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H255203697\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Radiation dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Concurrent ADT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ultrasensitive PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adjuvant hormone therapy without RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Persistently elevated PSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4111337\">",
"      SURVEILLANCE AFTER TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6934\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6934|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/19/41277\" title=\"table 1A\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/43/10941\" title=\"table 1B\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/33/3612\" title=\"table 2\">",
"      Pretreat risk stratify prost CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/62/23527?source=related_link\">",
"      Initial staging and evaluation of men with newly diagnosed prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_9_33944="Egg allergy: Clinical features and diagnosis";
var content_f33_9_33944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Egg allergy: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33944/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33944/contributors\">",
"     Julie Wang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33944/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33944/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/9/33944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hen's egg allergy is the second most common food allergy in infants and young children (milk is the most common) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Egg allergies are immunologic responses to proteins in foods, and include IgE antibody-mediated allergy as well as other allergic syndromes such as atopic dermatitis and eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, and diagnosis of egg allergy are presented in this topic review. Management of egg allergy is discussed separately. General discussions of food allergy are presented separately in appropriate topic reviews. The options for administration of the influenza vaccine in patients with egg allergy are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13223?source=see_link\">",
"     \"Egg allergy: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of egg allergy confirmed by oral challenge was 1.6 percent of children 3 years of age in an unselected population in Denmark [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/7\">",
"     7",
"    </a>",
"    ]. A subsequent meta-analysis of the prevalence of food allergy estimated that egg allergy affects 0.5 to 2.5 percent of young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/8\">",
"     8",
"    </a>",
"    ]. There were several limitations to the meta-analysis. There was significant variability in study design that made direct comparisons difficult. The majority of studies included in the meta-analysis were based upon self-reports of food allergy, which tend to overestimate the prevalence. Some studies used skin prick test and food-specific IgE levels to confirm sensitization to the allergen. However, only three studies used double-blind, placebo-controlled food challenges, the gold standard, to confirm the diagnosis of food allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. In these three studies of unselected populations, the prevalence of egg allergy ranged from 0.0004 percent in a cohort of German children aged zero to 17 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/9\">",
"     9",
"    </a>",
"    ], to 0.6 percent in nursery school children in Mexico [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/10\">",
"     10",
"    </a>",
"    ], to 1.6 percent in 3 year old Danish children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five major allergenic proteins from the egg of the domestic chicken (Gallus domesticus) have been identified that are responsible for IgE-mediated reactions; these are designated Gal d 1-5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of the allergenic egg proteins are found in egg white, including ovomucoid (Gal d 1), ovalbumin (Gal d 2), ovotransferrin (Gal d 3), lysozyme (Gal d 4), and ovomucin. Ovomucoid is the dominant allergen in egg, although ovalbumin is the most abundant protein comprising hen's egg white. Chicken serum albumin, or alpha-livetin (Gal d 5), is the major allergen in egg yolk, and is involved in the bird-egg syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=see_link\">",
"     \"Pathogenesis of food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=see_link\">",
"     \"Molecular features of food allergens\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link\">",
"     \"Food allergens: Overview of clinical features and cross-reactivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Egg specific IgE molecules that identify sequential or conformational epitopes can distinguish different clinical phenotypes of egg allergy. Sequential epitopes are determined by contiguous amino acids, whereas conformational epitopes contain amino acids from different regions of the protein that are in close proximity due to the folding of the protein. Conformational epitopes can be destroyed by heating or partial hydrolysis, which alter the tertiary structure of the protein.",
"   </p>",
"   <p>",
"    Studies have found that the majority of egg allergic individuals can tolerate extensively heated or baked egg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Heating denatures proteins, thus eliminating conformational epitopes. In addition, results from a murine study suggest that heating may reduce allergenicity of ovalbumin and ovomucoid by altering digestion and absorption of these proteins in the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/18\">",
"     18",
"    </a>",
"    ]. One study demonstrated that continued ingestion of extensively heated egg was associated with decreased median skin test wheal diameters (6 to 5 mm) and increased ovalbumin-specific and ovomucoid-specific IgG4 levels (O.4 to 4.6",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    and 0.1 to 0.6",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    respectively) in egg allergic children who tolerated heated forms of egg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/17\">",
"     17",
"    </a>",
"    ]. Ovalbumin epitopes are heat labile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/19\">",
"     19",
"    </a>",
"    ], but ovomucoid epitopes are not altered by extensive heating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/20\">",
"     20",
"    </a>",
"    ], suggesting that children who have specific IgE primarily to ovalbumin are likely to tolerate heated forms of egg. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=see_link\">",
"     \"Molecular features of food allergens\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of IgE specific to particular egg proteins may indicate a higher likelihood of persistent allergy. In one small study, children with persistent egg allergy had significantly higher specific IgE levels to ovomucoid than children who outgrow their egg allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/21\">",
"     21",
"    </a>",
"    ]. In another small study, children with persistent egg allergy had higher levels of specific IgE to ovomucoid and ovalbumin compared with those who had transient egg allergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/22\">",
"     22",
"    </a>",
"    ]. Seven patients with persistent egg allergy had IgE that recognized four sequential epitopes of ovomucoid. In contrast, none of the 11 children with transient egg allergy had specific IgE to these epitopes, indicating that binding of these specific sequential epitopes may be a marker for persistent egg allergy.",
"   </p>",
"   <p>",
"    Breakdown of proteins by gastric enzymes and the low pH of the stomach can alter the allergenicity of food proteins. Gastric digestion has been demonstrated to reduce the allergenicity of ovomucoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/23\">",
"     23",
"    </a>",
"    ], which can explain why some patients have skin contact reactions to egg, but not ingestion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of non-IgE mediated egg allergy is less clear. Egg allergy has been implicated as a trigger for atopic dermatitis and allergic eosinophilic esophagitis. Enteropathy induced by egg is rare. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mixed and non IgE-mediated reactions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE-mediated allergic reactions are the most common type of allergic reactions to egg. IgE-mediated reactions are rapid in onset (usually within minutes to two hours after ingestion), and symptoms such as urticaria, angioedema, respiratory symptoms, and laryngeal edema, are common. The severity of symptoms can range from mild to life threatening anaphylaxis. The clinical features of IgE-mediated reactions are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children can demonstrate symptoms of egg allergy starting in infancy, with most suffering from cutaneous symptoms. The development of sensitization in these patients is postulated to occur in utero [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/25\">",
"     25",
"    </a>",
"    ] or via exposure to maternal breastmilk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/26\">",
"     26",
"    </a>",
"    ]. For some children, the first known direct ingestion of egg can result in an allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/27\">",
"     27",
"    </a>",
"    ], supporting the idea that sensitization can occur early through the mother. Mouse models suggest that sensitization may also occur via epicutaneous exposure (prior to gut mucosa exposure) and may play a role in the development of atopic dermatitis and asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cutaneous symptoms are most common, gastrointestinal and respiratory symptoms are reported as well. The severity of reactions can be unpredictable and vary from episode to episode. Egg allergy is potentially life-threatening. Anaphylaxis can occur with exposure to egg, and asthmatics, in particular, are at high risk for severe allergic reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Egg accounted for seven percent of severe anaphylactic reactions in infants and children in a German survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/33\">",
"     33",
"    </a>",
"    ]. Fatal reactions to egg are rare, but have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=see_link\">",
"     \"Food-induced anaphylaxis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Egg allergy is associated with other IgE-mediated allergies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational asthma is reported in bakery workers who are frequently exposed to aerosolized egg and in people who work in egg-processing factories. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"       \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38776?source=see_link\">",
"       \"Respiratory manifestations of food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bird-egg syndrome is a condition where the primary sensitization is to airborne bird allergens and there is secondary sensitization or crossreactivity with albumin in egg yolk (Gal d 5). These patients experience respiratory symptoms (rhinitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      asthma) with bird exposure and allergic symptoms with egg ingestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/12,35\">",
"       12,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Food-dependent, exercise-induced anaphylaxis with egg as the trigger has been reported. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26777?source=see_link\">",
"       \"Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mixed and non IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg can trigger non-IgE-mediated and mixed IgE and non IgE-mediated reactions. Disorders that fall into these categories include atopic dermatitis and the eosinophilic gastroenteropathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Atopic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Egg allergy can present as infantile atopic dermatitis (eczema). A close association was found between early-onset, moderate-to-severe eczema and egg sensitization in an international multicenter study of children with atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/6\">",
"     6",
"    </a>",
"    ]. Eczema onset after 12 months of age was not associated with food allergy. However, sensitization is not equivalent to clinical allergy. A small randomized trial of egg avoidance in children with egg sensitization and atopic dermatitis demonstrated that egg elimination decreases the extent and severity of eczema, indicating that egg sensitization was clinically relevant in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of asthma was 80 percent in a small cohort of children with both egg allergy and atopic dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/37\">",
"     37",
"    </a>",
"    ]. If such patients develop asthma, they are at increased risk for more severe allergic reactions to foods.",
"   </p>",
"   <p>",
"    Some children with atopic dermatitis experience delayed flares one to two days after ingesting egg. These delayed reactions are not IgE-mediated, but instead are likely due to T-cell mediated mechanisms. Elimination of egg from the diet leads to improvement of skin symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Gastrointestinal reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic eosinophilic esophagitis (AEE or EoE) is an inflammatory disorder characterized by high numbers of intraepithelial eosinophils in the esophagus and is mediated by mixed IgE and non-IgE mediated processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In a series of over 500 patients diagnosed with AEE, egg was found to be the second most common allergen triggering symptoms, confirmed on endoscopy after allergy testing (prick skin testing and patch testing) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/42\">",
"     42",
"    </a>",
"    ]. Elimination of food triggers has been found to be an effective treatment for AEE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=see_link&amp;anchor=H12#H12\">",
"     \"Future diagnostic tools for food allergy\", section on 'Atopy patch testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Food protein-induced enteropathy due to egg has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/43\">",
"     43",
"    </a>",
"    ]. A five month old boy developed protein-losing enteropathy and resultant hypogammaglobulinemia due to egg exposure through maternal breastmilk. Maternal elimination of egg led to resolution of symptoms, and reintroduction of egg into the maternal diet caused recurrence of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Natural course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tolerance is achieved by the majority of children with egg allergy. An early report indicated that most children become tolerant by school-age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a more recent study suggested that egg allergy is more persistent, with children outgrowing egg allergy in adolescence (68 percent by 16 years of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/45\">",
"     45",
"    </a>",
"    ]. Whether these differing results are due to population differences or a change in the natural history of egg allergy is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"     \"The natural history of childhood food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several prognostic indicators for the development of tolerance to egg have been identified. These include lower level of egg-specific IgE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/46\">",
"     46",
"    </a>",
"    ], faster rate of decline of egg-specific IgE level over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/46\">",
"     46",
"    </a>",
"    ], earlier age at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/46\">",
"     46",
"    </a>",
"    ], milder symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/17,44\">",
"     17,44",
"    </a>",
"    ], smaller skin test wheal sizes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/47\">",
"     47",
"    </a>",
"    ], and tolerance to extensively heated egg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/17,48\">",
"     17,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A general discussion of the diagnosis of food allergy is presented elsewhere. A summary of this information, with a focus on those aspects that are most relevant to the diagnosis of egg allergy, is provided below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With the exception of in vitro immunoassays for specific IgE (which are still commonly referred to as IgE RAST tests), other diagnostic allergy procedures, including skin testing and food challenges, should be performed by allergy specialists with training in the management of serious allergic reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     IgE-mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history of an immediate reaction consisting of typical allergic symptoms, supported by positive tests for specific IgE antibodies, is sufficient to establish the diagnosis for suspected IgE-mediated reactions. Either skin prick tests or in vitro tests for IgE are usually performed initially. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"     \"Diagnostic evaluation of food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Double-blind, placebo-controlled oral food challenges (DBPCFC) are the gold standard for the diagnosis of food allergy. A physician-supervised oral food challenge is required if the history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IgE test results do not clearly indicate an allergy. The use of challenges in the diagnosis of food allergy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=see_link\">",
"     \"Oral food challenges for diagnosis and management of food allergies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The skin prick test wheal size and level of specific IgE correlate with the likelihood of an allergic reaction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies using the ImmunoCAP (Phadia, Uppsala, Sweden) have demonstrated that an IgE level of 7",
"      <span class=\"nowrap\">",
"       kU/L",
"      </span>",
"      to egg has a 95 percent positive predictive value (PPV) for clinical reactivity to egg for children over 2 years of age; for children two years or under, a level of 2",
"      <span class=\"nowrap\">",
"       kU/L",
"      </span>",
"      has a 95 percent PPV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/49-52\">",
"       49-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar analyses have been performed for skin testing; a wheal size of 7 mm has a 95 percent PPV for children over two years of age; for children two years or under, a 5 mm wheal has a 95 percent PPV for egg allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with skin prick or IgE results above these levels have at least a 95 percent chance of experiencing an allergic reaction with ingestion of egg, therefore, they are presumed to be clinically reactive, and oral food challenges are avoided in these cases.",
"   </p>",
"   <p>",
"    Skin test results may help guide the decision to challenge or continue avoidance in children with low serum egg-white specific IgE. In one retrospective series, children who passed an egg challenge had a median skin prick test wheal of 3 mm, compared with a median wheal of 5 mm in children who failed the challenge, although there was significant overlap between the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both skin prick testing and measurement of specific IgE levels also have high negative predictive values (91 percent for skin prick test &lt;3 mm, 86 percent for specific IgE &lt;0.35",
"    <span class=\"nowrap\">",
"     kU/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/52\">",
"     52",
"    </a>",
"    ]. Predictive values are much more dependent upon the population prevalence of the disease than sensitivity and specificity. Thus, these results may not apply to other populations, such as adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=see_link&amp;anchor=H20#H20\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Predictive values'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these tests provide an indication of likelihood of clinical reactivity to egg, neither is able to predict the severity of allergic reactions that may occur with each individual nor the natural history of the allergy. However, the rate of decline of specific IgE levels over time is a prognostic indicator for the development of tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of suspected occupational asthma due to egg allergy, which is also IgE-mediated, involves skin prick testing, pulmonary function testing, and possible bronchoprovocation challenge. Occupational asthma is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;IgE tests are expected to be negative if the symptoms do not suggest an IgE-mediated reaction, such as some cases of atopic dermatitis or allergic gastrointestinal disorders. Atopy patch testing may provide additional information in these cases. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mixed and non IgE-mediated reactions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=see_link\">",
"     \"Role of allergy in atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=see_link&amp;anchor=H12#H12\">",
"     \"Future diagnostic tools for food allergy\", section on 'Atopy patch testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnostic pitfalls",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several factors that can make the diagnosis of egg allergy challenging:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of undetectable IgE levels to egg (&lt;0.35",
"      <span class=\"nowrap\">",
"       kU/L)",
"      </span>",
"      does not exclude clinical reactivity to egg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/49,50,52\">",
"       49,50,52",
"      </a>",
"      ]. The rate of positive food challenges to egg in those with egg white-specific IgE levels &lt;0.35",
"      <span class=\"nowrap\">",
"       kU/L",
"      </span>",
"      ranges from approximately 10 percent to 33 percent.",
"     </li>",
"     <li>",
"      Heat treatment and digestion can also reduce the potential allergenicity of egg allergen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33944/abstract/19,20,23,24\">",
"       19,20,23,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p>",
"    Gastrointestinal symptoms, such and vomiting and diarrhea, occurring after ingestion of undercooked egg can be due to food poisoning, such as salmonella or campylobacter infection, rather than allergy. Onset of symptoms is 8 to 72 hours after exposure, unlike food allergy reactions that usually occur within minutes to a few hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16426?source=see_link\">",
"     \"Food poisoning in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allergies to foods other than egg should also be considered in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=see_link\">",
"     \"History and physical examination in the patient with possible food allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"       \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"       \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Egg is one of the most common food allergens in childhood. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients outgrow their egg allergy by adolescence. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Natural course'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=see_link\">",
"       \"The natural history of childhood food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Five major allergenic proteins in egg are responsible for IgE-mediated reactions. Ovomucoid (Gal d 1) is the dominant allergen in egg white. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Manifestations of IgE-mediated egg allergy include",
"      <span class=\"nowrap\">",
"       urticaria/angioedema/anaphylaxis,",
"      </span>",
"      atopic dermatitis, and occupational asthma. IgE-mediated egg allergy can be severe, but most children tend to outgrow this allergy. There are also mixed or non-IgE mediated forms of allergy that present with delayed skin or gastrointestinal reactions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of IgE-mediated egg allergy is based upon a careful history supported by skin prick tests and in vitro tests for egg-specific IgE. An oral food challenge is warranted if the diagnosis of egg allergy is uncertain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic food-specific IgE levels and skin test wheal sizes have been defined from limited studies in children, above which there is a greater than 95 percent likelihood of clinical reactivity to egg. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/1\">",
"      Sicherer SH, Sampson HA. 9. Food allergy. J Allergy Clin Immunol 2006; 117:S470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/2\">",
"      Eggesb&oslash; M, Botten G, Halvorsen R, Magnus P. The prevalence of allergy to egg: a population-based study in young children. Allergy 2001; 56:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/3\">",
"      Sampson HA. Role of immediate food hypersensitivity in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1983; 71:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/4\">",
"      Sampson HA, McCaskill CC. Food hypersensitivity and atopic dermatitis: evaluation of 113 patients. J Pediatr 1985; 107:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/5\">",
"      Sampson HA, Scanlon SM. Natural history of food hypersensitivity in children with atopic dermatitis. J Pediatr 1989; 115:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/6\">",
"      Hill DJ, Hosking CS, de Benedictis FM, et al. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy 2008; 38:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/7\">",
"      Osterballe M, Hansen TK, Mortz CG, et al. The prevalence of food hypersensitivity in an unselected population of children and adults. Pediatr Allergy Immunol 2005; 16:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/8\">",
"      Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol 2007; 120:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/9\">",
"      Roehr CC, Edenharter G, Reimann S, et al. Food allergy and non-allergic food hypersensitivity in children and adolescents. Clin Exp Allergy 2004; 34:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/10\">",
"      Madrigal BI, Alfaro AN, Jim&eacute;nez CC, Gonz&aacute;lez GJ. [Adverse reactions to food in daycare children]. Rev Alerg Mex 1996; 43:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/11\">",
"      Heine RG, Laske N, Hill DJ. The diagnosis and management of egg allergy. Curr Allergy Asthma Rep 2006; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/12\">",
"      Sz&eacute;pfalusi Z, Ebner C, Pandjaitan R, et al. Egg yolk alpha-livetin (chicken serum albumin) is a cross-reactive allergen in the bird-egg syndrome. J Allergy Clin Immunol 1994; 93:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/13\">",
"      Quirce S, Mara&ntilde;&oacute;n F, Umpi&eacute;rrez A, et al. Chicken serum albumin (Gal d 5*) is a partially heat-labile inhalant and food allergen implicated in the bird-egg syndrome. Allergy 2001; 56:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/14\">",
"      Urisu A, Ando H, Morita Y, et al. Allergenic activity of heated and ovomucoid-depleted egg white. J Allergy Clin Immunol 1997; 100:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/15\">",
"      Des Roches A, Nguyen M, Paradis L, et al. Tolerance to cooked egg in an egg allergic population. Allergy 2006; 61:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/16\">",
"      Konstantinou GN, Giavi S, Kalobatsou A, et al. Consumption of heat-treated egg by children allergic or sensitized to egg can affect the natural course of egg allergy: hypothesis-generating observations. J Allergy Clin Immunol 2008; 122:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/17\">",
"      Lemon-Mul&eacute; H, Sampson HA, Sicherer SH, et al. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol 2008; 122:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/18\">",
"      Martos G, Lopez-Exposito I, Bencharitiwong R, et al. Mechanisms underlying differential food allergy response to heated egg. J Allergy Clin Immunol 2011; 127:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/19\">",
"      Joo K, Kato Y. Assessment of allergenic activity of a heat-coagulated ovalbumin after in vivo digestion. Biosci Biotechnol Biochem 2006; 70:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/20\">",
"      DEUTSCH HF, MORTON JI. Immunochemical properties of heated ovomucoid. Arch Biochem Biophys 1956; 64:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/21\">",
"      Bernhisel-Broadbent J, Dintzis HM, Dintzis RZ, Sampson HA. Allergenicity and antigenicity of chicken egg ovomucoid (Gal d III) compared with ovalbumin (Gal d I) in children with egg allergy and in mice. J Allergy Clin Immunol 1994; 93:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/22\">",
"      J&auml;rvinen KM, Beyer K, Vila L, et al. Specificity of IgE antibodies to sequential epitopes of hen's egg ovomucoid as a marker for persistence of egg allergy. Allergy 2007; 62:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/23\">",
"      Takagi K, Teshima R, Okunuki H, et al. Kinetic analysis of pepsin digestion of chicken egg white ovomucoid and allergenic potential of pepsin fragments. Int Arch Allergy Immunol 2005; 136:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/24\">",
"      Yamada K, Urisu A, Haga Y, et al. A case retaining contact urticaria against egg white after gaining tolerance to ingestion. Acta Paediatr Jpn 1997; 39:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/25\">",
"      Vance GH, Grimshaw KE, Briggs R, et al. Serum ovalbumin-specific immunoglobulin G responses during pregnancy reflect maternal intake of dietary egg and relate to the development of allergy in early infancy. Clin Exp Allergy 2004; 34:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/26\">",
"      Palmer DJ, Gold MS, Makrides M. Effect of cooked and raw egg consumption on ovalbumin content of human milk: a randomized, double-blind, cross-over trial. Clin Exp Allergy 2005; 35:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/27\">",
"      de Boissieu D, Dupont C. Natural course of sensitization to hen's egg in children not previously exposed to egg ingestion. Eur Ann Allergy Clin Immunol 2006; 38:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/28\">",
"      Spergel JM, Mizoguchi E, Brewer JP, et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 1998; 101:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/29\">",
"      Oyoshi MK, Murphy GF, Geha RS. Filaggrin-deficient mice exhibit TH17-dominated skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol 2009; 124:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/30\">",
"      Colver AF, Nevantaus H, Macdougall CF, Cant AJ. Severe food-allergic reactions in children across the UK and Ireland, 1998-2000. Acta Paediatr 2005; 94:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/31\">",
"      Ross MP, Ferguson M, Street D, et al. Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System. J Allergy Clin Immunol 2008; 121:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/32\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/33\">",
"      Mehl A, Wahn U, Niggemann B. Anaphylactic reactions in children--a questionnaire-based survey in Germany. Allergy 2005; 60:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/34\">",
"      Macdougall CF, Cant AJ, Colver AF. How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across the UK and Ireland. Arch Dis Child 2002; 86:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/35\">",
"      Mandallaz MM, de Weck AL, Dahinden CA. Bird-egg syndrome. Cross-reactivity between bird antigens and egg-yolk livetins in IgE-mediated hypersensitivity. Int Arch Allergy Appl Immunol 1988; 87:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/36\">",
"      Lever R, MacDonald C, Waugh P, Aitchison T. Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs. Pediatr Allergy Immunol 1998; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/37\">",
"      Tariq SM, Matthews SM, Hakim EA, Arshad SH. Egg allergy in infancy predicts respiratory allergic disease by 4 years of age. Pediatr Allergy Immunol 2000; 11:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/38\">",
"      Kondo N, Fukutomi O, Agata H, et al. The role of T lymphocytes in patients with food-sensitive atopic dermatitis. J Allergy Clin Immunol 1993; 91:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/39\">",
"      Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/40\">",
"      Spergel JM, Beausoleil JL, Mascarenhas M, Liacouras CA. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002; 109:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/41\">",
"      Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004; 351:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/42\">",
"      Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr 2009; 48:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/43\">",
"      Kondo M, Fukao T, Omoya K, et al. Protein-losing enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol 2008; 18:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/44\">",
"      Ford RP, Taylor B. Natural history of egg hypersensitivity. Arch Dis Child 1982; 57:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/45\">",
"      Savage JH, Matsui EC, Skripak JM, Wood RA. The natural history of egg allergy. J Allergy Clin Immunol 2007; 120:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/46\">",
"      Shek LP, Soderstrom L, Ahlstedt S, et al. Determination of food specific IgE levels over time can predict the development of tolerance in cow's milk and hen's egg allergy. J Allergy Clin Immunol 2004; 114:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/47\">",
"      Boyano-Mart&iacute;nez T, Garc&iacute;a-Ara C, D&iacute;az-Pena JM, Mart&iacute;n-Esteban M. Prediction of tolerance on the basis of quantification of egg white-specific IgE antibodies in children with egg allergy. J Allergy Clin Immunol 2002; 110:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/48\">",
"      Clark A, Islam S, King Y, et al. A longitudinal study of resolution of allergy to well-cooked and uncooked egg. Clin Exp Allergy 2011; 41:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/49\">",
"      Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001; 107:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/50\">",
"      Perry TT, Matsui EC, Kay Conover-Walker M, Wood RA. The relationship of allergen-specific IgE levels and oral food challenge outcome. J Allergy Clin Immunol 2004; 114:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/51\">",
"      Boyano Mart&iacute;nez T, Garc&iacute;a-Ara C, D&iacute;az-Pena JM, et al. Validity of specific IgE antibodies in children with egg allergy. Clin Exp Allergy 2001; 31:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/52\">",
"      Caffarelli C, Cavagni G, Giordano S, et al. Relationship between oral challenges with previously uningested egg and egg-specific IgE antibodies and skin prick tests in infants with food allergy. J Allergy Clin Immunol 1995; 95:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/53\">",
"      Hill DJ, Heine RG, Hosking CS. The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol 2004; 15:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33944/abstract/54\">",
"      Knight AK, Shreffler WG, Sampson HA, et al. Skin prick test to egg white provides additional diagnostic utility to serum egg white-specific IgE antibody concentration in children. J Allergy Clin Immunol 2006; 117:842.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2409 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33944=[""].join("\n");
var outline_f33_9_33944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mixed and non IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Gastrointestinal reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Natural course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IgE-mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnostic pitfalls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13223?source=related_link\">",
"      Egg allergy: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26777?source=related_link\">",
"      Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/2/16426?source=related_link\">",
"      Food poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/0/38920?source=related_link\">",
"      Food-induced anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10585?source=related_link\">",
"      Future diagnostic tools for food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/17/26904?source=related_link\">",
"      History and physical examination in the patient with possible food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/56/23433?source=related_link\">",
"      Molecular features of food allergens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20409?source=related_link\">",
"      Oral food challenges for diagnosis and management of food allergies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/42/43689?source=related_link\">",
"      Pathogenesis of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=related_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=related_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38776?source=related_link\">",
"      Respiratory manifestations of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/59/26551?source=related_link\">",
"      Role of allergy in atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12746?source=related_link\">",
"      The natural history of childhood food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=related_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_9_33945="Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia";
var content_f33_9_33945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33945/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33945/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33945/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/9/33945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/9/33945/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/9/33945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H523774176\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapy can cause profound and sometimes prolonged neutropenia, which may result in hospitalization for treatment of fever or cause potentially fatal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although profound prolonged neutropenia is most likely in the pre-engraftment phase of hematopoietic cell transplantation (HCT, particularly allogeneic) and in patients undergoing induction therapy for acute leukemia, chemotherapy-related neutropenia can also occur in patients receiving standard-dose chemotherapy for other neoplasms. In an attempt to decrease infectious complications, recombinant human",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    and pegylated filgrastim) and granulocyte-macrophage colony-stimulating factor (GM-CSF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    ) have been used to reduce the duration and degree of neutropenia.",
"   </p>",
"   <p>",
"    The role of the granulocyte CSFs in patients receiving standard dose myelosuppressive chemotherapy for conditions other than acute leukemia or in patients undergoing HCT will be reviewed here. The role of granulocyte CSFs in patients undergoing induction chemotherapy for acute leukemia and in the setting of HCT is addressed elsewhere, as are the potential side effects of CSFs (eg, bone pain, risk of therapy-related myeloid neoplasms). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H20#H20\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of acute myeloid leukemia in older adults\", section on 'Use of growth factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=see_link&amp;anchor=H11#H11\">",
"     \"Introduction to recombinant hematopoietic growth factors\", section on 'Toxicity of colony-stimulating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of neutropenic fever syndromes; antibacterial, antifungal, and antiviral prophylaxis for patients undergoing myelosuppressive chemotherapy or induction therapy for acute leukemia or HCT; and the management of patients with neutropenic fever are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=see_link\">",
"     \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H20#H20\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774183\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774191\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although definitions are variable from institution to institution, neutropenia is defined as an absolute neutrophil count (ANC) of &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    within the next 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3\">",
"     3",
"    </a>",
"    ]. Profound neutropenia is defined as an ANC &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The ANC is equal to the product of the white blood cell count (WBC) and the fraction of polymorphonuclear cells (PMNs) and band forms:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;ANC = WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x percent (PMNs + bands) &divide; 100",
"   </p>",
"   <p>",
"    Neutrophilic metamyelocytes and younger forms are usually not included in this calculation (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The risk of clinically important infection rises as the neutrophil count falls below",
"    <span class=\"nowrap\">",
"     500/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms leukopenia and granulocytopenia are sometimes used interchangeably with neutropenia, although they are somewhat different. Leukopenia refers to a low total WBC, while granulocytopenia refers to a reduced number of all granulocytes (neutrophils, eosinophils, and basophils). Agranulocytosis literally means the absence of granulocytes, but the term is variably used in the literature to indicate very severe or profound neutropenia (ie, ANC",
"    <span class=\"nowrap\">",
"     &lt;100/microL,",
"    </span>",
"    or sometimes a value that is",
"    <span class=\"nowrap\">",
"     &lt;500/microL).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=see_link&amp;anchor=H1#H1\">",
"     \"Overview of neutropenia\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774198\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever in a neutropenic patient is usually defined as a single temperature &gt;38.3&ordm;C (101.3&ordm;F) or a temperature &gt;38&ordm;C (100.4&ordm;F) sustained for more than one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3\">",
"     3",
"    </a>",
"    ]. However, infection can occur in neutropenic patients and other immunocompromised patients in the absence of fever. This occurs more often in elderly patients and those receiving corticosteroids. Presenting signs of infection in such patients may include hypothermia, hypotension, confusion, or clinical deterioration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774205\">",
"    <span class=\"h1\">",
"     GRANULOCYTE COLONY STIMULATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte colony stimulating factors (CSFs), which are also known as myeloid growth factors, have been evaluated for prophylactic use following the administration of chemotherapy when neutropenia is anticipated (\"primary prophylaxis\"), during retreatment after a previous cycle of chemotherapy that caused neutropenic fever (\"secondary prophylaxis\"), and to shorten the duration of severe chemotherapy-induced neutropenia in patients who have neutropenia without fever (\"afebrile neutropenia&ldquo;). They are generally",
"    <strong>",
"     not",
"    </strong>",
"    recommended for routine use in patients with established fever and neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1183953\">",
"     'Therapeutic use in patients with neutropenia'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The likelihood of developing neutropenic fever in patients treated with a given chemotherapy regimen is the primary factor that determines whether or not prophylactic CSFs are indicated. The incidence of neutropenic fever following treatment is influenced by the intensity of chemotherapy, the presence and degree of injury to the gastrointestinal mucosa, the presence of underlying damage to the patient's hematopoietic stem cells, the concurrent use of radiation, and the overall clinical status of the patient (ie, age and comorbid conditions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774212\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prophylaxis refers to the use of granulocyte CSFs during the first cycle of myelosuppressive chemotherapy with the goal of preventing neutropenic complications. Primary prophylaxis may be used to decrease the incidence of neutropenic fever and the need for hospitalization. Primary prophylaxis may also be used to maintain dose-dense or dose-intense chemotherapy strategies that have survival benefits or if reductions in chemotherapy dose-intensity or dose-density are known to be associated with a poorer prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774219\">",
"    <span class=\"h3\">",
"     Indications, benefits, and guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 guidelines from the American Society of Clinical Oncology (ASCO), updated 2010 guidelines from the European Organization for Research and Treatment of Cancer (EORTC), updated 2010 guidelines from the Infectious Diseases Society of America (IDSA), and consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) all recommend primary prophylaxis when the anticipated incidence of neutropenic fever is approximately 20 percent or higher with a given regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Previous guidelines had recommended a cut-off of 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/7\">",
"     7",
"    </a>",
"    ]. The change in recommendation was driven by randomized trials showing that primary prophylaxis was cost effective when the risk of neutropenic fever with a specific regimen exceeded 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This benchmark may change, given the high cost of treatment for neutropenic fever, which typically involves hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence from multiple randomized trials and meta-analyses supports the benefit of primary prophylaxis in reducing the frequency of hospitalization for antibiotic therapy, documented infection, and rates of neutropenic fever in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. The impact on survival (both short-term and long-term) is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a systematic review of the literature and meta-analysis that included 3493 patients treated in 17 randomized controlled trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/11\">",
"       11",
"      </a>",
"      ], there was a 46 percent decrease in the risk of neutropenic fever (relative risk [RR] 0.54, 95% CI 0.43-0.67), a 45 percent decrease in infection-related mortality (RR 0.55, 95% CI 0.33-0.90), and a 40 percent decrease in all-cause mortality during the chemotherapy period (RR 0.60, 95% CI 0.43-0.87). This meta-analysis was not able to address the impact of primary prophylaxis on disease-free or overall survival.",
"     </li>",
"     <li>",
"      Another meta-analysis of 148 trials of CSF prophylaxis in patients with cancer or undergoing hematopoietic cell transplant also found a significant decrease in the rates of documented infections and neutropenic fever, but could not confirm a reduction in short-term all-cause mortality or infection-related death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential benefit of primary prophylaxis in children is even less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=see_link&amp;anchor=H2582454#H2582454\">",
"     \"Fever in children with chemotherapy-induced neutropenia\", section on 'Prophylactic use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Guidelines specifically recommend against the routine administration of granulocyte CSFs for primary prophylaxis in previously untreated adult patients receiving chemotherapy regimens with a low probability (&lt;10 percent) of causing fever during anticipated periods of neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, primary prophylaxis may be appropriate in a number of clinical settings in which the estimated risk of neutropenic fever is between 10 and 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary prophylaxis may be indicated in patients who are being treated with curative intent (eg, lymphoma, adjuvant treatment for breast cancer, testicular cancer) to reduce the likelihood of dose-limiting neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/15,17-19\">",
"       15,17-19",
"      </a>",
"      ]. The benefit of CSFs in this setting was illustrated in a controlled trial in which 80 patients with high-grade non-Hodgkin lymphoma were randomly assigned to receive VAPEC-B chemotherapy alone or with daily G-CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/17\">",
"       17",
"      </a>",
"      ]. The use of G-CSF was associated with less grade 4 neutropenia (37 versus 85 percent), less neutropenic fever (22 versus 44 percent), and a lesser likelihood of chemotherapy dose reduction (10 versus 33 percent).",
"     </li>",
"     <li>",
"      High-risk patients who are treated with less myelosuppressive regimens may also benefit from prophylactic CSFs. The key factors associated with an increased risk of neutropenic events include age &gt;65 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/20-22\">",
"       20-22",
"      </a>",
"      ], preexisting neutropenia or extensive bone marrow involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/22,23\">",
"       22,23",
"      </a>",
"      ], more advanced cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/24\">",
"       24",
"      </a>",
"      ], poor performance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nutritional status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/22\">",
"       22",
"      </a>",
"      ], renal or hepatic dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/23\">",
"       23",
"      </a>",
"      ], or in the case of epithelial ovarian cancer, extensive prechemotherapy surgery, particularly if it included a bowel resection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/25\">",
"       25",
"      </a>",
"      ]. Formal clinical risk prediction models have been validated to assist in clinical decision making [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774226\">",
"    <span class=\"h3\">",
"     Use with concomitant chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of some solid tumors, chemotherapy is given concurrently with radiation therapy (RT) in an effort to increase local control and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Combined modality treatment also increases the incidence of neutropenic fever, compared to RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, caution must be used in this setting as the use of granulocyte CSFs has been associated with adverse outcomes, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of GM-CSF has been associated with a higher incidence of thrombocytopenia and other complications when given with concurrent chemoradiotherapy. This was illustrated in a Southwest Oncology Group trial in which 215 patients with small cell lung cancer were randomly assigned to receive concurrent chemotherapy and thoracic RT with or without GM-CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/28\">",
"       28",
"      </a>",
"      ]. The incidence of grade 3 and 4 thrombocytopenia was significantly higher in the GM-CSF arm (91 versus 18 percent), and there were more treatment-related deaths among those receiving GM-CSF (9 versus 1, respectively). This increase in toxicity may be specific to thoracic chemoradiotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      GM-CSF. However, because of these data, many clinicians avoid CSFs in patients receiving concurrent chemoradiotherapy for lung cancer outside of a clinical trial setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link&amp;anchor=H23#H23\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Increased dose intensity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a trial of concurrent chemoradiotherapy with hyperfractionated accelerated RT for locally advanced oropharyngeal and hypopharyngeal cancer, patients randomized to prophylactic G-CSF experienced significantly reduced locoregional tumor control [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/29\">",
"       29",
"      </a>",
"      ]. Although it is unclear if this conclusion is applicable to all squamous cancers of the head and neck, these findings suggest that G-CSF should be used cautiously, if at all, during concomitant chemoradiotherapy for head and neck cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281028093#H281028093\">",
"       \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Granulocyte colony-stimulating factor'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774233\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prophylaxis refers to the administration of a granulocyte CSF in subsequent chemotherapy cycles after neutropenic fever has occurred in a prior cycle. A prior episode of fever during neutropenia is a risk factor for developing fever during neutropenia in later cycles, with recurrences noted in 50 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Secondary prophylaxis with CSFs reduces this risk by approximately one-half [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/33\">",
"     33",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The concept of secondary prophylaxis also includes the use of a granulocyte CSF to speed recovery from neutropenia due to a previous cycle of chemotherapy, thus preventing delay in the administration of a subsequent chemotherapy cycle. There are no data proving the benefit of CSFs in this setting, and it is not clear that they are needed. At least some data support the safety of administering adjuvant anthracycline-containing chemotherapy without CSF support and without the need for dose reduction in women with uncomplicated neutropenia whose neutrophil count on the day of planned treatment is &le;1500 cells per microL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both of these settings, the goal of secondary prophylaxis is to maintain chemotherapy dose intensity while avoiding dose reduction. However, dose reduction after an episode of severe neutropenia should be considered the primary therapeutic option, unless chemotherapy is being administered for the treatment of curable tumors (eg, lymphoma, germ cell cancer, early stage breast cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/7\">",
"     7",
"    </a>",
"    ]. In theory, the survival benefit associated with potentially curative chemotherapy is preserved as long as doses are not reduced below a critical level. However, no published regimen has ever shown improved disease-free or overall survival when secondary prophylaxis was instituted and the dose of chemotherapy maintained in any setting.",
"   </p>",
"   <p>",
"    ASCO and EORTC guidelines suggest that secondary prophylaxis with granulocyte CSFs be limited to patients who experience a neutropenic complication (ie, fever, treatment delay) from a prior cycle of chemotherapy (for which primary prophylaxis was not received) if reduced dose intensity might compromise treatment outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. We agree with these recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1183953\">",
"    <span class=\"h2\">",
"     Therapeutic use in patients with neutropenia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774240\">",
"    <span class=\"h3\">",
"     Neutropenia without fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no established role for the use of CSFs in afebrile patients who have already developed severe neutropenia after chemotherapy. This was illustrated in a controlled trial in which 138 afebrile outpatients with severe chemotherapy-induced neutropenia (ANC",
"    <span class=\"nowrap\">",
"     &le;500/microL)",
"    </span>",
"    were randomly assigned to G-CSF or placebo until the ANC recovered to at least",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/35\">",
"     35",
"    </a>",
"    ]. The duration of severe neutropenia was modestly shorter with G-CSF (two versus four days), but there was no effect on the rate of hospitalization or number of culture-positive infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1163951\">",
"    <span class=\"h3\">",
"     Neutropenic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of therapeutic granulocyte CSFs in patients with established fever and neutropenia is controversial. Although the duration of neutropenia, duration of fever, and length of hospital stay have been minimally (albeit statistically significantly) decreased in some randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/36-38\">",
"     36-38",
"    </a>",
"    ], two meta-analyses have concluded that there is no survival benefit associated with the therapeutic use of granulocyte CSFs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/39\">",
"     39",
"    </a>",
"    ]. Bone, joint pain, and arthralgias were more common in the CSF-treated patients.",
"   </p>",
"   <p>",
"    Clinical prediction models have been developed to help prospectively identify patients with cancer who are at high risk of complications as a result of neutropenic fever (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    ). However, while a number of clinical characteristics may provide prognostic information regarding the outcomes of patients with neutropenic fever, predictive models are needed to better identify high-risk patients who may benefit from the addition of granulocyte CSFs to antibiotics. A risk model for mortality in hospitalized cancer patients with neutropenic fever has been reported in which several independent risk factors were identified, including age &ge;65, cancer type (leukemia, lung cancer), comorbidities (heart failure, pulmonary embolus, lung, renal, liver, cerebrovascular disease), and infectious complications (hypotension, pneumonia, bacteremia, fungal infection) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are differences in the recommendations for use of therapeutic CSFs in established fever and neutropenia among expert groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given their cost and potential adverse effects, as well as the lack of consistent clinical data, guidelines from the IDSA recommend against the use of granulocyte CSFs for patients with established fever and neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Guidelines from ASCO also recommend against routine use of CSFs in this setting, but they suggest that CSFs be &ldquo;considered&rdquo; for patients at high risk for infection-associated complications or who have prognostic factors that are predictive of a poor clinical outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/5\">",
"       5",
"      </a>",
"      ]. High-risk features include expected prolonged (&gt;10 day) or profound (&lt;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      neutropenia, age &gt;65, uncontrolled primary disease, pneumonia, hypotension, and multiorgan dysfunction (sepsis syndrome), invasive fungal infection, or being hospitalized at the time of the development of fever.",
"     </li>",
"     <li>",
"      ESMO guidelines parallel those from ASCO [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/6\">",
"       6",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      The NCCN recommends that granulocyte CSF be continued in patients who are receiving prophylactic CSFs at the time of the presentation with neutropenic fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/4\">",
"       4",
"      </a>",
"      ]. They also suggest &ldquo;consideration&rdquo; of CSFs in patients who did not receive prophylactic CSFs and in whom there are risk factors for an infection-related complication, similar to those outlined in the ASCO guideline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We follow the guidelines from ASCO. Given that it takes several days for CSF to produce a response with increased circulating neutrophils, antibiotics will always work faster. CSFs can also be a useful adjunct for patients who remain neutropenic and febrile and are not rapidly responding to antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H938520\">",
"    <span class=\"h2\">",
"     GM-CSF versus G-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many placebo-controlled trials have shown that both G-CSF and GM-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    ) are effective at reducing the incidence of neutropenic fever and infectious complications in cancer patients receiving chemotherapy. In different markets, G-CSF is commercially available as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    [Neupogen] and lenograstim [Granocyte; Neutrogin; Myelostim]; an alternative non-glycosylated recombinant methionyl form of human G-CSF called tbo-filgrastim, which is marketed in Europe as Tevagrastim, was approved in the United States in 2012.&nbsp;There are only limited comparative data of G-CSF (Neupogen) versus GM-CSF, which are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only one randomized trial directly compared G-CSF and GM-CSF in 181 afebrile cancer patients undergoing myelosuppressive chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/41\">",
"       41",
"      </a>",
"      ]. Patients receiving G-CSF had a one-day shorter time to recovery from neutropenia, but the difference was neither clinically meaningful nor statistically significant.",
"     </li>",
"     <li>",
"      A prospective medication use evaluation study found similar efficacy, safety, and tolerability with G-CSF and GM-CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two retrospective studies reported more adverse events",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neutropenic fever with GM-CSF than with G-CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. In contrast, a retrospective matched pair cohort analysis derived from a health insurance claims database (and partially funded by the manufacturer of GM-CSF) concluded that patients receiving GM-CSF after outpatient chemotherapy had a lower risk of infection-related hospitalization compared to those receiving G-CSF or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"       pegfilgrastim",
"      </a>",
"      , a pegylated formulation of G-CSF that has a prolonged half-life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third retrospective comparative effectiveness analysis (which was funded by the maker of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"       pegfilgrastim",
"      </a>",
"      ), concluded that rates of hospitalization for neutropenic complications during cancer chemotherapy were lower with prophylactic pegfilgrastim as compared to either G-CSF or GM-CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of additional comparative data from randomized controlled trials, there is no basis for recommending one CSF over the other for prophylaxis of infection during chemotherapy-induced neutropenia. However, in practice, most institutions use G-CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774247\">",
"    <span class=\"h2\">",
"     Dose and timing of G-CSF and GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;When used for primary and secondary prophylaxis, the recommended dose of G-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    , tbo-filgrastim) is 5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per day and for GM-CSF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    ), 250",
"    <span class=\"nowrap\">",
"     microgram/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day. To reduce cost, the dose is usually rounded off to the nearest vial size. Therapy is usually begun 24 to 72 hours after cessation of chemotherapy and is often continued with twice weekly monitoring of blood counts, until the absolute neutrophil count reaches 5000 to",
"    <span class=\"nowrap\">",
"     10,000/microL;",
"    </span>",
"    continuation until clinically adequate neutrophil recovery is achieved is a reasonable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/7\">",
"     7",
"    </a>",
"    ]. Premature discontinuation of G-CSF or GM-CSF, before the nadir of the white blood cell count has been reached, should be avoided. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=see_link\">",
"     \"Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Shorter administration schedules may have similar efficacy with lower cost and increased convenience for the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/47\">",
"     47",
"    </a>",
"    ]. However, these approaches have not been compared to standard regimens in randomized trials.",
"   </p>",
"   <p>",
"    Because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy, growth factors should be discontinued several days before the next chemotherapy treatment and they should not be given on the same day as chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/48\">",
"     48",
"    </a>",
"    ]. Experience from clinical trials indicates that myelosuppression is more profound if the myeloid growth factors were given immediately prior to or on the same day as the chemotherapy. For the same reason, growth factors should not be given concurrently with radiation therapy directed at portals containing active marrow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774254\">",
"    <span class=\"h3\">",
"     Pegfilgrastim",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"     Pegfilgrastim",
"    </a>",
"    , a pegylated formulation of G-CSF, has a prolonged half-life, permitting the administration of a single dose rather than daily administration. The recommended dose (6 mg in adults, 100",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    [maximum 6 mg] in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/49\">",
"     49",
"    </a>",
"    ]) is given 24 hours after chemotherapy, with at least 14 days elapsing until the next planned chemotherapy dose. Blood counts are typically not routinely monitored in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Multiple randomized trials have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    is as effective as and more convenient to administer than G-CSF for primary prophylaxis in patients requiring CSF treatment during myelosuppressive chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. In the largest of these trials, 310 women with high-risk breast cancer receiving four courses of adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    every three weeks were assigned randomly to a single fixed dose of pegfilgrastim (100",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    on day 2 of each cycle, or G-CSF (5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day for 14 days or until the ANC was &ge;10,000",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/51\">",
"     51",
"    </a>",
"    ]. The severity and duration of neutropenia and the side effect profile were similar in both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774268\">",
"    <span class=\"h2\">",
"     Possible stimulation of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because myeloid growth factor receptors are expressed by several hematopoietic and nonhematopoietic cell types, there has been a concern that certain malignant cell lineages might respond to therapy with a granulocyte CSF, potentially worsening the underlying condition, or by triggering the development of malignancy in a susceptible individual. As an example of such a concern, the use of granulocyte CSFs in patients undergoing induction therapy for acute myeloid leukemia (AML) has been limited by evidence that malignant myeloblasts express receptors for such growth factors. Prophylactic antibacterial and antifungal agents are more commonly used during chemotherapy for AML rather than CSFs. The potential role of CSFs during induction therapy for AML is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several observational studies report that the use of CSFs during chemotherapy for other malignancies is associated with a small but real increased risk of therapy-related myeloid neoplasms, including AML and myelodysplastic syndrome (MDS). This issue was addressed in a systematic review of 25 randomized trials of chemotherapy with or without G-CSF for a variety of neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/54\">",
"     54",
"    </a>",
"    ]. Although",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    was reported in significantly more patients treated with G-CSF, all-cause mortality was significantly lower in patients receiving chemotherapy with G-CSF, and greater reductions in mortality were observed in patients who received greater chemotherapy dose intensity. Thus, while the use of myeloid growth factors during chemotherapy increases the risk of a therapy-related myeloid neoplasm, the absolute magnitude of the risk is small, and the risk is probably outweighed by the benefits of using CSFs in this setting. The addition of G-CSF to high intensity, rapidly repeating courses of chemotherapy containing both alkylating agents and topoisomerase II inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    for the adjuvant treatment of breast cancer, has been associated with therapy-related myeloid leukemia with a short latency period of two to three years. These data and this subject are addressed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=see_link&amp;anchor=H15#H15\">",
"     \"Introduction to recombinant hematopoietic growth factors\", section on 'Possible stimulation of malignancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774275\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte colony stimulating factors (CSFs) have been widely evaluated to minimize the extent and duration of neutropenia associated with intensive cytotoxic chemotherapy or radiation therapy (RT). Despite their effects on neutropenia, prophylactic use of granulocyte CSFs has not been shown to have an impact on survival in most clinical situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774282\">",
"    <span class=\"h2\">",
"     Primary prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In keeping with guidelines from the American Society of Clinical Oncology (ASCO), the Infectious Disease Society of America (IDSA), and the European Organization for Research and Treatment of Cancer (EORTC) guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3,5,6\">",
"       3,5,6",
"      </a>",
"      ], we recommend that CSFs not be routinely administered for primary prophylaxis if the incidence of neutropenic fever is expected to be less than 20 percent following chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). When the expected incidence of neutropenic fever is over 20 percent, we suggest prophylactic CSFs to reduce the need for hospitalization for antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H523774219\">",
"       'Indications, benefits, and guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the estimated risk of neutropenic fever is between 10 and 20 percent, the decision to use hematopoietic growth factor support should be individualized. Patients who may be at risk for increased complications from prolonged neutropenia for whom primary prophylaxis might be justified include the following categories [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/5\">",
"       5",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H523774219\">",
"       'Indications, benefits, and guidelines'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age 65 and older",
"     </li>",
"     <li>",
"      Poor performance status",
"     </li>",
"     <li>",
"      Prior episodes of neutropenic fever",
"     </li>",
"     <li>",
"      Large radiation portals",
"     </li>",
"     <li>",
"      Cytopenias due to marrow involvement",
"     </li>",
"     <li>",
"      Poor nutritional status",
"     </li>",
"     <li>",
"      Open wounds or active infection",
"     </li>",
"     <li>",
"      Advanced cancer or other serious comorbidities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulocyte CSFs may also be used to maintain dose intensity in patients treated with some potentially curative regimens or in settings where reductions in chemotherapy dose-intensity or dose-density are known to be associated with a poorer prognosis. Although this practice may lead to an increased incidence of therapy-related myeloid neoplasms, the absolute magnitude of the risk is small and probably outweighed by the benefits of using CSFs in this setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=see_link&amp;anchor=H15#H15\">",
"       \"Introduction to recombinant hematopoietic growth factors\", section on 'Possible stimulation of malignancy'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H523774233\">",
"       'Secondary prophylaxis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Given the concerns for adverse events, we suggest avoidance of granulocyte CSFs in patients receiving concomitant chemoradiotherapy for either head and neck cancer or lung cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H523774226\">",
"       'Use with concomitant chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the absence of additional comparative data from randomized controlled trials, there is no basis for recommending one granulocyte CSF (G-CSF or GM-CSF) over the other for prophylaxis of infection during chemotherapy-induced neutropenia. (See",
"      <a class=\"local\" href=\"#H938520\">",
"       'GM-CSF versus G-CSF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H523774290\">",
"    <span class=\"h2\">",
"     Secondary prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who had an episode of neutropenic fever after an earlier cycle of palliative chemotherapy, we suggest dose reduction or delay as the primary therapeutic option rather than routine administration of CSFs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      However, in keeping with ASCO guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/9/33945/abstract/5\">",
"       5",
"      </a>",
"      ], when the risk of neutropenic fever would prevent the administration of full doses of potentially curative chemotherapy, we suggest the use of granulocyte CSFs for secondary prophylaxis rather than dose reduction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H523774233\">",
"       'Secondary prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1183938\">",
"    <span class=\"h2\">",
"     Patients with neutropenia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no established role for granulocyte CSFs in afebrile patients who have already developed severe neutropenia after chemotherapy, and we recommend against their use in this setting (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H523774240\">",
"       'Neutropenia without fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using granulocyte CSFs routinely as an adjunct to antibiotics for most patients with established fever and neutropenia (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, CSFs can be a useful adjunct for patients who remain neutropenic and febrile after the initiation of antibiotics. Consistent with guidelines from the American Society of Clinical Oncology (ASCO), we restrict use of CSFs to patients at high risk for infection-associated complications or who have prognostic factors that are predictive of a poor clinical outcome. High-risk features include expected prolonged (&gt;10 day) or profound (&lt;100",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      neutropenia, age &gt;65, uncontrolled primary disease, pneumonia, hypotension, multiorgan dysfunction (sepsis syndrome), invasive fungal infection, or being hospitalized at the time of the development of fever. (See",
"      <a class=\"local\" href=\"#H1163951\">",
"       'Neutropenic fever'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/1\">",
"      Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103:1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/2\">",
"      Lyman GH, Michels SL, Reynolds MW, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010; 116:5555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/3\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/5\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/6\">",
"      Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/7\">",
"      Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/8\">",
"      Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol 2006; 24:2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/9\">",
"      Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005; 23:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/10\">",
"      Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010; 116:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/11\">",
"      Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25:3158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/12\">",
"      Sung L, Nathan PC, Alibhai SM, et al. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/13\">",
"      Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/14\">",
"      Bohlius J, Herbst C, Reiser M, et al. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008; :CD003189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/15\">",
"      Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013; 368:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/16\">",
"      Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/17\">",
"      Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/18\">",
"      Rivera E, Erder MH, Moore TD, et al. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer 2003; 98:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/19\">",
"      Foss&aring; SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998; 16:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/20\">",
"      Aapro M, Schwenkglenks M, Lyman GH, et al. Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Crit Rev Oncol Hematol 2010; 74:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/21\">",
"      Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 2001; 12:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/22\">",
"      Dranitsaris G, Rayson D, Vincent M, et al. Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 2008; 31:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/23\">",
"      Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011; 117:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/24\">",
"      Moreau M, Klastersky J, Schwarzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009; 20:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/25\">",
"      Sharma S, Rezai K, Driscoll D, et al. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2006; 103:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/26\">",
"      Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/27\">",
"      Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/28\">",
"      Bunn PA Jr, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995; 13:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/29\">",
"      Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/30\">",
"      Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 2005; 23:7974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/31\">",
"      Haim N, Shulman K, Goldberg H, Tsalic M. The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia. Med Oncol 2005; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/32\">",
"      Chouaid C, Bassinet L, Fuhrman C, et al. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol 1998; 16:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/33\">",
"      Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/34\">",
"      Debled M, Hou&eacute;d&eacute; N, Madranges N, et al. Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis. Br J Cancer 2007; 97:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/35\">",
"      Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 1997; 336:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/36\">",
"      Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/37\">",
"      Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/38\">",
"      Garc&iacute;a-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/39\">",
"      Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/40\">",
"      Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/41\">",
"      Beveridge RA, Miller JA, Kales AN, et al. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 1998; 16:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/42\">",
"      Stull DM, Bilmes R, Kim H, Fichtl R. Comparison of sargramostim and filgrastim in the treatment of chemotherapy-induced neutropenia. Am J Health Syst Pharm 2005; 62:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/43\">",
"      Wong SF, Chan HO. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Pharmacotherapy 2005; 25:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/44\">",
"      Milkovich G, Moleski RJ, Reitan JF, et al. Comparative safety of filgrastim versus sargramostim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 2000; 20:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/45\">",
"      Heaney ML, Toy EL, Vekeman F, et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 2009; 115:4839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/46\">",
"      Weycker D, Malin J, Barron R, et al. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy. Am J Clin Oncol 2012; 35:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/47\">",
"      Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 2005; 23:6908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/48\">",
"      Skarlos DV, Timotheadou E, Galani E, et al. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 2009; 77:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/49\">",
"      Spunt SL, Irving H, Frost J, et al. Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. J Clin Oncol 2010; 28:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/50\">",
"      Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/51\">",
"      Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/52\">",
"      Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/53\">",
"      Fox E, Widemann BC, Hawkins DS, et al. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. Clin Cancer Res 2009; 15:7361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/9/33945/abstract/54\">",
"      Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28:2914.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16889 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33945=[""].join("\n");
var outline_f33_9_33945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H523774275\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523774176\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523774183\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774191\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774198\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523774205\">",
"      GRANULOCYTE COLONY STIMULATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774212\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H523774219\">",
"      - Indications, benefits, and guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H523774226\">",
"      - Use with concomitant chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774233\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1183953\">",
"      Therapeutic use in patients with neutropenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H523774240\">",
"      - Neutropenia without fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1163951\">",
"      - Neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H938520\">",
"      GM-CSF versus G-CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774247\">",
"      Dose and timing of G-CSF and GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H523774254\">",
"      - Pegfilgrastim",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774268\">",
"      Possible stimulation of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H523774275\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774282\">",
"      Primary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H523774290\">",
"      Secondary prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1183938\">",
"      Patients with neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16890?source=related_link\">",
"      Introduction to recombinant hematopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3001?source=related_link\">",
"      Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/45/10969?source=related_link\">",
"      Use of recombinant hematopoietic growth factors in stem cell and progenitor cell mobilization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_9_33946="WHO weight for age girls 0 to 24 months";
var content_f33_9_33946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63877%7EPEDS%2F80511%7EPEDS%2F74503%7EPEDS%2F73036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63877%7EPEDS%2F80511%7EPEDS%2F74503%7EPEDS%2F73036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Weight-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 532px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Length-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 459px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 582px\">",
"   <div class=\"ttl\">",
"    Head circumference-for-age percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 562px; height: 423px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    Weight-for-length percentiles, girls 0 to 24 months, WHO growth standards",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 508px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention based on data from the WHO Child Growth Standards.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33946=[""].join("\n");
var outline_f33_9_33946=null;
var title_f33_9_33947="Etiologies of nasal septal perforation";
var content_f33_9_33947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of nasal septal perforation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Intranasal cocaine use (both cocaine and adulterants, such as borax or talcum powder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Piercings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Rheumatologic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psoriatic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Progressive systemic sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bevacizumab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Industrial exposure to metal plating solutions (chrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucocutaneous leishmaniasis, tuberculosis, syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head and neck tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intranasal glucocorticoid sprays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrophic rhinitis (primary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complication of septal surgery or cautery for epistaxis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33947=[""].join("\n");
var outline_f33_9_33947=null;
var title_f33_9_33948="Infection exclusion organ donor";
var content_f33_9_33948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious considerations in the evaluation of potential organ donors and recipients (possible exclusion criteria*)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Central nervous system infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalitis and/or meningitis of unknown etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated or incompletely treated encephalitis and/or meningitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Herpes simplex encephalitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of JC virus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        West Nile virus infection or other active arbovirus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcal infection of any site (or other disseminated fungal infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creutzfeld-Jacob disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Viral infection (see also CNS infections above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute viremia (eg, Herpes simplex virus, adenovirus, lymphocytic choriomeningitis virus, hepatitis A, West Nile virus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active shingles (varicella zoster infection) or herpes virus pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute Epstein-Barr virus (mononucleosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV infection (serologic or molecular evidence)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active hepatitis B or hepatitis C&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human T cell lymphotropic virus-I/-II (no longer an absolute contraindication in non-endemic regions)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SARS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bacterial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated bacterial or fungal sepsis (eg, candidemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Untreated syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multisystem organ failure due to overwhelming sepsis or gangrenous bowel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Parasitic infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active Trypanosoma cruzi infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active toxoplasmosis (prophylaxis effective)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leishmaniasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Strongyloidiasis (prophylaxis effective)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The use of organs for specific recipients must be considered in the clinical context of the intended recipient. This list is not all-inclusive.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Donor organs that are infected with hepatitis B or C are used occasionally if the recipient is infected with the same virus or when the transplant would be life-saving (eg, heart transplant).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33948=[""].join("\n");
var outline_f33_9_33948=null;
var title_f33_9_33949="Factors in SCD in dialysis pts";
var content_f33_9_33949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factors that contribute to sudden cardiac death (SCD) in dialysis patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 181px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33949=[""].join("\n");
var outline_f33_9_33949=null;
var title_f33_9_33950="Prophylaxis recommendations for vascular and IR procedures";
var content_f33_9_33950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Practice guidelines for antibiotic prophylaxis during percutaneous vascular and interventional radiology procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Procedure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential organisms encountered",
"       </td>",
"       <td class=\"subtitle1\">",
"        Routine prophylaxis recommended",
"       </td>",
"       <td class=\"subtitle1\">",
"        First-choice antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common antibiotic choices",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiography, angioplasty, thrombolysis, arterial closure device placement, stent placement",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1 g cefazolin IV (if high-risk stent infection); if penicillin-allergic, can use vancomycin or clindamycin",
"       </td>",
"       <td>",
"        Procedure classification: clean",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Endograft placement",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Cefazolin 1 g IV",
"       </td>",
"       <td>",
"        If penicillin-allergic, can use vancomycin or clindamycin",
"       </td>",
"       <td>",
"        Procedure classification: clean",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Superficial venous insufficiency treatment",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Procedure classification: clean",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        IVC filter placement",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Procedure classification: clean",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tunneled central venous access",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1g cefazolin IV (eg, immunocompromised patients before chemotherapy; history of catheter infection); if penicillin-allergic, can use vancomycin or clindamycin",
"       </td>",
"       <td>",
"        Procedure classification: clean (nontunneled catheter: no prophylaxis)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Embolization and chemoembolization (if intent to create infarction or high likelihood of infarction)",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Streptococcus spp",
"        </em>",
"        ,",
"        <em>",
"         Corynebacterium spp",
"        </em>",
"        , and/or enteric flora (if prior sphincter of Oddi manipulation or bilioenteric surgery)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        1.5-3 g ampicillin/sulbactam IV (hepatic chemoembolization); 1 g cefazolin and 500 mg metronidazole IV (hepatic chemoembolization); 2 g ampicillin IV and 1.5 mg/kg gentamicin (hepatic chemoembolization); 1 g ceftriaxone IV (hepatic chemoembolization or renal, splenic embolization); if penicillin-allergic, use vancomycin or clindamycin and aminoglycoside",
"       </td>",
"       <td>",
"        Special considerations: if patient without intact sphincter of Oddi, consider tazobactam/piperacillin and bowel preparation; procedure classification: clean-contaminated; contaminated (bilioenteric surgery)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        UAE",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Streptococcus spp",
"        </em>",
"        , and/or",
"        <em>",
"         E coli",
"        </em>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        (i) 1 g cefazolin IV; (ii) 900 mg clindamycin IV plus 1.5 mg/kg gentamicin IV; (iii) 2 g ampicillin IV; (iv) 1.5-3 g ampicillin/sulbactam IV; if penicillin-allergic, can use vancomycin or clindamycin",
"       </td>",
"       <td>",
"        If history of hydrosalpinx, doxycycline 100 mg twice daily for 7 d; procedure classification, clean; clean-contaminated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        TIPS creation",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Corynebacterium spp",
"        </em>",
"        , biliary pathogens, enteric gram-negative rods, anaerobes,",
"        <em>",
"         Enterococcus spp",
"        </em>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        (i) 1 g ceftriaxone IV; (ii) 1.5-3 g ampicillin/sulbactam IV; if penicillin-allergic, can use vancomycin and aminoglycoside",
"       </td>",
"       <td>",
"        Procedure classification: clean; clean-contaminated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Fluoroscopically guided gastrostomy and gastrojejunostomy tube placement",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Corynebacterium spp",
"        </em>",
"       </td>",
"       <td>",
"        No consensus (if introducer \"push\" technique); Yes (if pull gastrostomy)",
"       </td>",
"       <td>",
"        1g cefazolin IV (pull gastrostomy)",
"       </td>",
"       <td>",
"        -----",
"       </td>",
"       <td>",
"        Procedure classification: clean-contaminated; special considerations: if head and neck cancer, consider (i) a second-generation cephalosporin; (ii) second-generation cephalosporin followed by oral course of first-generation cephalosporin, or (iii) clindamycin or vancomycin in penicillin-allergic patients",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Liver and biliary interventions",
"       </td>",
"       <td>",
"        <em>",
"         Enterococcus spp",
"        </em>",
"        ,",
"        <em>",
"         Streptococcus spp",
"        </em>",
"        , aerobic gram-negative organisms (",
"        <em>",
"         E coli",
"        </em>",
"        ,",
"        <em>",
"         Klebsiella spp",
"        </em>",
"        , etc)",
"        <em>",
"         Clostridium spp",
"        </em>",
"        ,",
"        <em>",
"         Candida spp",
"        </em>",
"        , and anaerobes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        (i) 1 g ceftriaxone IV; (ii) 1.5-3 g ampicillin/sulbactamIV; (iii) 1 g cefotetan IV and 4 g mezlocillin IV; (iv)2 g ampicillin IV and 1.5 mg/kg gentamicin IV; (v) if penicillin-allergic, can use vancomycin or clindamycin and aminoglycoside",
"       </td>",
"       <td>",
"        Procedure classification: clean-contaminated, contaminated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        GU procedures",
"       </td>",
"       <td>",
"        <em>",
"         E coli",
"        </em>",
"        ,",
"        <em>",
"         Proteus",
"        </em>",
"        ,",
"        <em>",
"         Klebsiella",
"        </em>",
"        ,",
"        <em>",
"         Enterococcus",
"        </em>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        (i) 1 g cefazolin IV; (ii) 1 g ceftriaxone IV; (iii) 1.5-3 g ampicillin/sulbactam IV; (iv) 2 g ampicillin IV and 1.5 mg/kg gentamicin IV; (v) if penicillin-allergic, can use vancomycin or clindamycin and an aminoglycoside",
"       </td>",
"       <td>",
"        Procedure classification: clean-contaminated; contaminated; cover any organisms already found in urine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tumor ablation",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Streptococcus spp",
"        </em>",
"        , and/or",
"        <em>",
"         E coli",
"        </em>",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        (i) 1.5-3 g ampicillin/sulbactam IV (liver); (ii) 1 g ceftriaxone IV (renal); (iii) 1 g ceftriaxone IV (bone); (iv) if penicillin-allergic, can use vancomycin or clindamycin for gram-positive coverage and aminoglycoside for gram-negative coverage",
"       </td>",
"       <td>",
"        Procedure classification: (site-dependent) clean; clean-contaminated (eg, bilioenteric anastomosis/bypass)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Percutaneous abscess drainage",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Corynebacterium spp",
"        </em>",
"        ; aerobic gram-negative bacteria and anaerobes",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No consensus",
"       </td>",
"       <td>",
"        (i) 1-2 g cefoxitin IV every 6 h (ii) 1-2 g cefotetan IV every 12 h; (iii) 3 g ampicillin/sulbactam IV every 6 h; (iv) 3.375 g piperacillin/tazobactam IV; if penicillin-allergic, can use vancomycin or clindamycin for gram-positive coverage; aminoglycoside for gram-negative coverage with or without metronidazole for anaerobic coverage",
"       </td>",
"       <td>",
"        Procedure classification: dirty; antibiotics should cover anticipated organisms for empiric treatment and then adjusted for final culture results",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Percutaneous biopsy",
"       </td>",
"       <td>",
"        Transrectal: bowel flora, mostly anaerobes and aerobic gram-negative,",
"        <em>",
"         Streptococcus spp",
"        </em>",
"       </td>",
"       <td>",
"        No (nontransrectal); yes (transrectal)",
"       </td>",
"       <td>",
"        Nontransrectal, none; transrectal, 80 mg gentamicin IV/IM plus 250 mg ciprofloxacin twice daily orally for 5 d",
"       </td>",
"       <td>",
"        500 mg ciprofloxacin twice daily for 4 d commencing the day before biopsy",
"       </td>",
"       <td>",
"        Procedure classification: nontransrectal, clean; transrectal, contaminated",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Percutaneous vertebroplasty",
"       </td>",
"       <td>",
"        <em>",
"         S aureus",
"        </em>",
"        ,",
"        <em>",
"         S epidermidis",
"        </em>",
"        ,",
"        <em>",
"         Corynebacterium spp",
"        </em>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1 g cefazolin IV",
"       </td>",
"       <td>",
"        If penicillin-allergic, can use clindamycin or vancomycin",
"       </td>",
"       <td>",
"        Procedure classification: clean",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; IVC: inferior vena cava; UAE: uterine artery embolization; TIPS: transjugular intrahepatic portosystemic shunt; GU: genitourinary.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Venkatesan AM, Kundu S, Sacks D, et al. Practice guideline for adult antibiotic prophylaxis during vascular and interventional radiology procedures. J Vasc Interv Radiol 2010; 21:1611. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33950=[""].join("\n");
var outline_f33_9_33950=null;
var title_f33_9_33951="Solitary enchondroma";
var content_f33_9_33951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solitary enchondroma of the femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 466px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHSAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwOSRg556GmeY3rSTZ3k+tRmgCTzG9aPMb1qPj6fjSigCUSt608SN61BT1PIzQBOsjetSrI3TNVVqVDQBbjcirkEhJ5NZ6HmrMJ5FAHf8Aw1vWg8TW+TgMpXHrX1P4fnLQpz2r488KT+RrtjID0kA496+svC84a3jwe1AHVXUhwD3x+dZM8hyeeK0Zz+7z1rHumIY7eQTQAI7F+DwKvRyDYOTkVkqWByMDPrVuGTKcUAakUhwCGq5HJjHesiF8DANW4X54PNAGqjhqc/3TVaFuh7DrVk8igDzr4jRfuElAO5W6j3rziZ/mwcZ9q9f8dW3naXOMcgZFeOSDG0nigCB5TzntUZ6E457+9K+ASQQc9aikk+QhTg4oArTuQhx2qlNIwXgkmrUjqAA3JP6VmzNkHNAFaWQsSSfyrOuJGfv9KtzPgerHrWZdFsMc/wD1qAKVxIazppGB65q1O3Hv61n3DcUAVZ5DnrVR5W55qWaqsufWgBjzMKge4fPU/nTnqvJQA/z5CRhm596T7RJ/eP5moDmkNAFjz3/vH/vo0n2iT+8T/wACNQZ496AaAJ/tD/3j/wB9Gl+0PjBdsHtuNQDp1H070nc46UATm4f+835mlM7/AN4/nUAJHSkoAsee+M5/WnpMxqsOnrUkdAEkhwxpmafN941F0oAXHNApKUfrQAuTTwaZmnCgCRTUinFRDqKetAFhTzViMkYqqvWp06UAa+mzGG5hl/uuD+tfWPgqcSWUTA87RXyLbkqhbsDivp34ZXZn0q1bd1QfyoA9SZiYRzWJdthmAOCOtau4GDn0rGu2XLGgBrEkdckVNbPx14NZvmlCMkirMMqsuc4P86ANSOQZIB61bgfc/B4rLR19ulWYZNrd/wAKANiN+cVoRtuUVipJgZBFalpJuTBoAz9ejEtvIpGQVOa8G1MNDdTRNnCMQBX0BqQ3RNjqRXhXjSDyNbm2j73zY/nQBib8tj07VG7DnGMngmmucYyCB+ppJSyqxAA/WgCncMQduDkVSlOBxgCrkvIJIww5zWdMT1AyPagCpcPnOMk9c1lXTEtn/IrRm7nvWZOcnOPegCjMTjGazpz1zV+brWdPyTQBTlOaqyGrMh5qrJ3oAheoHqZycVA/WgBhppyTTiOabn2oAT8aM0dqTvQAtFFFAC0UUlADs1LGahHNTRjigCSb75qJqml+8aiz6UAJQPajoPf1oBoAdS9qbnpSigCVaeKjBp4oAmU1Mh6VWU1PGelAF6A5BT3r6D+D9yX0a2B7Db164r54hPIr2v4LXR+xbCThXI60Ae/RsfI61k3nEhIP1xV23kzbj6c1mX52tkdemc0AROQ6/NwQPzqSHCdcEVReTcpIPI6+lJFKVYkk4OKANkOCwxkVYjc7xkg46VmrL8o55qaCU79zHmgDZSTd8uea0rGT5sZ7VgQy/Pn3rTsnAkBJOKANO7+eM/SvGvidB5d5by/NgkqcdK9hZgVIz2rzr4lW3naYzAcxnfQB5c7EMvf6VHK4BK5Iz3zUbuQxy3GKRnyCASTgHp0oAiueCQCePSqErAjDVamzjggmqUxBGO3c0AUZlyD1+tZ10cZ5H0z0rQmxkgcd+tZt2SobOCaAM2YnryfrWdNkZq/McjnvVCXvQBTkPFQKQH+cEr3AOM1PJ9arv0oAglwWOAB7Cq79asPUD0ARmmU80w0AFGKAaTPNAC0tJRQAtFJQKAHAVNH0qHtU8XSgCSYfOahNT3Aw9QHv3oAQ0YoPWjrQAopRTacKAJMY/wAKcppmCDzTh0oAlWpoyKgWpUPSgC0hr1b4NXG2adD/AHwea8nQ16D8J5/L1eSPOAwBoA+m7F91sPpWdeuASDVjTZc2o78VVvyDnsSeKAM1nAyvbHNPhbjAbn3qs+Vc55FEUnzgMORQBqeYdoG2pEkwOM5qhkBd2ee9OSVmbk9fSgDctnO8Ank1pwy7XXB6GsK3cjbjrWlHJgZJ570AbqSbuQe1c54qgFxZTJjhlIrXt3yQQ3aoNVj3wt6mgD57mBhlZGx8p2kYppY45GT2q74ngNrrd0oGAW3DHvWWW+XOeTwaAGScnsPeqMjYLDj86tS8jjtVOQgnA6+maAKlwfkYn06AZrLu8dexrSmOQR0FZlzjnB7UAUJs+mDWfP1q/N0qhN7mgClL1qvJU8vfpUDmgCB+lQv1NTvUD9aAIjTTTzTKADFJ3opfSgApR1pKO9ACnpQKTtzQKAHrU8QGDVfFTwkc80ATXH3j2quatzj5jVVhxQAyilPfHSkoAWlFNxS+lAD6etR56U5TjocUATCpE+tQipFIHpzQBZSuv+HU/leIIwTgMMfrXHIa6DwdL5Wv2xzweKAPq3RHzajoQfeotQfa6k89+lV/DL7rZc8cVLqeCcjgjNAGbO5cb1zj0qMOCw4yfUVDLJ8xUHA68Go0dgwbPPt3oA02chOaWFhtB5Garh98Y9RxilDgHn/9VAGrFKBKvPGOa04JQVBzxXPQMd+CeB1NalvIOMA5xigDet5eB3qzdYkhPTpWPBKQf8K14SHtyAOelAHjfxGtPL1FJhwrDaa44tjkHNeqfEqy83S3lUZaJgfw715QxGRkYFADJTubdk47ZqpN16Yz681Yk+7z+XpVWQlhweT29KAKc7ZY8+1Z1z+P41flwck/zrPn9sH2oAoS+/WqM/f1q7OcGqE55NAFKSoHqxJnNQ7SxwBkntQBA9QSdasMARnNV5O9AEZph604009aAEopQSARng9aQg8E96ACnAjdkE7e2fSminjp+FADaUUhApQKAFFTRAnO0E1EBU0Zxk+tAFu4zuP+FVWHU9qvTD5jkgYqnJkH3oAhIpKU0AUAGOKSndBTaAHjqKUU0U4UASL1qRajGQB156U5TjrQBZQjNaehyeXqtqw/vislScj0q7ZvsuoWA6OD196APqnwi5axUnIJWrmpMdzjg96yfA0vmWEPptFaWpFtz4xkjFAGVdDk7SOeeahTPANFwzKgIIpkLAEBuc85FAFtWwvAyfakd9xGMj1FRvkHcrDBHbvSoSyjPWgC/A+NoyTk5JNXIpcuBk8dSKzkP7xAc+vSpYXKykZPWgDoLZ93TNbdk/yYJrnLJsAAnk1t2EgB2jmgCj4ptBc2E6EHDKRxXgc6tFM8bDlSVP4V9IajH5lu2R2rwPxXaG11y5QDAY7wPrQBhvyDjGfeq0oHUH8qtN1wBnFU5OQfQdaAKcxO4+h71nXQA55zWjORjOTis+5JzigDPmPHNUJuM8VflPBqhMcE7u3egCpLULjjip2ORkdD3qBzxxQBC7dSeSagYkHIx6VI5JqFutADDTCaecY68noKYaAEFKOWxkDJ6mkooAO9PH9Kb6c80qnGc5PFAC44pw6fWmA05Tz0oAcBgVIlMJ4ApU5zQBflOSTnvVWT61ZlB3Ec5qtIOKAIgcGmkk0ppO1AB25o47UfyoHT2oAdS/jTTz0p3XmgB6nt264qRTUQqRfagCZc+lWImwQfcVXTmpkoA+l/hxLvsIPm6qK6HV8ic47j86434VzB9MtyD/COtdnraEMjj0oAwZDkENjOeoqGHIY7Dkd6dMCHYDjvg1CiOvzKOAeTnrmgC/EPMyDjbjBBqVLdtgKjA/SnWmAD8pPGelWoY95xkbfTOaAEQKBy3zD0701F2ShicirCw5ZjgBBzzUDoyEEn5c96ANCyP70NuPtn0rdsnUFTu71z1owZvlPvmtS1Y52jp7UAdBIN0B57V5B8TrPyruG5UD5sqxr1mzcvGM+mK4z4kWP2jSpWCglBuH4UAeNycjJBqnJnsD9Kty8HIyc1UlBx836UAUpmHPX8qzpjyTWjP/471rNnx2784oApzH5etUJenPWr03TpxVGbvQBUk4qu9WJMZquwyeATQBA4qFqmfk8d6hbqaAIz1yOtIaU0lADaKXvSUAFKO9IRThjB9KAEpRRilXpQAp469qfEeKjqWLvQBoy/eOetVpDxzVuVDuNV3U45oAqNTc8U9xTfWgBO3Wjj0/WiigBaUH8qTpigUASA9KkUiohT1oAnU1Ohqup5FToRnnmgD3L4PSl9NiyenFek6yC0WM9q8m+DU2bYLnAViK9b1gr5UZ6cdRQBzzqDKdxAGM0IAEODjPYGoZmVdzYJxwferFooYDaAzdRQBajUgcbgKv2WFZSR7kdqbbQqkJjkbqKuQxl3VYsbW45oAhiYEkPnGc1WuGBYgbsjpWzd2YtLcHqcVjsFDjnkmgCW2KoffGea1LdgXUjPpWSFO8MSD9K07YZwTz6H0oA2LVysgB7cYqHxDbLcWcikcMuDRBJljxyOatzr5trk9QKAPnPUIGtruaB/vI5HSsyYDOccV2Pj2zNtrkj4+WUbvx6VyM69R/OgDOnHB5P+FZsnv1HvWncg7WxwPasybHbOe9AFOTnNUJjzV6Y8VQkPU0AVpMVXb6VPIKrv1NAEL81A3Wp5Khb3oAjNNpxGKb3oAKDSZpc8UAIKep4b6Uz0qUAbPf60ANH0oJFLtbbkZGKaO9ACjtVmEALUMYbHC++amQMRwOKAL8jYY81Vlbtmppz8+0CqcnU0AMY5NN704nPNNNACUUUdqAFoFLSDigB461IuKiHWng0ATjipEqHPFSocUAeq/BqYrPMg7PnFe26vg2CEdTxXgPwhl2arMmcZwa99viDpyn2zQBg4XdIpA4G7pxVrS41eVWXO4HtWd5gE+CcZH51e01mjuQ24c5J5oA3TbqXBcAAmrUapbjg9OfWoJ2LqFU9ux61GrN5TKx3evNAE+pXKyphW/CsqM/OQ2AQafcEqm5jx14pm4ybf1NAErZZflA64rStyFCgnnris6NlXlG5HarMLeWxZ8biOn9aANNG/e9gc1pW5DRlO+M4rHi5bqM1etmHmhiTnpQBwHxPscwJcDgxvycdjXlk+cENXv/jHT/temXEePvIccV4NcRlXdCOR8uPegDJuBnkgVmSjPJ49a1rhTkA9azrjgHHHGOlAGbMBg461QmHFX5x1xVKYdaAKUlVnPWrUoqs4oAgf9aiapXqFqAGHrzSHt70ppp60AJRRSUAFPzwR2pp6DkfnSqKAHbmA+8celIKSj+tAEgkIqVJTjtVapYxQBfuOGINU271dnIwSetVDwT70AR/Wm09+oplABR2oooAcetHYHtSGlFAC96cKQt0GOlKtAEq/pUq1CtSqeaAO3+Fsm3xDt7lQa+hrp86ftPda+bPh5KYvE0H+0CP1r6PkO/SwR1xmgDnrn/XZwKsWsuEKg/MOao3LP5nXBI6VJZkO3zHBbjjvQBv218GbH3CByPWnvK4j5JAHPHcVXS3xl2IYLx6HFXrc5tSFU9OT6UARKrmIYHBbHrSxW/7tlDYwc896fpscqMzSHdFnmrkyhmVMBYzzz3oAz4Y9n3DuY9wKuEnOT19BRDHHE2I+dvQHvTmikZ2JG08ZFAFqEHAYdTzzV+FgHUnHvWarlWwfTHFW7fPTnigDR1GPzbU4GcivBfFtobTWbiMDAJ3Dj1r32F/NhKivKfihY+XdRXPTJ2sf5UAeZ3a7WI/Osu4Xr1xWtdA5OSM/zrMuclf4R+FAGXMM54rPnrSuAR6cVnzdDQBQlHtVZ6tyjPfiqslAED1A3ep3qButADDTDTmpCaAEopKWgAo9fSiigBaBnqM8c5HagZNKFBzknPsKAE+vNTRimYA4zUkYyKALkw+c81WfPJq9cKAc1SkHOaAImptOam9qAAUUfrQKAF70CkNKBQAopy00YNP5GCQeaAHqalT73JNRLUi9aAN7whJ5fiCzbvuxX03C4bQ+fvYGCO9fLOhv5erWj+kgr6f0x/N0NdvGQMflQBh3oAODnk96ZbNtIZOvFF63PzYBPFR2soVlVgMDnNAHT2Tm5k8soVYcsc9q1tpiRoY1JTHX3rE0+6IGSu1AR9cVvwXMQ25GYz3NAEMYJljjkA2qcnFaFzai9ttinDqe3FTQrayjfuBIPSns6A7YScHnigCpa24hkCOmT03GpLt1VgHH5Usnmecu51IPTipbgCQBFALUAZLkbi33c8jNTxOVIOeDTbmPYoXnA7ntVeF/mUHp70AbtnJz1OMciub+IdgLrR59oyyjcPwrct3Hbr/OpNUiE1g2Rngj1oA+b70c5xjjg+tZcwBU/Wuh1y3+y6hcQkAKjkDjsawLhSqsBzz0oAy5uBjms6bHOcg1oznORWdcDmgClJVR/vGrknT3qrIMZNAFeT86rt1NWXFQOOaAITnpSHpT2XAphFADaKWkHB6UALRSUUAO4pc+hNNooAdmpUaoRUqgY4P1oA1JxjNVJB05zV6Ucnj8qqyADjoe5oAqt16Uw9akbrTOtAAoye3403mlBxQMUAFFB60q0AFOU9MkkDjGaaAT704DmgCQe2aetRg81ItAFu0bbcRMOMOD+tfT3hdzJoUZzn5Qa+XUOOfQ19LeBZvM8OxHPHlg5oAj1NPlfkbsY+lZ1qCEznO3jnrWpqJ3F25rOtcEHI56c0AbNrcHaEGCB0yK6SwIMRyEK+vpXJwNjC4OSetbFtdDYRKQqgAfWgC686QNIUIfcMcVcs7siAhVPA4rCDS+YQqr5BPWp47kwp8pOc0Ab6zgsh3fN0Oa0mniSJTxux1rl4b53IypHb61qwzb4w8gG0cA+lAGjehHhLYFYXl8k+nIq+0gZTvcsMdulUZZBsbBxxQBbtpNzKGz6VpRsJIHUY+grAjdiVIByK2bWT5ww78HFAHjfxLtDb6wJQuFlGOPauFmBAJINexfFfTzLppnA5hbd+FeOy57nPrQBm3HPTis2cCtKXIz6Vny96AKElVJquS1Ul6GgCu4qPbk9OKkakJwOKAIZhgVXNTSEk8cmom6+9ADaDRg0CgAo7H1oI96KACiiloAKlj6VEOtTR55oA15zhjg9apyHoOgq7Ooyapyg856UAV3PNRnv61I2c5qM9aAE7ZpKcTxjnIpKAD1oFHPrQKAAdelOXpSUooAkXrUi9qjXFSigCRDkH1xX0T8L5Vl8NR9T+7Ar53Tg1758GpPN8PInoCv60AbWpqN7bT24HpVCA5Q57HpWvqabZgeeCcj2rJ+VJCXOFzmgC5ZMEYh8ZzgZret7aOVgF5zXMICql85UnIFb2kXTZLNgKcdOv1oA0zAtoAHYqD2IzVHz4mZlUHaD94dquX8bzovntkHoaoRW7JdR4TdGxwcc4oA0YEDrvQbsdMfzq4rHyvKKgFupqW1tvJYqBx9OtWfkw67eRxjFAFOQbYQEbpx9ahVN5wQF7EVawfNKYGBzxVeRsyl1U8d6AIUJQgjt1FasRAUFW7dKyZCuSVGCTyKvW7fLx+XpQBD4othe6TKhGdyEV86XK+TM8TDBRiv5V9NuvnW0i+1fP8A47s/sHiCdduFl+ce+aAOTnHHNUJs8gdq0JyCeegqhNjseDQBQlPXI61Uk5JBNXJf8mqUo5oArn9KidjUzVC/egCJz0wc1Hzg4HHent70w0AN/KlxSHrRQAufQUlFJQAtGaKMZPHH1NACipkNQgVKlAG1MfmwearS4xzVmXliM1WkbjjpQBVkFRHrUr9/ftUeCSMdfSgBhHNFOOWPA/IdKQZOM5oAToeaBSkYzScZ70ALT16c00fh+NKtAEi9akTnj0qNaepoAlSvbPgZMTYSx5ztcgV4klevfAmbFxdxHoGB/OgD0fW12SHHNYkwG5VHJxXQeIEG5+T161gSAZRgPl2igB1jHvk2MOcdq3II0hiA4DnofSs3SvmuV3DGRwPata6aLzFUbQMcigCyYjLCVVi79ATxUtkJ4HUYVmzg98VmSSvASUY8cGrduzzuTuKDIyRQBu/bpISu9FyfXinxSGVwVBXJzVe3+ZcsQ2OATzU4dQV3EAA44oAfOxIyyYJ4x3qugCxEYOTyRVi4lWQKQoPcVLAqPAZCCrAd+9AGDcunm/ICM1LbzFGIblT1pl7GrSHaOSRUS7o2IIzxQB0FjKHGT3GK8u+Melnyo7yNeY22t9DXoGnXIRgoPU9M9qg8bacupaJOm0fMhGffFAHzVIcjBqlPirdwGilZHBDKSpHuKpzkHigClNVOQYBq5J6VVm70AVWqKTvUrdeKikoAgbimNkk5qQ8mo260ANooNFABRRR2oAKKKKAFFSpUQqVDigDal++cfnVWQ5qzIfm4/Oqz80AVn61GeDUrdKhbPagBD3ooxxQKADtz1/SlGOKQmge1ADwB60oAPbFIDTloAcOKevWkxz2pUHNAEi8c16V8E5iniGaMMBuRWwe+DXm3Hr+ldx8JJdni6ED+JCKAPevEEZ+Zx7GuYuDlPbqD6V1viDP2ZWwMYBxXI3REcTHoeoNAEUEkpcEMAfQGte3ZZD5cnD8YJ61gQPtkUEjcTx6Vp2bDc/3jx196AL7I298kNjkYNaFoxijLt8xbtjpWaJVZo4uVLcVqQ28xYFmYRngc0AXrFZZGX5uAcnHStWS3JRSpLHocCs2JzEhwwz6CtzSZmdFBI4HNAE9rZb4OVOfWq+owCODGcHvit6F9seRwPSs7UirkFlO32oA4+8OB1Ix3qulwMYl9CM1q6mVGVQDI7msOdHdlljI3L1HagCR5Ng3L0yCK6TTpVvbJoz1IrkpHw2NvyOnfsavaLeG3dWY5UnDf40AeK/EnSW0jxNMAMRznzF449642VuOK+gPjXoQ1DQRqNuu6W0+c46lO9fPsnB60AQScc1Ul+lWJT1qtJ3oAgbrULc98VK59qhY0ARGmHqakPU1Ge9ADD1oFLkYA9+tITnvmgAopKWgAo74oBwfpRQAv4c1Kgz6VCOhqRD6UAbjqSx9KgkXjrirUuc9RUD888YoApuME1C2euKsSEA9O1Rbd3bHtQBEMdxSYpzKV4IpuaACnAccUjY3HbkDPFHJ5PJPJNACipFpgp60APApy9aaKevWgB6jmuu+Gb7PF1lzjORXJL14rf8FsyeJLNl65oA+ntX+e1Q5GSvQ1x84DEq5GORXS3jONMjbODsBzXMXBUgnHJ5x60AUJY/mzt5zwRxWvYiMR7BknvWSr+YW/StC0jJAKZwO+epoAvtEouECE7q6K2WWOJPNA3Dvmsq1jBUyvgyZGAOtag3u4LtsGACp6CgB0dq8p3yFduccGtmwCWsi7jkdevaqMMYjQkYPuKv28akfvF+YUAdHD5cqBkwAKpanHuiOwjgVPp+0IVGM+lJcAb+QcUAcfeRsOZDwayLpNgBRtqk9a6PVYS5Yg8eneuav/AJIyByKAGXBUDLDoQCOwqKBsKQGG0cg+hqOSQmNhnBPXNVRIUduQF6H8utAHY2kkeoafLbzBWXGwg9CCOlfM3jTRW0LX7myIJhVsxt6qen+Fe76Xfm3uY93KnhsVhfFrQk1OwW/hTM0I5IHVP/rUAeAvVaQ81cuo2jcqwxg1SkPNAEEh5qFj7VM+KgY9aAGseaiPentTGoAaeTSUtJ0oAXvQRjr6UlFACjpRRSUAKB71IvFR5qVM0Abrj5znOKryAE8Hj0q1L949zVaTmgCpJjdmgH3pZBk+1RtigBJTnoaixUhf5MYzUY744oACMGnCkOMnrntQvNADu1PUCkA4z2py0APXmngYNNFOFAD1HNdH4GCnxVpwf7pkwfyrnRwa6LwJj/hLNMBPBl/pQB9MakqLp0YXAG2uPk2mRsEcjiul8VO0enQhM8rXCWJcxzDB2qxwTQBOjKrsHyMHHFb1kqysfLHHFc5aRO0jlwT82cHp7V0GnERgHeRJ0I9KANxYRbygMSoxyMc1ZgUyLljuI6is9rliP3ZLtnHHepbaZkc8sC3JzQBqwyGBXEhw38hU4uS7CNW5YfpVJvtE3zKRtb1HWpbCJxN5jMODjINAG1aTNE6jnJxkVqSzAxZ9O5rLTEIy5G4mppJD5XzsCp70AUbthMX3HANctqSYYhDuXpmtjUbgMjYBAU/nWDKf3bbW5BzxQBUI6hlGX45qu42jLLhu46irCMSF+mDntVadlC4DEDOMCgCDJQ7sEc9K6GGdLzTjFIQ3BUiuXlmXcV3ZyeDVywuCsbbTz1x3FAHlPj/Qmsb53RCEc5UjpiuDlUg819BeKLRNRsyOHyM9OleH63YvaXLowK4P6UAYr1C30qZ6gbrQAw0w04000AN4pKU0nagAooFLQAlApaKAADmpEFM7U+PvQB0Uw+c5FV3FW5h81VZRk9DQBUcZ4qJsVNL1JxULnPqKAIW9elNxT26d80g4IoAb3p68KeQc8EUw9aUUASZNPWo16VNjoaAFHSpF7UwU8UASLnrXS/D1PM8Y6WvJ/eZ/SubXpiu2+Edv53jay44QM36UAe7+Jk3pCnXaoOK5e6hS3TCgk54I7103iAF7p0BwNo/CsG8UtsOQozj8aAKUefJB9TmrMLOlwjLhuCSMVH5B3Fc4H8xVu3hDcDjt75oAu2Uz/aMhcRt149K1TCGn3orMGHYdKoabaYmBduEJxiui0vyh8kbEY5570AWraErAMjbx3p1pA7O5SMYz+daCLuVVbn39KVFe3I8vHJ6elAD5kDrtK/NjvWXepKIyAxGOtaN3u6l8DvWfdyxuhQtkgetAGOceU+PvDgrWK+ck5x6mtK7cBz1H171l+YTM27AGeOKAK7H5M++SBVS6JfJXqO4q3IDnocGobpV2soXqM8igDDkZs5OAd2flqvFeeXK6nPrnuOamu0wc5wx4qhKF875mXDjA7GgDS+3BcxnnI4x0rk/Fenx3yM8bL5q9QT1rUldlKAAgkA57VkXVztlzIFVTx9KAPNb63eGUqykH0qg6kDPau2160WV5JEXI9BXH3URVzQBUzzxSGnEYpuCegzQAhBwM9KbS9RRQAneloFBoASlooUZ70AAqSPoaZT0oA6aYfNVaTqetW5R8xqnIOowcUAQSYxk9KqyjBwKtt19PwqrKoBy2cH0oAiaoyfyqQgepP4Uw9KAENKKQ+1AoAeoyaskfIpquMg8jkVPuBjx78UAOBAHvUij1qNfrUoxxjJoAkFep/AawM3iC7vCPkhi2g+5ry4DJAr3/AOC9kNO8F3F+4UG4csM9cDgUAb+pMJZp2c8B+SaqGP5fUZxzU0f713O35c7vwq9BaAqd2OucelAGalpuYcE+9XobMl9o6dRWjBbL5g3KCAeavRWyJICODQBQtrUxlW9PXtWlbxxoxZQBu5zUpi3DA6Y5oSHABPTpigC8CQq/P83akSUxyDe2SexqmI2Mq9cdhVsxhvvrk5oAfdYkTPII7etY9wEcZXCtgjp1rbnGUHqPSsO6t2LEoDycjNAGTckqQGOVxxWa8fmSqwwNpzjpmte9hcRbWUEnnntVH7P8pYnpQBVnYfaFY4CngAdqivI0K/L1IwKnmUAeoxj6VXmIKAKfagDCukOCcA471j3XVdy8huvpXR3Fu2/5QDnnis25s5PLdcZbtz360AYcrloGXIGAQBWJqQJ55I6c9MetdILCbfJkMMtuFYt/ZzeVmSPA5HJoA5m7lfawJOR3+lYF5+85OAe/vXT6haSI7AJn+Lg9RXN3asjsrjFAGVIhU9KhYVclP0zVZxQBFRSkU00ALQOM+/WkoPSgApR1pBQOtAC1IntUfepE6UAdTNjJ5qpIKtTcMRVaQ/WgCu4OeTVWQEHOKty571Tl+8c5oAhOD2x7009Ac/WlJ/KkoASj1oPShaAHCpUNRL3+lPU80ATcjGKmj9qhXmrEK7jgDntQBe06zkvryG2hGZJWCj2zX0zcQR6NoWnaNCBiOIb8ewryT4T6bF/bMd3c/wCrg+csfXtXpl1ctd6gJ3ORu6dfyoA1NPt+QzAAEA8VsW6IjH5d2azIJDviDY6cVuwpkDjigByIM/dX8qsDJxkD0PFOjiPHfIqYR+1ADAgU5Kg545qQJGykEbT+lSpHkZ701oiDwOtAEJTY2MfSlkHAI57U/DB8EZXHNROT2FAEhbA5x71BMV5CgAVJJyhJwPeqzZzzz/KgClcIrFs5yeKoPAArbeQa0LvjnA9KrIMKPT1oAxrmMgDPJzxgVB5ACln+uK1Z4wxGB3qOWEiFj3oAxXKqSVAHPamSqDGScZPSpLlCGXaTyfTrVdt5ypAHegDNudomLeYcHPAPPSue1YxmNwF3dDg+pror5eeOB2x1rnb+MHft4bcFHsMfrQByWsSKqBlGBnaT3rndQ2yL0GV4B9a3NYGQDkgHkn36VztwexGAf1oAy5kKMc1CVq3I2TjAxnP0qq+Q3UH39aAISOtNYYPXNSk5prAEcnFAEYoxmlKkfe496TmgBMdKVRk4FOPSk4yBk4oABT4xxTeNvAGc9acnSgDpJG+cgVDIx6np1p0pPmE5qGRzj2oAjkkJY1UmOelTu3XtUDnNAEJ6Uh6e/rTsUEcnNADD0pB15pxpDxQA7NPU0xThgfTmnLxjoaAJlrV06Eu68ZJrKTrXQaUpwrfhQB6N4XAtLTy4iWZ8bgprtLaQFwAp+UY59a4nQytvFHK2SWGAK6LTbgNuQH5iMkelAHZacokKHOfauntQCi+v1rm9AXKo3HrXVWYBHbA4FAFiMfNg1ZRBzxSRAHk1OBx2oAYqc9qbIB1zmpuegApjjjPegCtKpK8GoyBjGO9WwM00R4zQBSkUlSPTmq7dOM9OavS7ctVV0+YigChcEEYI/KqpwE71eni78YzVWRewH0oArPjJIHagEMcEdeOTSyED7q5/Go95L45GelAGdqMW3JC9D27VlzdH55rf1NVCtknkdqwmClSMHcOmaAMq8wVYjJOSa5nUwYSzZJ5Uj2FdhOpCncg5BHSuS8QBViHBXKY59jmgDidSAlRwW5BII9s1z94uJf3nBC5A/Cuh1ldtzOSflPJyeh4P9awL0lpEBOTtoAyZTnjsagYVPIAAMn2qA8GgCPvQR8hpzDBodiIcYyCc4oAizgYPIpAaQ0dqAFbHGKPfikIIIyCDjNA96AFqWIZzUQqVBx2oA2pX5POBVaQ9aWVs5yfwqNm/KgBjHrmmNQW55puc9KAGjrQw5HOR19acRzTe2fWgBpoPQU7J/Sm9qAFpwpg68daeBQBLH1FdDpvygHHI5rnoQdw4rfsAAi5PfmgDr7C4kZY3bomcZ+ldV4buN10hflSCWOP0rirDeIgAcnBHP611ejN5UnJBRhnigD0zTWGVwMDp6V1dg3CnPHSuCsbncUZQdrDnPautsJGa3jccYPOKAOnjHAqWNQR71RtH3KnUnFWw2CeaAJNoA96a+CKjZsGmydB2oAXI4x1qKd8LwOtNB+b17CkmU7eemPyoAqyuc4Hr3qtKzADtUknU+lVLonywqMRn2oAkLErng1WlwT0qQscGqczEDI7e9ADjhNnAIJ5qNlTzsg5z29KTfuTLDn0pIFLy5PHpgUARaqvA29wDjNc8wdi2CB1zW1q43b2BKlRisSIOY9xxweMmgChdF/IOPmIfPB/z6VzPiWNvKAbLL5hAA9+ma624KeWVIwd/Wuf8RpHLa7WYKpkVhzyMHigDzzUYmdpAc8tnOPaufu422lmznpk11ep7YZXIBKncCO/U9f0rmblCLZwchs565FAGO6hVGRVdwM1bnXg8npVRxjrQAwjI+lNl+6tPA5NNl5UYoAgNAGaVu3FNNACgcUUUCgBRUqDAz29aiHWpY+lAF+QkE+lRtUkmN3TmmEUARle/5UijnmnMtA68UAN685pG5PFOYYpv86AGnp+FN708j9abigBVY5xmnoOetRd6cDz1oAsQ43Atk+wOK2dOYY64xWErHIrW09zmgDsNPYHyx1ywzx0rrIdsdwR8o+UDJri9KcfIxJxvwfpXdkbg0gJMWAQR/doA6TSJdzLETkKvHtzXa6QcRNyN2/kA5FeZ6XM6FyZAWJ4wMcZrv9ClWWIkbjkg/lQB1VmfmxnuOlX169e1ZdqGVwO3atZQOP0oAa4+bjvQ/wB33xUjrkDimsM/WgCoRtb1qWfLw8dQMUMvINSIpaMjHIoAxZQcHsao3pcKQpwB3Fbctv8AMeCM1RmtmySvPbFAGVvKnAJzSTAupAYZ68dqum23ZyOKBCU645oAzjHtQ8kj3qzbqQuQMHrg1KyKCTgZx3PFJGytlVGWxQBh6o5dnBYru4wKy7RQu4N0zgDPer+pOVkc4O3HrWVk+XhATg5xigCnduDI6HkAbsk9a53XX/0UE5U9OP6VtzgHzWfABXHvzxXP6mAbE8gHnB9ugoA5PWGZ/mLHcy5Pf0rnrksUkyxwBx75rotUXLFgcKwHFYV2uFVduCTz7cUAYUxOCevvVWQ5z61cuRt6fjVNj+gxQAwN8wpkvQD0pwPIps5HHJIHTnoPSgCIgk8UlLikoADRnFByQM8gcUUAKKlTpUYqRKANFwNxpoXg59akf71N780ARkdvakHAIxx1p5Hze1Jg85oAjIzTSMZqUqTjAOaaRzQBEelMI/KpSMVGe/rQA2nDrTT1paAJE5atKwcBhkHHSs2OrVs5RhigDt9IHycdvmBHNehaLCZ9K4BBDfiAe38q828JyMbpVJLRvwyjsMV6x4eVU03zdxEYUj6mgCC3thHchS2B0OTXWeH5/JkVVyRjOfWuYCgT7gck9j3710WiH7nAwM8DsKAO8s33oCK1IDwMDPaucsJGByoOPWt+0fcoJ7igC0VytNKcY61IPxzThQBXeMZqSNMe+aeQP8ilBO4e1AFeWErk9s1BLCGOCPqBV+UHucD3qszY69fWgCibUZBOcdqrXFuMNWi0gBqtdfMvY0AYc+F3ZyB1zVWMKsuQOGHUGp9QYKCBw/v0qnGPnDcjuaAMnVAQxxux0rLklKg4OCT3ra1MkuX+XnpnnNYk7eYygP1OfwoAz7vkbThiCcnFYMw/dujJ2Ofcf0rcvSQmeAepxxWBekRvIyMAQpHoOTQBzF4Qxw2eFJzj8qwb9iTyvYHJrd1LJYtkMO3ocjmsG+YOrENnggYHWgDEuDuDeuapP0NXbjv2OKpv/OgCMDnNROQalxgnkAHjmoD0zQAhNJStSUAFFHbrRQA6pUqIdKljGRQBoycsaQe9OkHzcU2gBpHOe1FKevWj6UAN6HIzTCT3709v1phJFADGPv35qMnNSE/hTDQAw0vQijBo9qAJEqeLrVdOvvViPrQBu+HLgwX0Z9xn6V7MZvs2n2kKH92+WOO59a8LsG2zKRnrXrdhdfbdHAO4SwNtwT2PIoA37cbfLYZKA966HSwNwK8npXLadIxCBgR0yM/nXV6chX0Ix2oA6mxchFBIyOlbds2PU1z9icKCeB2NbVs4wM5/pQBqRSHtTy3Gc5qj5u3k8Uv2jg+vegC20nycdjmozLVNpxk4PBFQm8VMj9aANKeX5QD171Vdm6jrXO6j4ihttwLAsODjk1hzeNTDudogV6DnmgDuWcr1HvzVaSfAzXL6d4xtb2RI2Yxu3QP3rbM0cq7lbGaAILx1dcMBuJ61UZRGuEY8n86sXC7jnIx7VTchXO3kAcc5oAo3qln2sAFHAPvWVLEArttOccY61q3TgqQeCDVGRk8v36Y6UAYN9gRMMAZGMY6iuZ1Nd6McZyARkV1GpKAhOQAPWubvwzrhjxkc+1AHNagm1WVeVDKM+h9KwrkjMhO3HOB/WtnUAOApOM55PPtWBd/KjDj5uD+FAGTOQx6ZHrVNsZJ9Kty/dNU5O9AEMhyfaox1pzU0Hg0AMPJopaSgAoAopRQA7GOKkjqIVKlAGlJjNNxinP8AeNNPI4oAYe/OBjPTvSbvSkYdqQDFACsaaaXoe1N7cUAID+VNP604/rTDQAhpD60h60elAD0POeRU6VXWrCUAXrM4kBGcjniu/wDCl/JJdFJZCTLGEBbuR0zXnsB2kH3rotGnQSrsfYwOQD/SgD1LT3LN8xGc9K6vTZSqqD0PGPSuH0m4ExV8ruPDc9/WustbhkCgkjn0oA6uzlPAzkda1opgExnpXNWlwqjJGfqK0IpywBwQPegDYe4B6moJbtYxlmxisHUdatrOM+ZKuc8ZNcZrPiuSUslrkL/fP9KAOz1XxHDZqRI5LdkX7xrmbrxLNdEiNvLTsAeT9a5F53kky253Y4JPJJq/BppCBrg4Zv4Qfu/WgCa61EAkF8+uDWNd3hlcZPyjp71fu9PzATCgL+1YskTIcMrZ5zkUATxyM7KEyTyQBW9oXiiexZYbvdJFnGc/Mv496oWOlTRWod12s43ZIxgVLd6cJoztXM2Pl9T7GgDvYdWinjWSJwyHHzA1I1zEwyGAJ5rya21C4sZi0TFCPvIeh9iK6C18SW9wmycCGToc/dP0NAHZXShkDAncTnGay7sPtz6HFZ32ssAQ2VxxtPFMbUiBgOx5780ARX037t9wI7VgXcy8E4J646k1rXN8siEugYjg1jalsdWIYqeMDNAHO6oy5YjkenpXM3b8tyMjjFbmp7w7Z6YH4VzlwwLGgCnPwMYOaoyNnParVy9UmINADTSN2HpSH0pM0AFJRRQAdqUUlKKAHLjBzmpY6iHvUsfSgDSk60zjFSSdaioAYaQcCnleKaOaAG96AMjgU7Y2AdpwaQAj2OKAGMKYelSHp196jOaAIzTlG44oPGcj86dD8sgyPUUANWp0OelQg596niUseKALUXSrkBxUdtaGXAEkY57nFb1j4cu7iJTbNA79wZQM0AQ2l3NEwMc0gx0welb9r4i1GOIIt7Mq+gIqo3hPXrdN7aXcun96IBx+lVxaTwMRcQyxEdpEK/zoA6W38TauG3DUJ8f71Wv+Eh1GbcJL2ds9t1c1b4zjIJq9bIzNgfMT2AyaALL3LzNlnLn1JzUkJkkkCICzE4CgVc0rw7qOouBbWkmzPLMuAK9F0PwhHpcYmuQDNjqRQBg6Xov2SFZ7kA3DDj/ZFPlh8+QBSBjp6mumu4Vw2TgetZEsO2VdgJJPX0oApT2sluuO2R8w/rT7fyncZQF/QCtxLZpLYPKDn6d6RLJPMOxslec7elADY7GOTzDPIA/YAZxVL+ynSU4BYZ+8KnurgWUTZz5meaXTtUjlUEkK4680Ac74o8LyTKbuxQNKf9Yg4JPtXA3MEsJKzIytnnIwa+gdPuI5SyzruXGenX8aL/w/YahGS0Mcgbn5hkigD5y+1XEHMMrp9D1p0mvagij98pHugzXsl54BsnU+VHGoPQY6VzWpfDxTu2K2fQYoA8zl8S3o4byiP92s+58RXT7srGM11+q+AbmIkxRSE+/FcnqHhm9gzm3m2g4yFyKAMqbWbhs/c6+lUJ76WQ/MI/wXFT3NhJE3zZHP8S1SlgYHqD9KAIpJCT0qJmJPWpTC+M7eKiZGU8igBvfNNp3PWm0AFHaijNAAfu9s560oo5wD2+lFADs1KlRAVLGM9KANKT71MPLADNTOOaTbx0oAi2HFIExU2PSkYYoAj6AY7Uj5IxwaU8cZ4pp46UAMOKjkOOtOZuajLnJ4GO47UANY+lIvKlielB+ZsAdegpzkLGoH3u9ADVPNXYeFGfvVRTkgVfjAOKANGzPzCuq0aXb8wHI9K5O2GW5P4Vv6eOSAeABz070Aej6Hqr24RkdgzHGVJHNdtp/iGRsLPiVcD5ZFDfzFeXabIwifcvCEEVu2k7JcE5weDz3oA9NhutNly0mm2LMO/kKKuQ3lhGpMNlZoR/ciANcNBeNHHj5cn1HWpI79yzfPz04OKAO2fXEVSCyRgf3VxWVeawhBIbJFc8JizgscN0/CmsYY1DbicDnnjigDVaRblyZDhMdu9SosYUZIXnjvWUJWaQMm3ay5GD2xzT3vlgj2KSz+pH5YoA32+ZQwHOPoKzrm6MTFVwB7Vlx6vJL+7kbCk8ZpzzLh5C/v9KAMnWd7ucMCG96pQExFcNgrn5hyPxq1dMDLuBARhnnrS2qxv+7kETIeSSOSPSgDoNAvGkRy4Gwjlh90jHrW5ZX5yChzgetca92kMYWEBU5AC1GmrkYJz9QOKAPR0vwfvqrN9MUyW7hHPl9BmuHs/EEQQnzDnBIDDrzUw8Qq8DvudMjIGQRQB0N5qECJn7MGIGQM9a5/VNchjVmFlGMHHK7qzNQ8QxYaN97YHp7elYep6qgtQ7RAsCDwcH69aAHat4qVA4NpAQvYwjn9K888Qa9LO5CQW8Q/2IgDzV3VdTglZggmDYBGWDDNcpqMxeQnd34oAzbuZ5D8zEn+dUWPXNWZmOSaqtQBG3Wm0rdfWkoASl7Un86cMsMBSeRQAnO3vjPrS/hQVIJyDwcGjrQA4Yx15z0x2+tSR57VF2qZBj8aANiQc02pJDkmmAHPtQAnQimOc9KkbrUZGOlAER6DHSmnJqRqY1AELGomNSsOKhagBoOPUUO25iRSMcnNJ9aAJbfliOnHWrcDYIqtaf6w/Q1ZjGDQBoQtyPXNatrPsxgAZ6E1lQg9sVfgcAqyn+LpQB3GjAzrhiCp4GPXFaFpJiXBOFX5Tnuaw9DlJtDhW3YznFbNrHIZdnyjfyWxx7UAb4JeOMqAzbc7jn8akhciZAdoxxwOOagaPcTI7YbYOOlSl1MgCkAdM5zzQBIzPhyM4AOOvSovNZUXOcq3QDqDTopcuTnBAx0p8a4jVWDA4wWP86AJrJ2kLJuIK8r7juKhhibzCjZAHIB4p0IiC5BIcjqBzTZ7iDzlZy2cbSSaAGyNtc54PXHala6QxlVBOR+BqC5uo2ZG5wcDI7A96oPcqvBBXsRnk0ATS3ABcOQCB3/xqA3m2QfNkFeMcdax77UQXKhiSG6AYqjPcSNc8ljkAgk9PagDbkvCyZAIDN1Bqo93hBhmJ9jg1QE7NuJOOx/+tUJkAZiWZc8AelAGrLep5TAnnb6d6p3GoN5JXjaDgDPHYVSlucRllYbSOcjFVpJSygDcAACRQBak1KQSSbXOOQQRWdqV1ukOcYAGc8HNV2YkjqSTk59ap3L7myzHnJIoAguJdzEjOCxxWZM24cetW5DhUxkVQlJ49qAK8hqFztXgnJ609+OKhckmgCMnPWkpxBoxQAb2GOcY9qGZmXDMxHpmkwaMUASLIWn3SZIYjeBxntTORwecd6McUuOOlAAPfNSx/SowDUseaAN2TrSgDJ4oooAjPSmHrRRQAw9qiNFFAETf1qF+poooAYf6U0UUUAWLX/WirndaKKALUVdJoSqUyVBP0+tFFAHR6X/x6se//wBetMk/aIhnjA4/GiigDXflRn+7TogPNHH8QoooAlPCrjjrQ/O7PNFFACRAb247f0qAAFBkDp/jRRQBVg5Tnn/9dZuo8zc/3qKKAOevOo/Cj+IfQUUUAFz1ce1RjmJs+/8AKiigCG6HyxjttX+VQjmB80UUAUhzG+f7tVJuj/hRRQBRn7VUfvRRQBWfpUB6miigAPWkHWiigAPWgUUUAFKetFFACjrU6DgfSiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enchondroma of the distal femur demonstrates flocculent matrix resembling rings, or Cs and Os. Calcification is concentrated in the center of the lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_9_33951=[""].join("\n");
var outline_f33_9_33951=null;
